{
  "data": {
    "genes": {
      "nodes": [
        {
          "name": "BRAF",
          "longName": "B-Raf proto-oncogene, serine/threonine kinase",
          "geneCategories": [
            {
              "name": "SERINE THREONINE KINASE"
            },
            {
              "name": "KINASE"
            },
            {
              "name": "DRUGGABLE GENOME"
            },
            {
              "name": "DRUG RESISTANCE"
            },
            {
              "name": "CLINICALLY ACTIONABLE"
            }
          ],
          "interactions": [
            {
              "interactionAttributes": [
                {
                  "name": "Combination Therapy",
                  "value": "Celecoxib + Vemurafenib"
                },
                {
                  "name": "Indication",
                  "value": "colorectal cancer"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Celecoxib + Gefitinib + Trametinib + Vemurafenib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Celecoxib + Trametinib + Vemurafenib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Celecoxib + Dabrafenib + Trametinib"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Pdx"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Celecoxib + Dabrafenib + Panitumumab + Trametinib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Celecoxib + Encorafenib + Panitumumab"
                }
              ],
              "drug": {
                "name": "CELECOXIB",
                "approved": true
              },
              "interactionScore": 0.0101953420736496,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Ruiz-Saenz A et al., 2023, A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAF(V600E) colorectal tumors., Nat Cancer",
                      "pmid": 36759733
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Indication",
                  "value": "high grade glioma"
                },
                {
                  "name": "Indication",
                  "value": "colorectal cancer"
                },
                {
                  "name": "Approval Status",
                  "value": "Case Reports/Case Series"
                },
                {
                  "name": "Indication",
                  "value": "thyroid gland cancer"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Phase I"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Belvarafenib + Cobimetinib"
                },
                {
                  "name": "Indication",
                  "value": "Advanced Solid Tumor"
                },
                {
                  "name": "Response Type",
                  "value": "resistant"
                },
                {
                  "name": "Direct Interaction",
                  "value": "true"
                },
                {
                  "name": "Mechanism of Action",
                  "value": "RAF serine/threonine protein kinase inhibitor"
                }
              ],
              "drug": {
                "name": "BELVARAFENIB",
                "approved": false
              },
              "interactionScore": 0.3313486173936121,
              "interactionTypes": [
                {
                  "type": "inhibitor"
                }
              ],
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "ChEMBL"
                  }
                },
                {
                  "publications": [
                    {
                      "citation": "Yen I et al., 2021, ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma., Nature",
                      "pmid": 33953400
                    },
                    {
                      "citation": "Schreck KC et al., 2021, Deconvoluting Mechanisms of Acquired Resistance to RAF Inhibitors in BRAF(V600E)-Mutant Human Glioma., Clin Cancer Res",
                      "pmid": 34433654
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Combination Therapy",
                  "value": "Dabrafenib + Hydroxychloroquine + Trametinib"
                },
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Phase Ib/II"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                }
              ],
              "drug": {
                "name": "HYDROXYCHLOROQUINE",
                "approved": true
              },
              "interactionScore": 0.04733551677051602,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Mehnert JM et al., 2022, BAMM (BRAF Autophagy and MEK Inhibition in Melanoma): A Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Advanced BRAFV600-mutant Melanoma., Clin Cancer Res",
                      "pmid": 35022320
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Indication",
                  "value": "colon carcinoma"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Indication",
                  "value": "melanoma"
                }
              ],
              "drug": {
                "name": "AGERAFENIB",
                "approved": false
              },
              "interactionScore": 0.220899078262408,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "James J et al., 2012, CEP-32496: a novel orally active BRAF(V600E) inhibitor with selective cellular and in vivo antitumor activity., Mol Cancer Ther",
                      "pmid": 22319199
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Approval Status",
                  "value": "Phase Ib/II"
                },
                {
                  "name": "Indication",
                  "value": "lung non-small cell carcinoma"
                },
                {
                  "name": "Response Type",
                  "value": "not predictive"
                },
                {
                  "name": "Approval Status",
                  "value": "Clinical Study - Cohort"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Atezolizumab + Vemurafenib"
                },
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Atezolizumab + Cobimetinib + Vemurafenib"
                },
                {
                  "name": "Approval Status",
                  "value": "FDA approved"
                }
              ],
              "drug": {
                "name": "ATEZOLIZUMAB",
                "approved": true
              },
              "interactionScore": 0.1325394469574448,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Dudnik E et al., 2018, BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors., J Thorac Oncol",
                      "pmid": 29723688
                    },
                    {
                      "citation": "Sullivan RJ et al., 2019, Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients., Nat Med",
                      "pmid": 31171876
                    },
                    {
                      "citation": "Gutzmer R et al., 2020, Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF(V600) mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial., Lancet",
                      "pmid": 32534646
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "CIViC"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "PharmGKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Novel Drug Target",
                  "value": "Established target"
                },
                {
                  "name": "Clinical Trial Name",
                  "value": "XL281"
                }
              ],
              "drug": {
                "name": "XL281",
                "approved": false
              },
              "interactionScore": 0.220899078262408,
              "interactionTypes": [
                {
                  "type": "inhibitor"
                }
              ],
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "MyCancerGenome"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TdgClinicalTrial"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Response Type",
                  "value": "predicted - resistant"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Fluorouracil + Irinotecan + Leucovorin + Panitumumab"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Fluorouracil + Leucovorin + Oxaliplatin + Panitumumab"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Approval Status",
                  "value": "Case Reports/Case Series"
                },
                {
                  "name": "Response Type",
                  "value": "not predictive"
                },
                {
                  "name": "Indication",
                  "value": "colorectal cancer"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Cetuximab + Fluorouracil + Irinotecan + Leucovorin"
                }
              ],
              "drug": {
                "name": "LEUCOVORIN CALCIUM",
                "approved": true
              },
              "interactionScore": 0.02137733015442658,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Yaeger R et al., 2019, Response to Anti-EGFR Therapy in Patients with BRAF non-V600-Mutant Metastatic Colorectal Cancer., Clin Cancer Res",
                      "pmid": 31515458
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Mechanism of Action",
                  "value": "Serine/threonine-protein kinase B-raf inhibitor"
                },
                {
                  "name": "Direct Interaction",
                  "value": "true"
                }
              ],
              "drug": {
                "name": "LY-3009120",
                "approved": false
              },
              "interactionScore": 0.110449539131204,
              "interactionTypes": [
                {
                  "type": "inhibitor"
                }
              ],
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "ChEMBL"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Mechanism of Action",
                  "value": "Serine/threonine-protein kinase B-raf inhibitor"
                },
                {
                  "name": "Direct Interaction",
                  "value": "true"
                },
                {
                  "name": "Mechanism of Action",
                  "value": "BRAF kinase inhibitor"
                },
                {
                  "name": "Cancer Type",
                  "value": "Ovarian cancer"
                },
                {
                  "name": "Indication",
                  "value": "Purpose: Vemurafenib has been approved by the FDA for treatment of patients with advanced melanoma that harbors a B-RAF mutation. Vemurafenib works by blocking a protein called B-RAF. %Inclusion criteria: Melanoma must be documented to contain a BRAFV600 mutation. %Exclusion criteria: Prior therapy with a MEK inhibitor or an inhibitor of mutant BRAF."
                },
                {
                  "name": "Clinical Trial ID",
                  "value": "NCT01813214"
                },
                {
                  "name": "Indication",
                  "value": "Purpose: study the activity of vemurafenib in untreated melanoma brain metastases harboring BRAF mutations. %Official title: Vemurafenib in Melanoma Patients With Untreated Brain Metastases, Whose Tumors Harbor B-raf Mutations."
                },
                {
                  "name": "Clinical Trial ID",
                  "value": "NCT01781026"
                },
                {
                  "name": "Indication",
                  "value": "Purpose: effect of vemurafenib on the pharmacokinetics of digoxin in patients with unresectable BRAFV600-mutation positive metastatic melanoma or other malignant tumor type that harbors a V600-activating mutation of BRAF. %Exclusion criteria: Prior treatment with vemurafenib or other BRAF inhibitor."
                },
                {
                  "name": "Clinical Trial ID",
                  "value": "NCT01765569"
                },
                {
                  "name": "Indication",
                  "value": "Purpose: Researchers have found that a large number of melanoma cells have mutations in the BRAF gene. It has been shown that vemurafenib blocks the effects of these mutations in the BRAF gene."
                },
                {
                  "name": "Clinical Trial ID",
                  "value": "NCT01754376"
                },
                {
                  "name": "Indication",
                  "value": "Official title: Vemurafenib Therapy in Patients With BRAFV600 Mutation."
                },
                {
                  "name": "Clinical Trial ID",
                  "value": "NCT01683188"
                },
                {
                  "name": "Indication",
                  "value": "Purpose: evaluate the efficacy and safety of vemurafenib in patients with completely resected, cutaneous BRAF-mutation positive melanoma. %Official title: Study of Vemurafenib (RO5185426) Adjuvant Therapy in Patients With Surgically Resected, Cutaneous BRAF Mutant Melanoma."
                },
                {
                  "name": "Indication",
                  "value": "Purpose: standard dosage of vemurafenib to patients with unresectable / metastatic v-raf murine sarcoma viral oncogene homolog B1 (BRAF)-mutated melanoma. %Inclusion criteria: Unresectable / metastatic BRAF-mutated melanomas."
                },
                {
                  "name": "Clinical Trial ID",
                  "value": "NCT01673737"
                },
                {
                  "name": "Indication",
                  "value": "Purpose: Vemurafenib is designed to block BRAF. %Official title:  BRAF Inhibitor Vemurafenib."
                },
                {
                  "name": "Clinical Trial ID",
                  "value": "NCT01596140"
                },
                {
                  "name": "Cancer Type",
                  "value": "Lung cancer"
                },
                {
                  "name": "Indication",
                  "value": "Purpose: Vemurafenib is designed to block BRAFV600 inside the cancer cells. %Inclusion criteria: Cancers with positive BRAF V600 mutation. %Keywords: BRAF mutant, BRAF V600 Mutant Advanced Solid Malignancies."
                },
                {
                  "name": "Clinical Trial ID",
                  "value": "NCT01787500"
                },
                {
                  "name": "Indication",
                  "value": "Purpose: This open-label, multicenter, non-randomized study will provide continued access to vemurafenib for eligible patients with BRAF V600 mutation-positive malignancy. %Official title: A Phase IV, PostMarketing, Open-Label, Extension (Rollover) Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Malignancies. %Inclusion criteria: BRAF V600 mutation-positive malignancy."
                },
                {
                  "name": "Clinical Trial ID",
                  "value": "NCT01739764"
                },
                {
                  "name": "Cancer Type",
                  "value": "GIST"
                },
                {
                  "name": "Indication",
                  "value": "Purpose: Vemurafenib is designed to block a protein (called mutated BRAF). %Inclusion criteria: Patient must have histologically or cytologically confirmed diagnosis of advanced solid tumor or lymphoma harboring a BRAF mutation"
                },
                {
                  "name": "Clinical Trial ID",
                  "value": "NCT01636622"
                },
                {
                  "name": "Indication",
                  "value": "Official title: Vemurafenib (BRAF Inhibitor). %Inclusion criteria: Patients with advanced or metastatic cancers and BRAF mutations"
                },
                {
                  "name": "Clinical Trial ID",
                  "value": "NCT01531361"
                },
                {
                  "name": "Indication",
                  "value": "Official title: Vemurafenib in Patients With BRAF V600 Mutation-positive Cancers. %Inclusion criteria: Histologically confirmed cancers (excluding melanoma and papillary thyroid cancer) with a BRAF V600 mutation"
                },
                {
                  "name": "Cancer Type",
                  "value": "Colorectal cancer"
                },
                {
                  "name": "Clinical Trial ID",
                  "value": "NCT01524978"
                },
                {
                  "name": "Indication",
                  "value": "Inclusion criteria: BRAF V600E mutation detected in the primary tumor or the recurrent/persistent tumor."
                },
                {
                  "name": "Clinical Trial ID",
                  "value": "NCT01709292"
                },
                {
                  "name": "Cancer Type",
                  "value": "Thyroid Cancer"
                },
                {
                  "name": "Clinical Trial ID",
                  "value": "NCT01667419"
                },
                {
                  "name": "Indication",
                  "value": "Official title: Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma."
                },
                {
                  "name": "Clinical Trial ID",
                  "value": "NCT01657591"
                },
                {
                  "name": "Indication",
                  "value": "Official title: Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations. %Inclusion criteria: activating BRAF mutation."
                },
                {
                  "name": "Clinical Trial ID",
                  "value": "NCT01586195"
                },
                {
                  "name": "Indication",
                  "value": "Purpose: Vemurafenib targets melanoma cells that have a mutation in the B-raf gene. %Inclusion criteria: Measurable metastatic melanoma that expresses the VtoE BRAF mutation."
                },
                {
                  "name": "Clinical Trial ID",
                  "value": "NCT01585415"
                },
                {
                  "name": "Indication",
                  "value": "Purpose: vemurafenib (RO5185426) in pediatric patients (aged 12 through 17) with newly diagnosed or recurrent surgically incurable and unresectable Stage IIIC or Stage IV melanoma harboring BRAFV600 mutations. %Official title: RO5185426 in Pediatric Patients With Surgically Incurable and Unresectable Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations Mutations. %Inclusion criteria: Positive BRAF mutation result. %Exclusion criteria: Previous treatment with selective/specific BRAF or MEK inhibitor."
                },
                {
                  "name": "Clinical Trial ID",
                  "value": "NCT01519323"
                },
                {
                  "name": "Indication",
                  "value": "Purpose: Vemurafenib works by blocking a protein called B-RAF."
                },
                {
                  "name": "Cancer Type",
                  "value": "Melanoma"
                },
                {
                  "name": "Clinical Trial ID",
                  "value": "NCT01495988"
                },
                {
                  "name": "Indication",
                  "value": "Purpose: Vemurafenib is designed to block BRAFV600. %Official title: Patients With BRAF V600 Mutant Advanced Solid Malignancies. %Inclusion criteria: Cancers with positive BRAF V600 mutation"
                },
                {
                  "name": "Indication",
                  "value": "Purpose: treatment is being tested in a subgroup of patients with colorectal cancer whose tumors have changes in the BRAF gene that may make them more likely to respond to this new drug combination. %Inclusion criteria: Patient must have metastatic colorectal cancer with a V600E BRAF mutation. %Keywords: V600E BRAF mutation"
                },
                {
                  "name": "Clinical Trial ID",
                  "value": "NCT01791309"
                },
                {
                  "name": "Indication",
                  "value": "Purpose:  vemurafenib in patients with BRAF V600 mutation positive cancer. %Official title: Vemurafenib in BRAF V600 Mutation Positive Cancer Patients. %Inclusion criteria: confirmed BRAF V600 mutation"
                },
                {
                  "name": "Clinical Trial ID",
                  "value": "NCT01767623"
                },
                {
                  "name": "Indication",
                  "value": "Purpose: in patients with unresectable BRAFV600-mutation positive metastatic melanoma or other malignant tumor type that harbors a V600-activating mutation of BRAF. %Inclusion criteria: positive for the BRAFV600 mutation or other malignant tumor type that harbors a V600-activating mutation of BRAF"
                },
                {
                  "name": "Clinical Trial ID",
                  "value": "NCT01765543"
                },
                {
                  "name": "Approval Status",
                  "value": "FDA-approved"
                },
                {
                  "name": "Pathway",
                  "value": "activation"
                },
                {
                  "name": "Variant Effect",
                  "value": "gain-of-function"
                },
                {
                  "name": "Approval Status",
                  "value": "early trials"
                },
                {
                  "name": "Approval Status",
                  "value": "case report"
                },
                {
                  "name": "Approval Status",
                  "value": "late trials"
                },
                {
                  "name": "Clinical Trial Name",
                  "value": "PLX4032, RG7204"
                },
                {
                  "name": "Novel Drug Target",
                  "value": "Established target"
                },
                {
                  "name": "Mechanism of Action",
                  "value": "Sensitivity"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Irinotecan;Vemurafenib;Cetuximab"
                },
                {
                  "name": "Alteration",
                  "value": "BRAF:V600."
                },
                {
                  "name": "Alteration",
                  "value": "BRAF:V600D,V600K,V600M,V600G,V600R"
                },
                {
                  "name": "Alteration",
                  "value": "BRAF:V600E"
                },
                {
                  "name": "Alteration",
                  "value": "BRAF:V600E,V600D,V600K,V600M,V600G,V600R"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Vemurafenib;Cobimetinib"
                },
                {
                  "name": "Alteration",
                  "value": "BRAF:V600E,V600K"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Crizotinib;Vemurafenib"
                },
                {
                  "name": "Alteration",
                  "value": "MET:amp;BRAF:V600E"
                },
                {
                  "name": "Alteration",
                  "value": "BRAF::consequence::inframe_deletion:L485.,::inframe_deletion:P490."
                },
                {
                  "name": "Alteration",
                  "value": "NF1:.;BRAF:."
                },
                {
                  "name": "Alteration",
                  "value": "NF1:del;BRAF:."
                },
                {
                  "name": "Combination Therapy",
                  "value": "Vemurafenib;Panitumumab"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Vemurafenib + Cobimetinib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Vemurafenib + Panitumumab"
                },
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "no benefit"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Patient cell culture"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Response Type",
                  "value": "resistant"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                },
                {
                  "name": "Indication",
                  "value": "hairy cell leukemia"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Case Reports/Case Series"
                },
                {
                  "name": "Approval Status",
                  "value": "Phase II"
                },
                {
                  "name": "Indication",
                  "value": "sarcoma"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                },
                {
                  "name": "Indication",
                  "value": "thyroid gland cancer"
                },
                {
                  "name": "Response Type",
                  "value": "conflicting"
                },
                {
                  "name": "Indication",
                  "value": "pancreatic endocrine carcinoma"
                },
                {
                  "name": "Indication",
                  "value": "neuroendocrine carcinoma"
                },
                {
                  "name": "Approval Status",
                  "value": "Phase I"
                },
                {
                  "name": "Approval Status",
                  "value": "FDA approved - On Companion Diagnostic"
                },
                {
                  "name": "Indication",
                  "value": "ovarian cancer"
                },
                {
                  "name": "Indication",
                  "value": "larynx cancer"
                },
                {
                  "name": "Indication",
                  "value": "glioblastoma"
                },
                {
                  "name": "Indication",
                  "value": "high grade glioma"
                },
                {
                  "name": "Approval Status",
                  "value": "Guideline"
                },
                {
                  "name": "Indication",
                  "value": "anaplastic astrocytoma"
                },
                {
                  "name": "Indication",
                  "value": "lung non-small cell carcinoma"
                },
                {
                  "name": "Approval Status",
                  "value": "Clinical Study"
                },
                {
                  "name": "Indication",
                  "value": "thyroid gland follicular carcinoma"
                },
                {
                  "name": "Indication",
                  "value": "thyroid gland papillary carcinoma"
                },
                {
                  "name": "Indication",
                  "value": "Erdheim-Chester disease"
                },
                {
                  "name": "Indication",
                  "value": "renal cell carcinoma"
                },
                {
                  "name": "Indication",
                  "value": "pilocytic astrocytoma"
                },
                {
                  "name": "Indication",
                  "value": "pleomorphic xanthoastrocytoma"
                },
                {
                  "name": "Indication",
                  "value": "cholangiocarcinoma"
                },
                {
                  "name": "Indication",
                  "value": "ganglioglioma"
                },
                {
                  "name": "Indication",
                  "value": "histiocytic and dendritic cell cancer"
                },
                {
                  "name": "Indication",
                  "value": "ovary serous adenocarcinoma"
                },
                {
                  "name": "Indication",
                  "value": "ovarian serous cystadenocarcinoma"
                },
                {
                  "name": "Indication",
                  "value": "thyroid gland Hurthle cell carcinoma"
                },
                {
                  "name": "Indication",
                  "value": "salivary gland cancer"
                },
                {
                  "name": "Indication",
                  "value": "skin melanoma"
                },
                {
                  "name": "Indication",
                  "value": "colorectal cancer"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                },
                {
                  "name": "Indication",
                  "value": "salivary gland carcinoma"
                },
                {
                  "name": "Indication",
                  "value": "thyroid gland anaplastic carcinoma"
                },
                {
                  "name": "Indication",
                  "value": "IDH-wildtype glioblastoma"
                },
                {
                  "name": "Indication",
                  "value": "Advanced Solid Tumor"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Cetuximab + Irinotecan + Vemurafenib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Cobimetinib + Vemurafenib"
                },
                {
                  "name": "Indication",
                  "value": "breast cancer"
                },
                {
                  "name": "Indication",
                  "value": "pancreatic ductal adenocarcinoma"
                },
                {
                  "name": "Indication",
                  "value": "large cell carcinoma"
                },
                {
                  "name": "Indication",
                  "value": "anaplastic oligodendroglioma"
                },
                {
                  "name": "Indication",
                  "value": "low grade glioma"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Lapatinib + Vemurafenib"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Gefitinib + Vemurafenib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Erlotinib + Vemurafenib"
                },
                {
                  "name": "Approval Status",
                  "value": "Phase Ib/II"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Cetuximab + Vemurafenib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Panitumumab + Vemurafenib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "SBI-0640756 + Vemurafenib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Navitoclax + Vemurafenib"
                },
                {
                  "name": "Indication",
                  "value": "colon cancer"
                },
                {
                  "name": "Combination Therapy",
                  "value": "TW-37 + Vemurafenib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "DETD-35 + Vemurafenib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Trametinib + Vemurafenib"
                },
                {
                  "name": "Indication",
                  "value": "neuroendocrine tumor"
                },
                {
                  "name": "Combination Therapy",
                  "value": "PAC-1 + Trametinib + Vemurafenib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "PAC-1 + Vemurafenib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Ponatinib + Vemurafenib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Cobimetinib + Pembrolizumab + Vemurafenib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Capecitabine + Vemurafenib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Bevacizumab + Capecitabine + Vemurafenib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Irinotecan + Vemurafenib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Ruxolitinib + Vemurafenib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "ASTX029 + Vemurafenib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "LY3009120 + Vemurafenib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Vemurafenib + ZM336372"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Nab-paclitaxel + Vemurafenib"
                },
                {
                  "name": "Indication",
                  "value": "triple-receptor negative breast cancer"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Pyrvinium + Vemurafenib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Axitinib + Vemurafenib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Panobinostat + Vemurafenib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Saracatinib + Vemurafenib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Dasatinib + Vemurafenib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Bosutinib + Vemurafenib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Dasatinib + Gefitinib + Vemurafenib"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Pdx & cell culture"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Celecoxib + Vemurafenib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Celecoxib + Gefitinib + Trametinib + Vemurafenib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Celecoxib + Trametinib + Vemurafenib"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - resistant"
                },
                {
                  "name": "Indication",
                  "value": "colon adenocarcinoma"
                },
                {
                  "name": "Combination Therapy",
                  "value": "MK2206 + Vemurafenib"
                },
                {
                  "name": "Response Type",
                  "value": "decreased response"
                },
                {
                  "name": "Indication",
                  "value": "refractory hairy cell leukemia"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Palbociclib + Vemurafenib"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Biochemical"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Bevacizumab + Vemurafenib"
                },
                {
                  "name": "Indication",
                  "value": "lung papillary adenocarcinoma"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Vemurafenib + Voruciclib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "S63845 + Vemurafenib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "PET-16 + Vemurafenib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "UNC2025 + Vemurafenib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "SAR260301 + Vemurafenib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Vemurafenib + XL888"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Vemurafenib + ZSTK474"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Selumetinib + Vemurafenib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Dactolisib + Vemurafenib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "PX-866 + Vemurafenib"
                },
                {
                  "name": "Indication",
                  "value": "lung adenocarcinoma"
                },
                {
                  "name": "Approval Status",
                  "value": "Clinical Study - Cohort"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Pdx"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Atezolizumab + Vemurafenib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Buparlisib + Vemurafenib"
                },
                {
                  "name": "Approval Status",
                  "value": "Phase III"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Atezolizumab + Cobimetinib + Vemurafenib"
                },
                {
                  "name": "Approval Status",
                  "value": "FDA approved"
                },
                {
                  "name": "Indication",
                  "value": "pancreatic cancer"
                }
              ],
              "drug": {
                "name": "VEMURAFENIB",
                "approved": true
              },
              "interactionScore": 1.997837251932072,
              "interactionTypes": [
                {
                  "type": "inhibitor"
                },
                {
                  "type": "activator"
                }
              ],
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "CancerCommons"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "ChEMBL"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "ClearityFoundationBiomarkers"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "ClearityFoundationClinicalTrial"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "COSMIC"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "FDA"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "MyCancerGenomeClinicalTrial"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "OncoKB"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "PharmGKB"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TALC"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TdgClinicalTrial"
                  }
                },
                {
                  "publications": [
                    {
                      "citation": "Davies H et al., 2002, Mutations of the BRAF gene in human cancer., Nature",
                      "pmid": 12068308
                    },
                    {
                      "citation": "Gautschi O et al., 2012, A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib., J Thorac Oncol",
                      "pmid": 22743296
                    },
                    {
                      "citation": "Xing M et al., 2014, BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence., J Clin Oncol",
                      "pmid": 25024077
                    },
                    {
                      "citation": "Naoki K et al., 2002, Missense mutations of the BRAF gene in human lung adenocarcinoma., Cancer Res",
                      "pmid": 12460919
                    },
                    {
                      "citation": "Paik PK et al., 2011, Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations., J Clin Oncol",
                      "pmid": 21483012
                    },
                    {
                      "citation": "Falchook GS et al., 2012, Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial., Lancet",
                      "pmid": 22608338
                    },
                    {
                      "citation": "Ohashi K et al., 2012, Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1., Proc Natl Acad Sci U S A",
                      "pmid": 22773810
                    },
                    {
                      "citation": "Flaherty KT et al., 2010, Inhibition of mutated, activated BRAF in metastatic melanoma., N Engl J Med",
                      "pmid": 20818844
                    },
                    {
                      "citation": "Chen D et al., 2014, BRAFV600E mutation and its association with clinicopathological features of colorectal cancer: a systematic review and meta-analysis., PLoS One",
                      "pmid": 24594804
                    },
                    {
                      "citation": "MacConaill LE et al., 2014, Prospective enterprise-level molecular genotyping of a cohort of cancer patients., J Mol Diagn",
                      "pmid": 25157968
                    },
                    {
                      "citation": "Andrulis M et al., 2013, Targeting the BRAF V600E mutation in multiple myeloma., Cancer Discov",
                      "pmid": 23612012
                    },
                    {
                      "citation": "Falchook GS et al., 2012, Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial., Lancet Oncol",
                      "pmid": 22805292
                    },
                    {
                      "citation": "Kurman RJ et al., 2011, Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm., Hum Pathol",
                      "pmid": 21683865
                    },
                    {
                      "citation": "Coffee EM et al., 2013, Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer., Clin Cancer Res",
                      "pmid": 23549875
                    },
                    {
                      "citation": "Flaherty KT et al., 2012, Improved survival with MEK inhibition in BRAF-mutated melanoma., N Engl J Med",
                      "pmid": 22663011
                    },
                    {
                      "citation": "Wan PT et al., 2004, Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF., Cell",
                      "pmid": 15035987
                    },
                    {
                      "citation": "De Roock W et al., 2011, KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer., Lancet Oncol",
                      "pmid": 21163703
                    },
                    {
                      "citation": "Ascierto PA et al., 2013, Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma., J Clin Oncol",
                      "pmid": 23918947
                    },
                    {
                      "citation": "Chang MT et al., 2016, Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity., Nat Biotechnol",
                      "pmid": 26619011
                    },
                    {
                      "citation": "Hayes DN et al., 2012, Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements., Clin Cancer Res",
                      "pmid": 22241789
                    },
                    {
                      "citation": "Zecchin D et al., 2013, BRAF V600E is a determinant of sensitivity to proteasome inhibitors., Mol Cancer Ther",
                      "pmid": 24107445
                    },
                    {
                      "citation": "Nissan MH et al., 2014, Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence., Cancer Res",
                      "pmid": 24576830
                    },
                    {
                      "citation": "Lam ET et al., 2010, Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer., J Clin Oncol",
                      "pmid": 20368568
                    },
                    {
                      "citation": "Patel SP et al., 2013, Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma., Cancer",
                      "pmid": 22972589
                    },
                    {
                      "citation": "Sen B et al., 2012, Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib., Sci Transl Med",
                      "pmid": 22649091
                    },
                    {
                      "citation": "Morris EJ et al., 2013, Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors., Cancer Discov",
                      "pmid": 23614898
                    },
                    {
                      "citation": "Tol J et al., 2010, Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab., Eur J Cancer",
                      "pmid": 20413299
                    },
                    {
                      "citation": "Chapman PB et al., 2011, Improved survival with vemurafenib in melanoma with BRAF V600E mutation., N Engl J Med",
                      "pmid": 21639808
                    },
                    {
                      "citation": "Sarker D et al., 2015, First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors., Clin Cancer Res",
                      "pmid": 25370471
                    },
                    {
                      "citation": "Crescenzi A et al., 2014, Immunohistochemistry for BRAF(V600E) antibody VE1 performed in core needle biopsy samples identifies mutated papillary thyroid cancers., Horm Metab Res",
                      "pmid": 24570209
                    },
                    {
                      "citation": "Dienstmann R et al., 2011, BRAF as a target for cancer therapy., Anticancer Agents Med Chem",
                      "pmid": 21426297
                    },
                    {
                      "citation": "Kim KB et al., 2013, Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation., Thyroid",
                      "pmid": 23489023
                    },
                    {
                      "citation": "Rubinstein JC et al., 2010, Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032., J Transl Med",
                      "pmid": 20630094
                    },
                    {
                      "citation": "Rudin CM et al., 2013, Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer., J Thorac Oncol",
                      "pmid": 23524406
                    },
                    {
                      "citation": "Boulalas I et al., 2009, Mutational analysis of the BRAF gene in transitional cell carcinoma of the bladder., Int J Biol Markers",
                      "pmid": 19404918
                    },
                    {
                      "citation": "Prahallad A et al., 2012, Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR., Nature",
                      "pmid": 22281684
                    },
                    {
                      "citation": "Hauschild A et al., 2012, Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial., Lancet",
                      "pmid": 22735384
                    },
                    {
                      "citation": "Gandhi J et al., 2009, Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines., PLoS One",
                      "pmid": 19238210
                    },
                    {
                      "citation": "Jalili A et al., 2012, Dual suppression of the cyclin-dependent kinase inhibitors CDKN2C and CDKN1A in human melanoma., J Natl Cancer Inst",
                      "pmid": 22997239
                    },
                    {
                      "citation": "Flaherty KT et al., 2012, Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations., N Engl J Med",
                      "pmid": 23020132
                    },
                    {
                      "citation": "Greger JG et al., 2012, Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations., Mol Cancer Ther",
                      "pmid": 22389471
                    },
                    {
                      "citation": "Cardarella S et al., 2013, Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer., Clin Cancer Res",
                      "pmid": 23833300
                    },
                    {
                      "citation": "Meckbach D et al., 2014, BRAF-V600 mutations have no prognostic impact in stage IV melanoma patients treated with monochemotherapy., PLoS One",
                      "pmid": 24586605
                    },
                    {
                      "citation": "Kirkwood JM et al., 2012, Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma., Clin Cancer Res",
                      "pmid": 22048237
                    },
                    {
                      "citation": "Paraiso KH et al., 2012, The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms., Clin Cancer Res",
                      "pmid": 22351686
                    },
                    {
                      "citation": "Ponti G et al., 2012, Overwhelming response to Dabrafenib in a patient with double BRAF mutation (V600E; V600M) metastatic malignant melanoma., J Hematol Oncol",
                      "pmid": 23031422
                    },
                    {
                      "citation": "Kloos RT et al., 2009, Phase II trial of sorafenib in metastatic thyroid cancer., J Clin Oncol",
                      "pmid": 19255327
                    },
                    {
                      "citation": "Agaimy A et al., 2009, V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours., J Clin Pathol",
                      "pmid": 19561230
                    },
                    {
                      "citation": "Faber AC et al., 2014, mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1., Cancer Discov",
                      "pmid": 24163374
                    },
                    {
                      "citation": "Howell GM et al., 2011, Both BRAF V600E mutation and older age ( 65 years) are associated with recurrent papillary thyroid cancer., Ann Surg Oncol",
                      "pmid": 21594703
                    },
                    {
                      "citation": "Tejpar S et al., 2010, Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery., Oncologist",
                      "pmid": 20350999
                    },
                    {
                      "citation": "Corcoran RB et al., 2012, EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib., Cancer Discov",
                      "pmid": 22448344
                    },
                    {
                      "citation": "De Roock W et al., 2010, Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis., Lancet Oncol",
                      "pmid": 20619739
                    },
                    {
                      "citation": "Tiacci E et al., 2011, BRAF mutations in hairy-cell leukemia., N Engl J Med",
                      "pmid": 21663470
                    },
                    {
                      "citation": "Haldar K et al., 2011, Epidermal growth factor receptor blockers for the treatment of ovarian cancer., Cochrane Database Syst Rev",
                      "pmid": 21975775
                    },
                    {
                      "citation": "Rowland A et al., 2015, Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer., Br J Cancer",
                      "pmid": 25989278
                    },
                    {
                      "citation": "De Roock W et al., 2009, Clinical biomarkers in oncology: focus on colorectal cancer., Mol Diagn Ther",
                      "pmid": 19537845
                    },
                    {
                      "citation": "Rad R et al., 2013, A genetic progression model of Braf(V600E)-induced intestinal tumorigenesis reveals targets for therapeutic intervention., Cancer Cell",
                      "pmid": 23845441
                    },
                    {
                      "citation": "Mao C et al., 2011, BRAF V600E mutation and resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer: a meta-analysis., Mol Biol Rep",
                      "pmid": 20857202
                    },
                    {
                      "citation": "McArthur GA et al., 2014, Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study., Lancet Oncol",
                      "pmid": 24508103
                    },
                    {
                      "citation": "Yang H et al., 2012, Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer., Cancer Res",
                      "pmid": 22180495
                    },
                    {
                      "citation": "Pratilas CA et al., 2008, Genetic predictors of MEK dependence in non-small cell lung cancer., Cancer Res",
                      "pmid": 19010912
                    },
                    {
                      "citation": "Peeters M et al., 2013, Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer., Clin Cancer Res",
                      "pmid": 23325582
                    },
                    {
                      "citation": "Hatzivassiliou G et al., 2013, Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers., Nature",
                      "pmid": 23934108
                    },
                    {
                      "citation": "Huillard E et al., 2012, Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy., Proc Natl Acad Sci U S A",
                      "pmid": 22586120
                    },
                    {
                      "citation": "Nakayama N et al., 2008, KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer., Br J Cancer",
                      "pmid": 19018267
                    },
                    {
                      "citation": "Mao M et al., 2013, Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents., Clin Cancer Res",
                      "pmid": 23251002
                    },
                    {
                      "citation": "Falchook GS et al., 2013, BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance., Oncotarget",
                      "pmid": 23470635
                    },
                    {
                      "citation": "Di Nicolantonio F et al., 2008, Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer., J Clin Oncol",
                      "pmid": 19001320
                    },
                    {
                      "citation": "Lovly CM et al., 2012, Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials., PLoS One",
                      "pmid": 22536370
                    },
                    {
                      "citation": "Rizzo S et al., 2010, Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?, Cancer Treat Rev",
                      "pmid": 21129611
                    },
                    {
                      "citation": "Ji Z et al., 2013, Vemurafenib synergizes with nutlin-3 to deplete survivin and suppresses melanoma viability and tumor growth., Clin Cancer Res",
                      "pmid": 23812671
                    },
                    {
                      "citation": "Ho AL et al., 2013, Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer., N Engl J Med",
                      "pmid": 23406027
                    },
                    {
                      "citation": "Gupta-Abramson V et al., 2008, Phase II trial of sorafenib in advanced thyroid cancer., J Clin Oncol",
                      "pmid": 18541894
                    },
                    {
                      "citation": "Menzies AM et al., 2014, Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma., Clin Cancer Res",
                      "pmid": 24583796
                    },
                    {
                      "citation": "Brose MS et al., 2002, BRAF and RAS mutations in human lung cancer and melanoma., Cancer Res",
                      "pmid": 12460918
                    },
                    {
                      "citation": "Sosman JA et al., 2012, Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib., N Engl J Med",
                      "pmid": 22356324
                    },
                    {
                      "citation": "Villanueva J et al., 2010, Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K., Cancer Cell",
                      "pmid": 21156289
                    },
                    {
                      "citation": "Maldonado JL et al., 2003, Determinants of BRAF mutations in primary melanomas., J Natl Cancer Inst",
                      "pmid": 14679157
                    },
                    {
                      "citation": "Nagore E et al., 2014, Prognostic value of BRAF mutations in localized cutaneous melanoma., J Am Acad Dermatol",
                      "pmid": 24388723
                    },
                    {
                      "citation": "Hoftijzer H et al., 2009, Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma., Eur J Endocrinol",
                      "pmid": 19773371
                    },
                    {
                      "citation": "He G et al., 2014, Prognostic value of the BRAF V600E mutation in papillary thyroid carcinoma., Oncol Lett",
                      "pmid": 24396464
                    },
                    {
                      "citation": "Walczyk A et al., 2014, The BRAF(V600E) mutation in papillary thyroid microcarcinoma: does the mutation have an impact on clinical outcome?, Clin Endocrinol (Oxf)",
                      "pmid": 24354346
                    },
                    {
                      "citation": "Nicolaides TP et al., 2011, Targeted therapy for BRAFV600E malignant astrocytoma., Clin Cancer Res",
                      "pmid": 22038996
                    },
                    {
                      "citation": "Penna I et al., 2016, Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade., Oncotarget",
                      "pmid": 26678033
                    },
                    {
                      "citation": "Dienstmann R et al., 2015, Database of genomic biomarkers for cancer drugs and clinical targetability in solid tumors., Cancer Discov",
                      "pmid": 25656898
                    }
                  ],
                  "source": {
                    "sourceDbName": "DoCM"
                  }
                },
                {
                  "publications": [
                    {
                      "citation": "Bahadoran P et al., 2013, Major clinical response to a BRAF inhibitor in a patient with a BRAF L597R-mutated melanoma., J Clin Oncol",
                      "pmid": 23715574
                    },
                    {
                      "citation": "Karoulia Z et al., 2016, An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling., Cancer Cell",
                      "pmid": 27523909
                    },
                    {
                      "citation": "Johnson AE et al., 2023, Case report: A case of classic hairy cell leukemia with CNS involvement treated with vemurafenib., Front Oncol",
                      "pmid": 36713531
                    },
                    {
                      "citation": "Tiacci E et al., 2015, Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia., N Engl J Med",
                      "pmid": 26352686
                    },
                    {
                      "citation": "Subbiah V et al., 2020, Pan-Cancer Efficacy of Vemurafenib in BRAF (V600)-Mutant Non-Melanoma Cancers., Cancer Discov",
                      "pmid": 32029534
                    },
                    {
                      "citation": "Hainsworth JD et al., 2018, Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study., J Clin Oncol",
                      "pmid": 29320312
                    },
                    {
                      "citation": "Allen A et al., 2019, Rare BRAF mutations in pancreatic neuroendocrine tumors may predict response to RAF and MEK inhibition., PLoS One",
                      "pmid": 31158244
                    },
                    {
                      "citation": "Flaherty KT et al., 2010, Inhibition of mutated, activated BRAF in metastatic melanoma., N Engl J Med",
                      "pmid": 20818844
                    },
                    {
                      "citation": "Chapman PB et al., 2017, Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study., Ann Oncol",
                      "pmid": 28961848
                    },
                    {
                      "citation": "Chapman PB et al., 2011, Improved survival with vemurafenib in melanoma with BRAF V600E mutation., N Engl J Med",
                      "pmid": 21639808
                    },
                    {
                      "citation": "Leaver KE et al., 2016, Response of metastatic glioma to vemurafenib., Neurooncol Pract",
                      "pmid": 31386052
                    },
                    {
                      "citation": "Woo PYM et al., 2019, Regression of BRAF (V600E) mutant adult glioblastoma after primary combined BRAF-MEK inhibitor targeted therapy: a report of two cases., Oncotarget",
                      "pmid": 31217909
                    },
                    {
                      "citation": "Kaley T et al., 2018, BRAF Inhibition in BRAF(V600)-Mutant Gliomas: Results From the VE-BASKET Study., J Clin Oncol",
                      "pmid": 30351999
                    },
                    {
                      "citation": "Peters S et al., 2013, Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma., J Clin Oncol",
                      "pmid": 23733758
                    },
                    {
                      "citation": "Gautschi O et al., 2015, Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort., J Thorac Oncol",
                      "pmid": 26200454
                    },
                    {
                      "citation": "Brose MS et al., 2016, Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial., Lancet Oncol",
                      "pmid": 27460442
                    },
                    {
                      "citation": "Banerjee N et al., 2016, A Rare Finding of a BRAF Mutation in Renal Cell Carcinoma with Response to BRAF-Directed Targeted Therapy., Cureus",
                      "pmid": 26918217
                    },
                    {
                      "citation": "Combe P et al., 2015, Sustained response to vemurafenib in a low grade serous ovarian cancer with a BRAF V600E mutation., Invest New Drugs",
                      "pmid": 26490654
                    },
                    {
                      "citation": "Anchisi S et al., 2023, Deep and lasting response and acquired resistance to BRAFV600E targeting in a low-grade ovarian cancer patient., Cancer Biol Ther",
                      "pmid": 36967525
                    },
                    {
                      "citation": "Kopetz S et al., 2015, Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer., J Clin Oncol",
                      "pmid": 26460303
                    },
                    {
                      "citation": "Oddo D et al., 2016, Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer., Cancer Res",
                      "pmid": 27312529
                    },
                    {
                      "citation": "Prahallad A et al., 2012, Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR., Nature",
                      "pmid": 22281684
                    },
                    {
                      "citation": "Kurzrock R et al., 2020, Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study., Ann Oncol",
                      "pmid": 32067683
                    },
                    {
                      "citation": "Lang M et al., 2023, Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer., Thyroid Res",
                      "pmid": 36855200
                    },
                    {
                      "citation": "Lin Z et al., 2022, Effective treatment of a BRAF V600E-mutant epithelioid glioblastoma patient by vemurafenib: a case report., Anticancer Drugs",
                      "pmid": 34232949
                    },
                    {
                      "citation": "Kopetz S et al., 2021, Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406)., J Clin Oncol",
                      "pmid": 33356422
                    },
                    {
                      "citation": "Yang H et al., 2012, Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer., Cancer Res",
                      "pmid": 22180495
                    },
                    {
                      "citation": "Ascierto PA et al., 2016, Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial., Lancet Oncol",
                      "pmid": 27480103
                    },
                    {
                      "citation": "Li HS et al., 2021, Remarkable response of BRAF (V600E)-mutated metastatic pancreatic cancer to BRAF/MEK inhibition: a case report., Gastroenterol Rep (Oxf)",
                      "pmid": 35382161
                    },
                    {
                      "citation": "Hoes LR et al., 2022, Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment., Clin Cancer Res",
                      "pmid": 35046062
                    },
                    {
                      "citation": "Bernocchi O et al., 2021, Tumor Type Agnostic Therapy Carrying BRAF Mutation: Case Reports and Review of Literature., Pharmaceuticals (Basel)",
                      "pmid": 33669326
                    },
                    {
                      "citation": "Klute KA et al., 2022, Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study., JCO Precis Oncol",
                      "pmid": 36409971
                    },
                    {
                      "citation": "Kirouac DC et al., 2017, Clinical responses to ERK inhibition in BRAF(V600E)-mutant colorectal cancer predicted using a computational model., NPJ Syst Biol Appl",
                      "pmid": 28649441
                    },
                    {
                      "citation": "Montero-Conde C et al., 2013, Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas., Cancer Discov",
                      "pmid": 23365119
                    },
                    {
                      "citation": "Corcoran RB et al., 2012, EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib., Cancer Discov",
                      "pmid": 22448344
                    },
                    {
                      "citation": "Tan L et al., 2023, A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study., Clin Cancer Res",
                      "pmid": 36638198
                    },
                    {
                      "citation": "Connolly K et al., 2014, Anticancer activity of combination targeted therapy using cetuximab plus vemurafenib for refractory BRAF (V600E)-mutant metastatic colorectal carcinoma., Curr Oncol",
                      "pmid": 24523613
                    },
                    {
                      "citation": "Yaeger R et al., 2015, Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients., Clin Cancer Res",
                      "pmid": 25589621
                    },
                    {
                      "citation": "Feng Y et al., 2015, SBI-0640756 Attenuates the Growth of Clinically Unresponsive Melanomas by Disrupting the eIF4F Translation Initiation Complex., Cancer Res",
                      "pmid": 26603897
                    },
                    {
                      "citation": "Lin L et al., 2015, The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies., Nat Genet",
                      "pmid": 25665005
                    },
                    {
                      "citation": "Feng JH et al., 2016, A Novel Plant Sesquiterpene Lactone Derivative, DETD-35, Suppresses BRAFV600E Mutant Melanoma Growth and Overcomes Acquired Vemurafenib Resistance in Mice., Mol Cancer Ther",
                      "pmid": 27048951
                    },
                    {
                      "citation": "Klempner SJ et al., 2016, BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy., Cancer Discov",
                      "pmid": 27048246
                    },
                    {
                      "citation": "Wang Z et al., 2022, Vemurafenib Combined With Trametinib Significantly Benefits the Survival of a Patient With Stage IV Pancreatic Ductal Adenocarcinoma With BRAF V600E Mutation: A Case Report., Front Oncol",
                      "pmid": 35145907
                    },
                    {
                      "citation": "Peh J et al., 2016, The Combination of Vemurafenib and Procaspase-3 Activation Is Synergistic in Mutant BRAF Melanomas., Mol Cancer Ther",
                      "pmid": 27297867
                    },
                    {
                      "citation": "Ghosh C et al., 2020, A Combinatorial Strategy for Targeting BRAF (V600E)-Mutant Cancers with BRAF(V600E) Inhibitor (PLX4720) and Tyrosine Kinase Inhibitor (Ponatinib)., Clin Cancer Res",
                      "pmid": 31937621
                    },
                    {
                      "citation": "Tiacci E et al., 2021, Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia., N Engl J Med",
                      "pmid": 33979489
                    },
                    {
                      "citation": "Munck JM et al., 2021, ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK., Mol Cancer Ther",
                      "pmid": 34330842
                    },
                    {
                      "citation": "Schreck KC et al., 2021, Deconvoluting Mechanisms of Acquired Resistance to RAF Inhibitors in BRAF(V600E)-Mutant Human Glioma., Clin Cancer Res",
                      "pmid": 34433654
                    },
                    {
                      "citation": "Wang L et al., 2022, BRAF V600E Mutation in Triple-Negative Breast Cancer: A Case Report and Literature Review., Oncol Res Treat",
                      "pmid": 34818649
                    },
                    {
                      "citation": "Tran KB et al., 2022, Response to BRAF-targeted Therapy Is Enhanced by Cotargeting VEGFRs or WNT/-Catenin Signaling in BRAF-mutant Colorectal Cancer Models., Mol Cancer Ther",
                      "pmid": 36198029
                    },
                    {
                      "citation": "Jenkins LJ et al., 2023, Genotype-Tailored ERK/MAPK Pathway and HDAC Inhibition Rewires the Apoptotic Rheostat to Trigger Colorectal Cancer Cell Death., Mol Cancer Ther",
                      "pmid": 36343387
                    },
                    {
                      "citation": "Ruiz-Saenz A et al., 2023, A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAF(V600E) colorectal tumors., Nat Cancer",
                      "pmid": 36759733
                    },
                    {
                      "citation": "Nassar KW et al., 2021, Targeting CDK4/6 Represents a Therapeutic Vulnerability in Acquired BRAF/MEK Inhibitor-Resistant Melanoma., Mol Cancer Ther",
                      "pmid": 34376578
                    },
                    {
                      "citation": "Nazarian R et al., 2010, Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation., Nature",
                      "pmid": 21107323
                    },
                    {
                      "citation": "Yaeger R et al., 2017, Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition., Cancer Res",
                      "pmid": 28951457
                    },
                    {
                      "citation": "Hoogstraat M et al., 2015, Detailed imaging and genetic analysis reveal a secondary BRAF(L505H) resistance mutation and extensive intrapatient heterogeneity in metastatic BRAF mutant melanoma patients treated with vemurafenib., Pigment Cell Melanoma Res",
                      "pmid": 25515853
                    },
                    {
                      "citation": "Wagle N et al., 2011, Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling., J Clin Oncol",
                      "pmid": 21383288
                    },
                    {
                      "citation": "Brady DC et al., 2017, Copper Chelation Inhibits BRAF(V600E)-Driven Melanomagenesis and Counters Resistance to BRAF(V600E) and MEK1/2 Inhibitors., Cancer Res",
                      "pmid": 28986383
                    },
                    {
                      "citation": "Narita Y et al., 2014, Novel ATP-competitive MEK inhibitor E6201 is effective against vemurafenib-resistant melanoma harboring the MEK1-C121S mutation in a preclinical model., Mol Cancer Ther",
                      "pmid": 24448821
                    },
                    {
                      "citation": "Herrero A et al., 2015, Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes., Cancer Cell",
                      "pmid": 26267534
                    },
                    {
                      "citation": "Emery CM et al., 2017, BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity., Mol Cancer Res",
                      "pmid": 28655712
                    },
                    {
                      "citation": "Mizuno S et al., 2023, High-Throughput Functional Evaluation of MAP2K1 Variants in Cancer., Mol Cancer Ther",
                      "pmid": 36442478
                    },
                    {
                      "citation": "Greger JG et al., 2012, Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations., Mol Cancer Ther",
                      "pmid": 22389471
                    },
                    {
                      "citation": "Zick A et al., 2017, Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients., Medicine (Baltimore)",
                      "pmid": 28514312
                    },
                    {
                      "citation": "Van Allen EM et al., 2014, The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma., Cancer Discov",
                      "pmid": 24265153
                    },
                    {
                      "citation": "Wang J et al., 2018, A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAF(V600E)-Mutant Brain Tumor., Cancer Discov",
                      "pmid": 29880583
                    },
                    {
                      "citation": "Caeser R et al., 2019, Targeting MEK in vemurafenib-resistant hairy cell leukemia., Leukemia",
                      "pmid": 30341394
                    },
                    {
                      "citation": "Mologni L et al., 2018, Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells., Neoplasia",
                      "pmid": 29605720
                    },
                    {
                      "citation": "Olbryt M et al., 2020, Genetic Profiling of Advanced Melanoma: Candidate Mutations for Predicting Sensitivity and Resistance to Targeted Therapy., Target Oncol",
                      "pmid": 31980996
                    },
                    {
                      "citation": "Yao Z et al., 2019, RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling., Nat Med",
                      "pmid": 30559419
                    },
                    {
                      "citation": "Ortiz-Cuaran S et al., 2020, Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with BRAF-Mutant Metastatic Non-Small Cell Lung Cancer., Clin Cancer Res",
                      "pmid": 32859654
                    },
                    {
                      "citation": "Louveau B et al., 2021, Phase I-II Open-Label Multicenter Study of Palbociclib + Vemurafenib in BRAF (V600MUT) Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism., Clin Cancer Res",
                      "pmid": 33947696
                    },
                    {
                      "citation": "Foster SA et al., 2016, Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2., Cancer Cell",
                      "pmid": 26996308
                    },
                    {
                      "citation": "Jiang J et al., 2021, Case Report: Vemurafenib Treatment in Brain Metastases of BRAF(S365L) -Mutant Lung Papillary Cancer by Genetic Sequencing of Cerebrospinal Fluid Circulating Tumor DNA Detection., Front Oncol",
                      "pmid": 34178685
                    },
                    {
                      "citation": "Mazieres J et al., 2020, Vemurafenib in non-small-cell lung cancer patients with BRAF(V600) and BRAF(nonV600) mutations., Ann Oncol",
                      "pmid": 31959346
                    },
                    {
                      "citation": "Kotschy A et al., 2016, The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models., Nature",
                      "pmid": 27760111
                    },
                    {
                      "citation": "Budina-Kolomets A et al., 2016, HSP70 Inhibition Limits FAK-Dependent Invasion and Enhances the Response to Melanoma Treatment with BRAF Inhibitors., Cancer Res",
                      "pmid": 26984758
                    },
                    {
                      "citation": "Sinik L et al., 2019, Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma., Mol Cancer Ther",
                      "pmid": 30482852
                    },
                    {
                      "citation": "Bonnevaux H et al., 2016, Concomitant Inhibition of PI3K and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3K-Selective Inhibitor., Mol Cancer Ther",
                      "pmid": 27196754
                    },
                    {
                      "citation": "Eroglu Z et al., 2018, Combined BRAF and HSP90 Inhibition in Patients with Unresectable BRAF (V600E)-Mutant Melanoma., Clin Cancer Res",
                      "pmid": 29674508
                    },
                    {
                      "citation": "Sweetlove M et al., 2015, Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth., Front Oncol",
                      "pmid": 26137449
                    },
                    {
                      "citation": "Yam C et al., 2018, A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid Tumors., Clin Cancer Res",
                      "pmid": 29051322
                    },
                    {
                      "citation": "Joshi M et al., 2015, Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer., PLoS One",
                      "pmid": 25706985
                    },
                    {
                      "citation": "Negrao MV et al., 2020, Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations., J Thorac Oncol",
                      "pmid": 32540409
                    },
                    {
                      "citation": "Yao Z et al., 2015, BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition., Cancer Cell",
                      "pmid": 26343582
                    },
                    {
                      "citation": "Dankner M et al., 2018, Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas., Clin Cancer Res",
                      "pmid": 29903896
                    },
                    {
                      "citation": "Moiseyenko FV et al., 2019, Lack of Response to Vemurafenib in Melanoma Carrying BRAF K601E Mutation., Case Rep Oncol",
                      "pmid": 31182949
                    },
                    {
                      "citation": "Dahlman KB et al., 2012, BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors., Cancer Discov",
                      "pmid": 22798288
                    },
                    {
                      "citation": "Yao Z et al., 2017, Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS., Nature",
                      "pmid": 28783719
                    },
                    {
                      "citation": "Hyman DM et al., 2015, Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations., N Engl J Med",
                      "pmid": 26287849
                    },
                    {
                      "citation": "Sullivan RJ et al., 2019, Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients., Nat Med",
                      "pmid": 31171876
                    },
                    {
                      "citation": "Shi H et al., 2014, A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition., Cancer Discov",
                      "pmid": 24265152
                    },
                    {
                      "citation": "Michielin O et al., 2019, Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up., Ann Oncol",
                      "pmid": 31566661
                    },
                    {
                      "citation": "Gutzmer R et al., 2020, Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF(V600) mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial., Lancet",
                      "pmid": 32534646
                    },
                    {
                      "citation": "Peng SB et al., 2015, Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers., Cancer Cell",
                      "pmid": 26343583
                    },
                    {
                      "citation": "Kordes M et al., 2016, Cooperation of BRAF(F595L) and mutant HRAS in histiocytic sarcoma provides new insights into oncogenic BRAF signaling., Leukemia",
                      "pmid": 26582644
                    },
                    {
                      "citation": "Choi J et al., 2014, Identification of PLX4032-resistance mechanisms and implications for novel RAF inhibitors., Pigment Cell Melanoma Res",
                      "pmid": 24283590
                    },
                    {
                      "citation": "Yap J et al., 2021, The stability of R-spine defines RAF inhibitor resistance: A comprehensive analysis of oncogenic BRAF mutants with in-frame insertion of C-4 loop., Sci Adv",
                      "pmid": 34108213
                    },
                    {
                      "citation": "Gautschi O et al., 2013, Lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenib., Lung Cancer",
                      "pmid": 24035431
                    },
                    {
                      "citation": "Khater F et al., 2019, Recurrent somatic BRAF insertion (p.V504_R506dup): a tumor marker and a potential therapeutic target in pilocytic astrocytoma., Oncogene",
                      "pmid": 30575814
                    },
                    {
                      "citation": "Chen SH et al., 2016, Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120., Cancer Discov",
                      "pmid": 26732095
                    },
                    {
                      "citation": "Oberl M et al., 2022, Response to BRAF and MEK Inhibitors in BRAF Thr599dup-Mutated Melanoma., JCO Precis Oncol",
                      "pmid": 35319964
                    },
                    {
                      "citation": "Lobo-Martins S et al., 2021, BRAF L597K mutation: an opportunity to treat., Dermatol Online J",
                      "pmid": 33560788
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TTD"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "CIViC"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "MyCancerGenome"
                  }
                },
                {
                  "publications": [
                    {
                      "citation": "Gautschi O et al., 2012, A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib., J Thorac Oncol",
                      "pmid": 22743296
                    },
                    {
                      "citation": "Dietrich S et al., 2012, BRAF inhibition in refractory hairy-cell leukemia., N Engl J Med",
                      "pmid": 22621641
                    },
                    {
                      "citation": "Andrulis M et al., 2013, Targeting the BRAF V600E mutation in multiple myeloma., Cancer Discov",
                      "pmid": 23612012
                    },
                    {
                      "citation": "Falchook GS et al., 2012, Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial., Lancet",
                      "pmid": 22608338
                    },
                    {
                      "citation": "Flaherty KT et al., 2010, Inhibition of mutated, activated BRAF in metastatic melanoma., N Engl J Med",
                      "pmid": 20818844
                    },
                    {
                      "citation": "Kim KB et al., 2013, Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation., Thyroid",
                      "pmid": 23489023
                    },
                    {
                      "citation": "Whittaker SR et al., 2013, A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition., Cancer Discov",
                      "pmid": 23288408
                    },
                    {
                      "citation": "Savarese JJ et al., 1979, beta-Adrenergic receptor decrease in diabetic rat hearts., Life Sci",
                      "pmid": 231718
                    }
                  ],
                  "source": {
                    "sourceDbName": "CGI"
                  }
                },
                {
                  "publications": [
                    {
                      "citation": "Yang W et al., 2015, Design, synthesis and biological evaluation of bis-aryl ureas and amides based on 2-amino-3-purinylpyridine scaffold as DFG-out B-Raf kinase inhibitors., Eur J Med Chem",
                      "pmid": 25462267
                    }
                  ],
                  "source": {
                    "sourceDbName": "DTC"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Response Type",
                  "value": "predicted - resistant"
                },
                {
                  "name": "Response Type",
                  "value": "resistant"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical"
                },
                {
                  "name": "Indication",
                  "value": "Advanced Solid Tumor"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Indication",
                  "value": "melanoma"
                }
              ],
              "drug": {
                "name": "SB590885",
                "approved": false
              },
              "interactionScore": 0.9940458521808363,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Karoulia Z et al., 2016, An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling., Cancer Cell",
                      "pmid": 27523909
                    },
                    {
                      "citation": "Whittaker S et al., 2010, Gatekeeper mutations mediate resistance to BRAF-targeted therapies., Sci Transl Med",
                      "pmid": 20538618
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Combination Therapy",
                  "value": "Vemurafenib + Panitumumab"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Panitumumab + Dabrafenib + Trametinib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Fluorouracil + Irinotecan + Leucovorin + Panitumumab"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Fluorouracil + Leucovorin + Oxaliplatin + Panitumumab"
                },
                {
                  "name": "Response Type",
                  "value": "not predictive"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Irinotecan + Panitumumab"
                },
                {
                  "name": "Approval Status",
                  "value": "Case Reports/Case Series"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - resistant"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Celecoxib + Encorafenib + Panitumumab"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Pdx"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Celecoxib + Dabrafenib + Panitumumab + Trametinib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Dabrafenib + Panitumumab + Trametinib"
                },
                {
                  "name": "Response Type",
                  "value": "no benefit"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Panitumumab + Trametinib"
                },
                {
                  "name": "Approval Status",
                  "value": "Phase Ib/II"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Dabrafenib + Panitumumab"
                },
                {
                  "name": "Approval Status",
                  "value": "Phase I"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Panitumumab + Vemurafenib"
                },
                {
                  "name": "Indication",
                  "value": "rectum cancer"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Approval Status",
                  "value": "Guideline"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                },
                {
                  "name": "Indication",
                  "value": "colon cancer"
                },
                {
                  "name": "Approval Status",
                  "value": "Clinical Study"
                },
                {
                  "name": "Response Type",
                  "value": "decreased response"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Binimetinib + Panitumumab"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Encorafenib + Panitumumab"
                },
                {
                  "name": "Indication",
                  "value": "colorectal cancer"
                },
                {
                  "name": "Response Type",
                  "value": "resistant"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Panitumumab;Dabrafenib;BYL719"
                },
                {
                  "name": "Alteration",
                  "value": "BRAF:V600."
                },
                {
                  "name": "Combination Therapy",
                  "value": "Panitumumab;Dabrafenib;Trametinib"
                },
                {
                  "name": "Alteration",
                  "value": "BRAF:V600E"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Vemurafenib;Panitumumab"
                },
                {
                  "name": "Alteration",
                  "value": "MET:amp;BRAF:V600E"
                },
                {
                  "name": "Approval Status",
                  "value": "late trials"
                },
                {
                  "name": "Pathway",
                  "value": "activation"
                },
                {
                  "name": "Variant Effect",
                  "value": "gain-of-function"
                }
              ],
              "drug": {
                "name": "PANITUMUMAB",
                "approved": true
              },
              "interactionScore": 1.743940091545326,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "De Roock W et al., 2010, Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis., Lancet Oncol",
                      "pmid": 20619739
                    },
                    {
                      "citation": "De Roock W et al., 2011, KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer., Lancet Oncol",
                      "pmid": 21163703
                    },
                    {
                      "citation": "Peeters M et al., 2013, Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer., Clin Cancer Res",
                      "pmid": 23325582
                    }
                  ],
                  "source": {
                    "sourceDbName": "CGI"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "OncoKB"
                  }
                },
                {
                  "publications": [
                    {
                      "citation": "Davies H et al., 2002, Mutations of the BRAF gene in human cancer., Nature",
                      "pmid": 12068308
                    },
                    {
                      "citation": "Gautschi O et al., 2012, A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib., J Thorac Oncol",
                      "pmid": 22743296
                    },
                    {
                      "citation": "Xing M et al., 2014, BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence., J Clin Oncol",
                      "pmid": 25024077
                    },
                    {
                      "citation": "Naoki K et al., 2002, Missense mutations of the BRAF gene in human lung adenocarcinoma., Cancer Res",
                      "pmid": 12460919
                    },
                    {
                      "citation": "Paik PK et al., 2011, Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations., J Clin Oncol",
                      "pmid": 21483012
                    },
                    {
                      "citation": "Falchook GS et al., 2012, Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial., Lancet",
                      "pmid": 22608338
                    },
                    {
                      "citation": "Ohashi K et al., 2012, Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1., Proc Natl Acad Sci U S A",
                      "pmid": 22773810
                    },
                    {
                      "citation": "Flaherty KT et al., 2010, Inhibition of mutated, activated BRAF in metastatic melanoma., N Engl J Med",
                      "pmid": 20818844
                    },
                    {
                      "citation": "Chen D et al., 2014, BRAFV600E mutation and its association with clinicopathological features of colorectal cancer: a systematic review and meta-analysis., PLoS One",
                      "pmid": 24594804
                    },
                    {
                      "citation": "MacConaill LE et al., 2014, Prospective enterprise-level molecular genotyping of a cohort of cancer patients., J Mol Diagn",
                      "pmid": 25157968
                    },
                    {
                      "citation": "Andrulis M et al., 2013, Targeting the BRAF V600E mutation in multiple myeloma., Cancer Discov",
                      "pmid": 23612012
                    },
                    {
                      "citation": "Falchook GS et al., 2012, Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial., Lancet Oncol",
                      "pmid": 22805292
                    },
                    {
                      "citation": "Kurman RJ et al., 2011, Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm., Hum Pathol",
                      "pmid": 21683865
                    },
                    {
                      "citation": "Coffee EM et al., 2013, Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer., Clin Cancer Res",
                      "pmid": 23549875
                    },
                    {
                      "citation": "Flaherty KT et al., 2012, Improved survival with MEK inhibition in BRAF-mutated melanoma., N Engl J Med",
                      "pmid": 22663011
                    },
                    {
                      "citation": "Wan PT et al., 2004, Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF., Cell",
                      "pmid": 15035987
                    },
                    {
                      "citation": "De Roock W et al., 2011, KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer., Lancet Oncol",
                      "pmid": 21163703
                    },
                    {
                      "citation": "Ascierto PA et al., 2013, Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma., J Clin Oncol",
                      "pmid": 23918947
                    },
                    {
                      "citation": "Chang MT et al., 2016, Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity., Nat Biotechnol",
                      "pmid": 26619011
                    },
                    {
                      "citation": "Hayes DN et al., 2012, Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements., Clin Cancer Res",
                      "pmid": 22241789
                    },
                    {
                      "citation": "Zecchin D et al., 2013, BRAF V600E is a determinant of sensitivity to proteasome inhibitors., Mol Cancer Ther",
                      "pmid": 24107445
                    },
                    {
                      "citation": "Nissan MH et al., 2014, Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence., Cancer Res",
                      "pmid": 24576830
                    },
                    {
                      "citation": "Lam ET et al., 2010, Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer., J Clin Oncol",
                      "pmid": 20368568
                    },
                    {
                      "citation": "Patel SP et al., 2013, Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma., Cancer",
                      "pmid": 22972589
                    },
                    {
                      "citation": "Sen B et al., 2012, Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib., Sci Transl Med",
                      "pmid": 22649091
                    },
                    {
                      "citation": "Morris EJ et al., 2013, Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors., Cancer Discov",
                      "pmid": 23614898
                    },
                    {
                      "citation": "Tol J et al., 2010, Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab., Eur J Cancer",
                      "pmid": 20413299
                    },
                    {
                      "citation": "Chapman PB et al., 2011, Improved survival with vemurafenib in melanoma with BRAF V600E mutation., N Engl J Med",
                      "pmid": 21639808
                    },
                    {
                      "citation": "Sarker D et al., 2015, First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors., Clin Cancer Res",
                      "pmid": 25370471
                    },
                    {
                      "citation": "Crescenzi A et al., 2014, Immunohistochemistry for BRAF(V600E) antibody VE1 performed in core needle biopsy samples identifies mutated papillary thyroid cancers., Horm Metab Res",
                      "pmid": 24570209
                    },
                    {
                      "citation": "Dienstmann R et al., 2011, BRAF as a target for cancer therapy., Anticancer Agents Med Chem",
                      "pmid": 21426297
                    },
                    {
                      "citation": "Kim KB et al., 2013, Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation., Thyroid",
                      "pmid": 23489023
                    },
                    {
                      "citation": "Rubinstein JC et al., 2010, Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032., J Transl Med",
                      "pmid": 20630094
                    },
                    {
                      "citation": "Rudin CM et al., 2013, Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer., J Thorac Oncol",
                      "pmid": 23524406
                    },
                    {
                      "citation": "Boulalas I et al., 2009, Mutational analysis of the BRAF gene in transitional cell carcinoma of the bladder., Int J Biol Markers",
                      "pmid": 19404918
                    },
                    {
                      "citation": "Prahallad A et al., 2012, Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR., Nature",
                      "pmid": 22281684
                    },
                    {
                      "citation": "Hauschild A et al., 2012, Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial., Lancet",
                      "pmid": 22735384
                    },
                    {
                      "citation": "Gandhi J et al., 2009, Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines., PLoS One",
                      "pmid": 19238210
                    },
                    {
                      "citation": "Jalili A et al., 2012, Dual suppression of the cyclin-dependent kinase inhibitors CDKN2C and CDKN1A in human melanoma., J Natl Cancer Inst",
                      "pmid": 22997239
                    },
                    {
                      "citation": "Flaherty KT et al., 2012, Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations., N Engl J Med",
                      "pmid": 23020132
                    },
                    {
                      "citation": "Greger JG et al., 2012, Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations., Mol Cancer Ther",
                      "pmid": 22389471
                    },
                    {
                      "citation": "Cardarella S et al., 2013, Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer., Clin Cancer Res",
                      "pmid": 23833300
                    },
                    {
                      "citation": "Meckbach D et al., 2014, BRAF-V600 mutations have no prognostic impact in stage IV melanoma patients treated with monochemotherapy., PLoS One",
                      "pmid": 24586605
                    },
                    {
                      "citation": "Kirkwood JM et al., 2012, Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma., Clin Cancer Res",
                      "pmid": 22048237
                    },
                    {
                      "citation": "Paraiso KH et al., 2012, The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms., Clin Cancer Res",
                      "pmid": 22351686
                    },
                    {
                      "citation": "Ponti G et al., 2012, Overwhelming response to Dabrafenib in a patient with double BRAF mutation (V600E; V600M) metastatic malignant melanoma., J Hematol Oncol",
                      "pmid": 23031422
                    },
                    {
                      "citation": "Kloos RT et al., 2009, Phase II trial of sorafenib in metastatic thyroid cancer., J Clin Oncol",
                      "pmid": 19255327
                    },
                    {
                      "citation": "Agaimy A et al., 2009, V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours., J Clin Pathol",
                      "pmid": 19561230
                    },
                    {
                      "citation": "Faber AC et al., 2014, mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1., Cancer Discov",
                      "pmid": 24163374
                    },
                    {
                      "citation": "Howell GM et al., 2011, Both BRAF V600E mutation and older age ( 65 years) are associated with recurrent papillary thyroid cancer., Ann Surg Oncol",
                      "pmid": 21594703
                    },
                    {
                      "citation": "Tejpar S et al., 2010, Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery., Oncologist",
                      "pmid": 20350999
                    },
                    {
                      "citation": "Corcoran RB et al., 2012, EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib., Cancer Discov",
                      "pmid": 22448344
                    },
                    {
                      "citation": "De Roock W et al., 2010, Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis., Lancet Oncol",
                      "pmid": 20619739
                    },
                    {
                      "citation": "Tiacci E et al., 2011, BRAF mutations in hairy-cell leukemia., N Engl J Med",
                      "pmid": 21663470
                    },
                    {
                      "citation": "Haldar K et al., 2011, Epidermal growth factor receptor blockers for the treatment of ovarian cancer., Cochrane Database Syst Rev",
                      "pmid": 21975775
                    },
                    {
                      "citation": "Rowland A et al., 2015, Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer., Br J Cancer",
                      "pmid": 25989278
                    },
                    {
                      "citation": "De Roock W et al., 2009, Clinical biomarkers in oncology: focus on colorectal cancer., Mol Diagn Ther",
                      "pmid": 19537845
                    },
                    {
                      "citation": "Rad R et al., 2013, A genetic progression model of Braf(V600E)-induced intestinal tumorigenesis reveals targets for therapeutic intervention., Cancer Cell",
                      "pmid": 23845441
                    },
                    {
                      "citation": "Mao C et al., 2011, BRAF V600E mutation and resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer: a meta-analysis., Mol Biol Rep",
                      "pmid": 20857202
                    },
                    {
                      "citation": "McArthur GA et al., 2014, Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study., Lancet Oncol",
                      "pmid": 24508103
                    },
                    {
                      "citation": "Yang H et al., 2012, Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer., Cancer Res",
                      "pmid": 22180495
                    },
                    {
                      "citation": "Pratilas CA et al., 2008, Genetic predictors of MEK dependence in non-small cell lung cancer., Cancer Res",
                      "pmid": 19010912
                    },
                    {
                      "citation": "Peeters M et al., 2013, Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer., Clin Cancer Res",
                      "pmid": 23325582
                    },
                    {
                      "citation": "Hatzivassiliou G et al., 2013, Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers., Nature",
                      "pmid": 23934108
                    },
                    {
                      "citation": "Huillard E et al., 2012, Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy., Proc Natl Acad Sci U S A",
                      "pmid": 22586120
                    },
                    {
                      "citation": "Nakayama N et al., 2008, KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer., Br J Cancer",
                      "pmid": 19018267
                    },
                    {
                      "citation": "Mao M et al., 2013, Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents., Clin Cancer Res",
                      "pmid": 23251002
                    },
                    {
                      "citation": "Falchook GS et al., 2013, BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance., Oncotarget",
                      "pmid": 23470635
                    },
                    {
                      "citation": "Di Nicolantonio F et al., 2008, Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer., J Clin Oncol",
                      "pmid": 19001320
                    },
                    {
                      "citation": "Lovly CM et al., 2012, Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials., PLoS One",
                      "pmid": 22536370
                    },
                    {
                      "citation": "Rizzo S et al., 2010, Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?, Cancer Treat Rev",
                      "pmid": 21129611
                    },
                    {
                      "citation": "Ji Z et al., 2013, Vemurafenib synergizes with nutlin-3 to deplete survivin and suppresses melanoma viability and tumor growth., Clin Cancer Res",
                      "pmid": 23812671
                    },
                    {
                      "citation": "Ho AL et al., 2013, Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer., N Engl J Med",
                      "pmid": 23406027
                    },
                    {
                      "citation": "Gupta-Abramson V et al., 2008, Phase II trial of sorafenib in advanced thyroid cancer., J Clin Oncol",
                      "pmid": 18541894
                    },
                    {
                      "citation": "Menzies AM et al., 2014, Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma., Clin Cancer Res",
                      "pmid": 24583796
                    },
                    {
                      "citation": "Brose MS et al., 2002, BRAF and RAS mutations in human lung cancer and melanoma., Cancer Res",
                      "pmid": 12460918
                    },
                    {
                      "citation": "Sosman JA et al., 2012, Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib., N Engl J Med",
                      "pmid": 22356324
                    },
                    {
                      "citation": "Villanueva J et al., 2010, Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K., Cancer Cell",
                      "pmid": 21156289
                    },
                    {
                      "citation": "Maldonado JL et al., 2003, Determinants of BRAF mutations in primary melanomas., J Natl Cancer Inst",
                      "pmid": 14679157
                    },
                    {
                      "citation": "Nagore E et al., 2014, Prognostic value of BRAF mutations in localized cutaneous melanoma., J Am Acad Dermatol",
                      "pmid": 24388723
                    },
                    {
                      "citation": "Hoftijzer H et al., 2009, Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma., Eur J Endocrinol",
                      "pmid": 19773371
                    },
                    {
                      "citation": "He G et al., 2014, Prognostic value of the BRAF V600E mutation in papillary thyroid carcinoma., Oncol Lett",
                      "pmid": 24396464
                    },
                    {
                      "citation": "Walczyk A et al., 2014, The BRAF(V600E) mutation in papillary thyroid microcarcinoma: does the mutation have an impact on clinical outcome?, Clin Endocrinol (Oxf)",
                      "pmid": 24354346
                    },
                    {
                      "citation": "Nicolaides TP et al., 2011, Targeted therapy for BRAFV600E malignant astrocytoma., Clin Cancer Res",
                      "pmid": 22038996
                    },
                    {
                      "citation": "Penna I et al., 2016, Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade., Oncotarget",
                      "pmid": 26678033
                    }
                  ],
                  "source": {
                    "sourceDbName": "DoCM"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "CIViC"
                  }
                },
                {
                  "publications": [
                    {
                      "citation": "Cervantes A et al., 2023, Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up., Ann Oncol",
                      "pmid": 36307056
                    },
                    {
                      "citation": "Yaeger R et al., 2015, Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients., Clin Cancer Res",
                      "pmid": 25589621
                    },
                    {
                      "citation": "Corcoran RB et al., 2018, Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF(V600E)-Mutant Colorectal Cancer., Cancer Discov",
                      "pmid": 29431699
                    },
                    {
                      "citation": "Ruiz-Saenz A et al., 2023, A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAF(V600E) colorectal tumors., Nat Cancer",
                      "pmid": 36759733
                    },
                    {
                      "citation": "Yaeger R et al., 2017, Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition., Cancer Res",
                      "pmid": 28951457
                    },
                    {
                      "citation": "Zick A et al., 2017, Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients., Medicine (Baltimore)",
                      "pmid": 28514312
                    },
                    {
                      "citation": "2016, Triple Therapy Improves Colorectal Cancer Response., Cancer Discov",
                      "pmid": 27770002
                    },
                    {
                      "citation": "Yaeger R et al., 2019, Response to Anti-EGFR Therapy in Patients with BRAF non-V600-Mutant Metastatic Colorectal Cancer., Clin Cancer Res",
                      "pmid": 31515458
                    },
                    {
                      "citation": "Gao Y et al., 2019, V211D Mutation in MEK1 Causes Resistance to MEK Inhibitors in Colon Cancer., Cancer Discov",
                      "pmid": 31227518
                    },
                    {
                      "citation": "Yao Z et al., 2017, Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS., Nature",
                      "pmid": 28783719
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Approval Status",
                  "value": "Phase Ib/II"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Encorafenib + Ribociclib"
                }
              ],
              "drug": {
                "name": "RIBOCICLIB",
                "approved": true
              },
              "interactionScore": 0.03681651304373468,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Tripathy D et al., 2017, Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors., Clin Cancer Res",
                      "pmid": 28351928
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Approval Status",
                  "value": "Phase I"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                },
                {
                  "name": "Indication",
                  "value": "Advanced Solid Tumor"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Pimasertib + SAR405838"
                }
              ],
              "drug": {
                "name": "P53-HDM2 INTERACTION INHIBITOR MI-773",
                "approved": false
              },
              "interactionScore": 0.220899078262408,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "de Weger VA et al., 2019, A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours., Br J Cancer",
                      "pmid": 30585255
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Alteration",
                  "value": "MET:amp;BRAF:V600E"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Crizotinib;Vemurafenib"
                }
              ],
              "drug": {
                "name": "CRIZOTINIB",
                "approved": true
              },
              "interactionScore": 0.01506130079061873,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "CGI"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Patient cell culture"
                },
                {
                  "name": "Response Type",
                  "value": "resistant"
                },
                {
                  "name": "Indication",
                  "value": "lung adenocarcinoma"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                },
                {
                  "name": "Indication",
                  "value": "Advanced Solid Tumor"
                },
                {
                  "name": "Indication",
                  "value": "colorectal cancer"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Approval Status",
                  "value": "Phase I"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Direct Interaction",
                  "value": "true"
                },
                {
                  "name": "Mechanism of Action",
                  "value": "RAF serine/threonine protein kinase inhibitor"
                },
                {
                  "name": "Clinical Trial ID",
                  "value": "NCT01425008"
                },
                {
                  "name": "Cancer Type",
                  "value": "Thyroid Cancer"
                },
                {
                  "name": "Indication",
                  "value": "Exclusion criteria: Dose Expansion phase: Previous treatment with RAF or MEK inhibitors."
                }
              ],
              "drug": {
                "name": "TOVORAFENIB",
                "approved": false
              },
              "interactionScore": 0.3313486173936121,
              "interactionTypes": [
                {
                  "type": "inhibitor"
                }
              ],
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "ChEMBL"
                  }
                },
                {
                  "publications": [
                    {
                      "citation": "Negrao MV et al., 2020, Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations., J Thorac Oncol",
                      "pmid": 32540409
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "MyCancerGenomeClinicalTrial"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Combination Therapy",
                  "value": "Lifirafenib + Trametinib"
                },
                {
                  "name": "Approval Status",
                  "value": "Phase I"
                },
                {
                  "name": "Indication",
                  "value": "lung non-small cell carcinoma"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Lifirafenib + PD-0325901"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Cetuximab + Lifirafenib"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Patient cell culture"
                },
                {
                  "name": "Indication",
                  "value": "lung adenocarcinoma"
                },
                {
                  "name": "Indication",
                  "value": "ovarian serous carcinoma"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Pdx & cell culture"
                },
                {
                  "name": "Indication",
                  "value": "colorectal cancer"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Approval Status",
                  "value": "Case Reports/Case Series"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                },
                {
                  "name": "Indication",
                  "value": "thyroid gland cancer"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                },
                {
                  "name": "Response Type",
                  "value": "no benefit"
                },
                {
                  "name": "Indication",
                  "value": "Advanced Solid Tumor"
                },
                {
                  "name": "Direct Interaction",
                  "value": "true"
                },
                {
                  "name": "Mechanism of Action",
                  "value": "Serine/threonine-protein kinase B-raf inhibitor"
                }
              ],
              "drug": {
                "name": "LIFIRAFENIB",
                "approved": false
              },
              "interactionScore": 1.159720160877642,
              "interactionTypes": [
                {
                  "type": "inhibitor"
                }
              ],
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "ChEMBL"
                  }
                },
                {
                  "publications": [
                    {
                      "citation": "Tang Z et al., 2015, BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers., Mol Cancer Ther",
                      "pmid": 26208524
                    },
                    {
                      "citation": "Desai J et al., 2020, Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors., J Clin Oncol",
                      "pmid": 32182156
                    },
                    {
                      "citation": "Hong A et al., 2021, Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity., Cancer Discov",
                      "pmid": 33318037
                    },
                    {
                      "citation": "Negrao MV et al., 2020, Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations., J Thorac Oncol",
                      "pmid": 32540409
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TTD"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Combination Therapy",
                  "value": "Imatinib + PLX4720"
                },
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                }
              ],
              "drug": {
                "name": "IMATINIB",
                "approved": true
              },
              "interactionScore": 0.009467103354103203,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Vinik A et al., 2016, Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial., Target Oncol",
                      "pmid": 27924459
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Phase I"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Palbociclib + Trametinib"
                },
                {
                  "name": "Response Type",
                  "value": "decreased response"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                },
                {
                  "name": "Indication",
                  "value": "thyroid gland cancer"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "FDA approved - On Companion Diagnostic"
                },
                {
                  "name": "Indication",
                  "value": "lung adenocarcinoma"
                },
                {
                  "name": "Approval Status",
                  "value": "Case Reports/Case Series"
                },
                {
                  "name": "Indication",
                  "value": "pleomorphic xanthoastrocytoma"
                },
                {
                  "name": "Indication",
                  "value": "intrahepatic cholangiocarcinoma"
                },
                {
                  "name": "Indication",
                  "value": "peritoneal serous papillary adenocarcinoma"
                },
                {
                  "name": "Indication",
                  "value": "colorectal cancer"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical"
                },
                {
                  "name": "Indication",
                  "value": "ovarian serous carcinoma"
                },
                {
                  "name": "Indication",
                  "value": "histiocytic sarcoma"
                },
                {
                  "name": "Indication",
                  "value": "Advanced Solid Tumor"
                },
                {
                  "name": "Approval Status",
                  "value": "Phase II"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Dabrafenib + Trametinib"
                },
                {
                  "name": "Indication",
                  "value": "neuroendocrine tumor"
                },
                {
                  "name": "Approval Status",
                  "value": "Guideline"
                },
                {
                  "name": "Indication",
                  "value": "hairy cell leukemia"
                },
                {
                  "name": "Indication",
                  "value": "ovary epithelial cancer"
                },
                {
                  "name": "Indication",
                  "value": "basal cell carcinoma"
                },
                {
                  "name": "Indication",
                  "value": "glioblastoma"
                },
                {
                  "name": "Indication",
                  "value": "high grade glioma"
                },
                {
                  "name": "Indication",
                  "value": "brain glioblastoma multiforme"
                },
                {
                  "name": "Indication",
                  "value": "anaplastic astrocytoma"
                },
                {
                  "name": "Indication",
                  "value": "pancreatic ductal adenocarcinoma"
                },
                {
                  "name": "Indication",
                  "value": "ampulla of Vater adenocarcinoma"
                },
                {
                  "name": "Indication",
                  "value": "esophagus squamous cell carcinoma"
                },
                {
                  "name": "Indication",
                  "value": "lung non-small cell carcinoma"
                },
                {
                  "name": "Indication",
                  "value": "thyroid gland follicular carcinoma"
                },
                {
                  "name": "Indication",
                  "value": "thyroid gland carcinoma"
                },
                {
                  "name": "Indication",
                  "value": "thyroid gland papillary carcinoma"
                },
                {
                  "name": "Indication",
                  "value": "pancreatic adenocarcinoma"
                },
                {
                  "name": "Indication",
                  "value": "biliary tract cancer"
                },
                {
                  "name": "Indication",
                  "value": "pilocytic astrocytoma"
                },
                {
                  "name": "Indication",
                  "value": "esophagus adenocarcinoma"
                },
                {
                  "name": "Indication",
                  "value": "gastroesophageal junction adenocarcinoma"
                },
                {
                  "name": "Indication",
                  "value": "cholangiocarcinoma"
                },
                {
                  "name": "Indication",
                  "value": "ganglioglioma"
                },
                {
                  "name": "Indication",
                  "value": "epithelial predominant Wilms' tumor"
                },
                {
                  "name": "Indication",
                  "value": "lung papillary adenocarcinoma"
                },
                {
                  "name": "Indication",
                  "value": "pancreatic acinar cell adenocarcinoma"
                },
                {
                  "name": "Indication",
                  "value": "anaplastic oligodendroglioma"
                },
                {
                  "name": "Indication",
                  "value": "thyroid gland Hurthle cell carcinoma"
                },
                {
                  "name": "Indication",
                  "value": "salivary gland cancer"
                },
                {
                  "name": "Indication",
                  "value": "skin melanoma"
                },
                {
                  "name": "Indication",
                  "value": "gastrointestinal stromal tumor"
                },
                {
                  "name": "Approval Status",
                  "value": "Phase Ib/II"
                },
                {
                  "name": "Indication",
                  "value": "stomach cancer"
                },
                {
                  "name": "Indication",
                  "value": "spermatic cord cancer"
                },
                {
                  "name": "Indication",
                  "value": "salivary gland carcinoma"
                },
                {
                  "name": "Indication",
                  "value": "Her2-receptor negative breast cancer"
                },
                {
                  "name": "Indication",
                  "value": "thyroid gland anaplastic carcinoma"
                },
                {
                  "name": "Indication",
                  "value": "low grade glioma"
                },
                {
                  "name": "Approval Status",
                  "value": "FDA approved"
                },
                {
                  "name": "Indication",
                  "value": "anaplastic pleomorphic xanthoastrocytoma"
                },
                {
                  "name": "Indication",
                  "value": "IDH-wildtype glioblastoma"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Navitoclax + Trametinib"
                },
                {
                  "name": "Indication",
                  "value": "colon cancer"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Dabrafenib + Pembrolizumab + Trametinib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Dabrafenib + KRT-232 + Trametinib"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Pdx"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Panitumumab + Trametinib"
                },
                {
                  "name": "Response Type",
                  "value": "no benefit"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Dabrafenib + Panitumumab + Trametinib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "GSK2126458 + Trametinib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Trametinib + TW-37"
                },
                {
                  "name": "Combination Therapy",
                  "value": "BI 882370 + Trametinib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Trametinib + Vemurafenib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Cetuximab + Dabrafenib + Trametinib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Dasatinib + Trametinib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "PAC-1 + Trametinib + Vemurafenib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Dabrafenib + Spartalizumab + Trametinib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Dabrafenib + SCH772984 + Trametinib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Chloroquine + Trametinib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Trametinib + YM-254890"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Lifirafenib + Trametinib"
                },
                {
                  "name": "Response Type",
                  "value": "conflicting"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Dabrafenib + Regorafenib + Trametinib"
                },
                {
                  "name": "Indication",
                  "value": "colon adenocarcinoma"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Pdx & cell culture"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Dabrafenib + LXH 254 + Trametinib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Dabrafenib + RAF709 + Trametinib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Dabrafenib + Rabeprazole + Rifampin + Trametinib"
                },
                {
                  "name": "Indication",
                  "value": "endometrial adenocarcinoma"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Trametinib + Ulixertinib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Panobinostat + Trametinib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Trametinib + Vorinostat"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Romidepsin + Trametinib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Mocetinostat + Trametinib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Entinostat + Trametinib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Trametinib + Valproic acid"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Celecoxib + Gefitinib + Trametinib + Vemurafenib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Celecoxib + Trametinib + Vemurafenib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Celecoxib + Dabrafenib + Trametinib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Celecoxib + Dabrafenib + Panitumumab + Trametinib"
                },
                {
                  "name": "Response Type",
                  "value": "resistant"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - resistant"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Dabrafenib + Enzalutamide + Trametinib"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Biochemical"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Dabrafenib + Everolimus + Trametinib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Miransertib + Trametinib"
                },
                {
                  "name": "Indication",
                  "value": "multiple myeloma"
                },
                {
                  "name": "Indication",
                  "value": "lymphoma"
                },
                {
                  "name": "Combination Therapy",
                  "value": "S63845 + Trametinib"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Patient cell culture"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Encorafenib + Trametinib"
                },
                {
                  "name": "Indication",
                  "value": "pancreatic endocrine carcinoma"
                },
                {
                  "name": "Indication",
                  "value": "prostate adenocarcinoma"
                },
                {
                  "name": "Indication",
                  "value": "breast ductal carcinoma"
                },
                {
                  "name": "Indication",
                  "value": "female reproductive organ cancer"
                },
                {
                  "name": "Indication",
                  "value": "gastrointestinal system cancer"
                },
                {
                  "name": "Indication",
                  "value": "prostate cancer"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Cetuximab + Trametinib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Buparlisib + Trametinib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "MK2206 + Trametinib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Dabrafenib + Nivolumab + Trametinib"
                },
                {
                  "name": "Approval Status",
                  "value": "Phase III"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Dabrafenib + Hydroxychloroquine + Trametinib"
                },
                {
                  "name": "Indication",
                  "value": "osteosarcoma"
                },
                {
                  "name": "Indication",
                  "value": "sarcomatoid carcinoma"
                },
                {
                  "name": "Indication",
                  "value": "mucosal melanoma"
                },
                {
                  "name": "Indication",
                  "value": "collecting duct carcinoma"
                },
                {
                  "name": "Indication",
                  "value": "ovarian cancer"
                },
                {
                  "name": "Indication",
                  "value": "lymphatic system cancer"
                },
                {
                  "name": "Combination Therapy",
                  "value": "LY3009120 + Trametinib"
                },
                {
                  "name": "Indication",
                  "value": "pancreatic cancer"
                },
                {
                  "name": "Approval Status",
                  "value": "case report"
                },
                {
                  "name": "Variant Effect",
                  "value": "gain-of-function"
                },
                {
                  "name": "Pathway",
                  "value": "activation"
                },
                {
                  "name": "Approval Status",
                  "value": "FDA-approved"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Panitumumab + Dabrafenib + Trametinib"
                },
                {
                  "name": "Alteration",
                  "value": "BRAF__."
                },
                {
                  "name": "Alteration",
                  "value": "BRAF:K601R,L597R,V600R"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Dabrafenib;Trametinib"
                },
                {
                  "name": "Alteration",
                  "value": "BRAF:V600E"
                },
                {
                  "name": "Alteration",
                  "value": "BRAF:V600E,V600K"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Panitumumab;Dabrafenib;Trametinib"
                },
                {
                  "name": "Mechanism of Action",
                  "value": "Sensitivity"
                }
              ],
              "drug": {
                "name": "TRAMETINIB DIMETHYL SULFOXIDE",
                "approved": true
              },
              "interactionScore": 1.686865688549297,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Nakaoku T et al., 2014, Druggable oncogene fusions in invasive mucinous lung adenocarcinoma., Clin Cancer Res",
                      "pmid": 24727320
                    },
                    {
                      "citation": "Hutchinson KE et al., 2013, BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition., Clin Cancer Res",
                      "pmid": 24345920
                    },
                    {
                      "citation": "Palanisamy N et al., 2010, Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma., Nat Med",
                      "pmid": 20526349
                    },
                    {
                      "citation": "Kim KB et al., 2013, Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor., J Clin Oncol",
                      "pmid": 23248257
                    },
                    {
                      "citation": "Falchook GS et al., 2012, Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial., Lancet Oncol",
                      "pmid": 22805292
                    },
                    {
                      "citation": "Corcoran RB et al., 2015, Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer., J Clin Oncol",
                      "pmid": 26392102
                    },
                    {
                      "citation": "Silen W et al., 1975, Acid-base balance in amphibian gastric mucosa., Am J Physiol",
                      "pmid": 2015
                    },
                    {
                      "citation": "Sakaguchi H et al., 1976, Microbiological oxidation of synthetic chalcocite and covellite by Thiobacillus ferrooxidans., Appl Environ Microbiol",
                      "pmid": 8006
                    }
                  ],
                  "source": {
                    "sourceDbName": "CGI"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "ClearityFoundationBiomarkers"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "FDA"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "CIViC"
                  }
                },
                {
                  "publications": [
                    {
                      "citation": "Davies H et al., 2002, Mutations of the BRAF gene in human cancer., Nature",
                      "pmid": 12068308
                    },
                    {
                      "citation": "Gautschi O et al., 2012, A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib., J Thorac Oncol",
                      "pmid": 22743296
                    },
                    {
                      "citation": "Xing M et al., 2014, BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence., J Clin Oncol",
                      "pmid": 25024077
                    },
                    {
                      "citation": "Naoki K et al., 2002, Missense mutations of the BRAF gene in human lung adenocarcinoma., Cancer Res",
                      "pmid": 12460919
                    },
                    {
                      "citation": "Paik PK et al., 2011, Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations., J Clin Oncol",
                      "pmid": 21483012
                    },
                    {
                      "citation": "Falchook GS et al., 2012, Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial., Lancet",
                      "pmid": 22608338
                    },
                    {
                      "citation": "Ohashi K et al., 2012, Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1., Proc Natl Acad Sci U S A",
                      "pmid": 22773810
                    },
                    {
                      "citation": "Flaherty KT et al., 2010, Inhibition of mutated, activated BRAF in metastatic melanoma., N Engl J Med",
                      "pmid": 20818844
                    },
                    {
                      "citation": "Chen D et al., 2014, BRAFV600E mutation and its association with clinicopathological features of colorectal cancer: a systematic review and meta-analysis., PLoS One",
                      "pmid": 24594804
                    },
                    {
                      "citation": "MacConaill LE et al., 2014, Prospective enterprise-level molecular genotyping of a cohort of cancer patients., J Mol Diagn",
                      "pmid": 25157968
                    },
                    {
                      "citation": "Andrulis M et al., 2013, Targeting the BRAF V600E mutation in multiple myeloma., Cancer Discov",
                      "pmid": 23612012
                    },
                    {
                      "citation": "Falchook GS et al., 2012, Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial., Lancet Oncol",
                      "pmid": 22805292
                    },
                    {
                      "citation": "Kurman RJ et al., 2011, Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm., Hum Pathol",
                      "pmid": 21683865
                    },
                    {
                      "citation": "Coffee EM et al., 2013, Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer., Clin Cancer Res",
                      "pmid": 23549875
                    },
                    {
                      "citation": "Flaherty KT et al., 2012, Improved survival with MEK inhibition in BRAF-mutated melanoma., N Engl J Med",
                      "pmid": 22663011
                    },
                    {
                      "citation": "Wan PT et al., 2004, Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF., Cell",
                      "pmid": 15035987
                    },
                    {
                      "citation": "De Roock W et al., 2011, KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer., Lancet Oncol",
                      "pmid": 21163703
                    },
                    {
                      "citation": "Ascierto PA et al., 2013, Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma., J Clin Oncol",
                      "pmid": 23918947
                    },
                    {
                      "citation": "Chang MT et al., 2016, Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity., Nat Biotechnol",
                      "pmid": 26619011
                    },
                    {
                      "citation": "Hayes DN et al., 2012, Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements., Clin Cancer Res",
                      "pmid": 22241789
                    },
                    {
                      "citation": "Zecchin D et al., 2013, BRAF V600E is a determinant of sensitivity to proteasome inhibitors., Mol Cancer Ther",
                      "pmid": 24107445
                    },
                    {
                      "citation": "Nissan MH et al., 2014, Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence., Cancer Res",
                      "pmid": 24576830
                    },
                    {
                      "citation": "Lam ET et al., 2010, Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer., J Clin Oncol",
                      "pmid": 20368568
                    },
                    {
                      "citation": "Patel SP et al., 2013, Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma., Cancer",
                      "pmid": 22972589
                    },
                    {
                      "citation": "Sen B et al., 2012, Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib., Sci Transl Med",
                      "pmid": 22649091
                    },
                    {
                      "citation": "Morris EJ et al., 2013, Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors., Cancer Discov",
                      "pmid": 23614898
                    },
                    {
                      "citation": "Tol J et al., 2010, Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab., Eur J Cancer",
                      "pmid": 20413299
                    },
                    {
                      "citation": "Chapman PB et al., 2011, Improved survival with vemurafenib in melanoma with BRAF V600E mutation., N Engl J Med",
                      "pmid": 21639808
                    },
                    {
                      "citation": "Sarker D et al., 2015, First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors., Clin Cancer Res",
                      "pmid": 25370471
                    },
                    {
                      "citation": "Crescenzi A et al., 2014, Immunohistochemistry for BRAF(V600E) antibody VE1 performed in core needle biopsy samples identifies mutated papillary thyroid cancers., Horm Metab Res",
                      "pmid": 24570209
                    },
                    {
                      "citation": "Dienstmann R et al., 2011, BRAF as a target for cancer therapy., Anticancer Agents Med Chem",
                      "pmid": 21426297
                    },
                    {
                      "citation": "Kim KB et al., 2013, Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation., Thyroid",
                      "pmid": 23489023
                    },
                    {
                      "citation": "Rubinstein JC et al., 2010, Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032., J Transl Med",
                      "pmid": 20630094
                    },
                    {
                      "citation": "Rudin CM et al., 2013, Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer., J Thorac Oncol",
                      "pmid": 23524406
                    },
                    {
                      "citation": "Boulalas I et al., 2009, Mutational analysis of the BRAF gene in transitional cell carcinoma of the bladder., Int J Biol Markers",
                      "pmid": 19404918
                    },
                    {
                      "citation": "Prahallad A et al., 2012, Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR., Nature",
                      "pmid": 22281684
                    },
                    {
                      "citation": "Hauschild A et al., 2012, Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial., Lancet",
                      "pmid": 22735384
                    },
                    {
                      "citation": "Gandhi J et al., 2009, Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines., PLoS One",
                      "pmid": 19238210
                    },
                    {
                      "citation": "Jalili A et al., 2012, Dual suppression of the cyclin-dependent kinase inhibitors CDKN2C and CDKN1A in human melanoma., J Natl Cancer Inst",
                      "pmid": 22997239
                    },
                    {
                      "citation": "Flaherty KT et al., 2012, Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations., N Engl J Med",
                      "pmid": 23020132
                    },
                    {
                      "citation": "Greger JG et al., 2012, Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations., Mol Cancer Ther",
                      "pmid": 22389471
                    },
                    {
                      "citation": "Cardarella S et al., 2013, Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer., Clin Cancer Res",
                      "pmid": 23833300
                    },
                    {
                      "citation": "Meckbach D et al., 2014, BRAF-V600 mutations have no prognostic impact in stage IV melanoma patients treated with monochemotherapy., PLoS One",
                      "pmid": 24586605
                    },
                    {
                      "citation": "Kirkwood JM et al., 2012, Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma., Clin Cancer Res",
                      "pmid": 22048237
                    },
                    {
                      "citation": "Paraiso KH et al., 2012, The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms., Clin Cancer Res",
                      "pmid": 22351686
                    },
                    {
                      "citation": "Ponti G et al., 2012, Overwhelming response to Dabrafenib in a patient with double BRAF mutation (V600E; V600M) metastatic malignant melanoma., J Hematol Oncol",
                      "pmid": 23031422
                    },
                    {
                      "citation": "Kloos RT et al., 2009, Phase II trial of sorafenib in metastatic thyroid cancer., J Clin Oncol",
                      "pmid": 19255327
                    },
                    {
                      "citation": "Agaimy A et al., 2009, V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours., J Clin Pathol",
                      "pmid": 19561230
                    },
                    {
                      "citation": "Faber AC et al., 2014, mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1., Cancer Discov",
                      "pmid": 24163374
                    },
                    {
                      "citation": "Howell GM et al., 2011, Both BRAF V600E mutation and older age ( 65 years) are associated with recurrent papillary thyroid cancer., Ann Surg Oncol",
                      "pmid": 21594703
                    },
                    {
                      "citation": "Tejpar S et al., 2010, Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery., Oncologist",
                      "pmid": 20350999
                    },
                    {
                      "citation": "Corcoran RB et al., 2012, EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib., Cancer Discov",
                      "pmid": 22448344
                    },
                    {
                      "citation": "De Roock W et al., 2010, Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis., Lancet Oncol",
                      "pmid": 20619739
                    },
                    {
                      "citation": "Tiacci E et al., 2011, BRAF mutations in hairy-cell leukemia., N Engl J Med",
                      "pmid": 21663470
                    },
                    {
                      "citation": "Haldar K et al., 2011, Epidermal growth factor receptor blockers for the treatment of ovarian cancer., Cochrane Database Syst Rev",
                      "pmid": 21975775
                    },
                    {
                      "citation": "Rowland A et al., 2015, Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer., Br J Cancer",
                      "pmid": 25989278
                    },
                    {
                      "citation": "De Roock W et al., 2009, Clinical biomarkers in oncology: focus on colorectal cancer., Mol Diagn Ther",
                      "pmid": 19537845
                    },
                    {
                      "citation": "Rad R et al., 2013, A genetic progression model of Braf(V600E)-induced intestinal tumorigenesis reveals targets for therapeutic intervention., Cancer Cell",
                      "pmid": 23845441
                    },
                    {
                      "citation": "Mao C et al., 2011, BRAF V600E mutation and resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer: a meta-analysis., Mol Biol Rep",
                      "pmid": 20857202
                    },
                    {
                      "citation": "McArthur GA et al., 2014, Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study., Lancet Oncol",
                      "pmid": 24508103
                    },
                    {
                      "citation": "Yang H et al., 2012, Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer., Cancer Res",
                      "pmid": 22180495
                    },
                    {
                      "citation": "Pratilas CA et al., 2008, Genetic predictors of MEK dependence in non-small cell lung cancer., Cancer Res",
                      "pmid": 19010912
                    },
                    {
                      "citation": "Peeters M et al., 2013, Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer., Clin Cancer Res",
                      "pmid": 23325582
                    },
                    {
                      "citation": "Hatzivassiliou G et al., 2013, Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers., Nature",
                      "pmid": 23934108
                    },
                    {
                      "citation": "Huillard E et al., 2012, Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy., Proc Natl Acad Sci U S A",
                      "pmid": 22586120
                    },
                    {
                      "citation": "Nakayama N et al., 2008, KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer., Br J Cancer",
                      "pmid": 19018267
                    },
                    {
                      "citation": "Mao M et al., 2013, Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents., Clin Cancer Res",
                      "pmid": 23251002
                    },
                    {
                      "citation": "Falchook GS et al., 2013, BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance., Oncotarget",
                      "pmid": 23470635
                    },
                    {
                      "citation": "Di Nicolantonio F et al., 2008, Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer., J Clin Oncol",
                      "pmid": 19001320
                    },
                    {
                      "citation": "Lovly CM et al., 2012, Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials., PLoS One",
                      "pmid": 22536370
                    },
                    {
                      "citation": "Rizzo S et al., 2010, Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?, Cancer Treat Rev",
                      "pmid": 21129611
                    },
                    {
                      "citation": "Ji Z et al., 2013, Vemurafenib synergizes with nutlin-3 to deplete survivin and suppresses melanoma viability and tumor growth., Clin Cancer Res",
                      "pmid": 23812671
                    },
                    {
                      "citation": "Ho AL et al., 2013, Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer., N Engl J Med",
                      "pmid": 23406027
                    },
                    {
                      "citation": "Gupta-Abramson V et al., 2008, Phase II trial of sorafenib in advanced thyroid cancer., J Clin Oncol",
                      "pmid": 18541894
                    },
                    {
                      "citation": "Menzies AM et al., 2014, Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma., Clin Cancer Res",
                      "pmid": 24583796
                    },
                    {
                      "citation": "Brose MS et al., 2002, BRAF and RAS mutations in human lung cancer and melanoma., Cancer Res",
                      "pmid": 12460918
                    },
                    {
                      "citation": "Sosman JA et al., 2012, Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib., N Engl J Med",
                      "pmid": 22356324
                    },
                    {
                      "citation": "Villanueva J et al., 2010, Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K., Cancer Cell",
                      "pmid": 21156289
                    },
                    {
                      "citation": "Maldonado JL et al., 2003, Determinants of BRAF mutations in primary melanomas., J Natl Cancer Inst",
                      "pmid": 14679157
                    },
                    {
                      "citation": "Nagore E et al., 2014, Prognostic value of BRAF mutations in localized cutaneous melanoma., J Am Acad Dermatol",
                      "pmid": 24388723
                    },
                    {
                      "citation": "Hoftijzer H et al., 2009, Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma., Eur J Endocrinol",
                      "pmid": 19773371
                    },
                    {
                      "citation": "He G et al., 2014, Prognostic value of the BRAF V600E mutation in papillary thyroid carcinoma., Oncol Lett",
                      "pmid": 24396464
                    },
                    {
                      "citation": "Walczyk A et al., 2014, The BRAF(V600E) mutation in papillary thyroid microcarcinoma: does the mutation have an impact on clinical outcome?, Clin Endocrinol (Oxf)",
                      "pmid": 24354346
                    },
                    {
                      "citation": "Nicolaides TP et al., 2011, Targeted therapy for BRAFV600E malignant astrocytoma., Clin Cancer Res",
                      "pmid": 22038996
                    },
                    {
                      "citation": "Penna I et al., 2016, Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade., Oncotarget",
                      "pmid": 26678033
                    },
                    {
                      "citation": "Dienstmann R et al., 2015, Database of genomic biomarkers for cancer drugs and clinical targetability in solid tumors., Cancer Discov",
                      "pmid": 25656898
                    },
                    {
                      "citation": "Dahlman KB et al., 2012, BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors., Cancer Discov",
                      "pmid": 22798288
                    },
                    {
                      "citation": "Bahadoran P et al., 2013, Major clinical response to a BRAF inhibitor in a patient with a BRAF L597R-mutated melanoma., J Clin Oncol",
                      "pmid": 23715574
                    },
                    {
                      "citation": "Mller-Grtner HW et al., 1989, [Long-term results following surgery or radioiodine treatment of solitary autonomous adenoma of the thyroid gland]., Chirurg",
                      "pmid": 2493360
                    }
                  ],
                  "source": {
                    "sourceDbName": "DoCM"
                  }
                },
                {
                  "publications": [
                    {
                      "citation": "Falchook GS et al., 2012, Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial., Lancet Oncol",
                      "pmid": 22805292
                    },
                    {
                      "citation": "Teh JL et al., 2016, An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma., Cancer Res",
                      "pmid": 27488531
                    },
                    {
                      "citation": "Beadnell TC et al., 2016, The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer., Mol Cancer Ther",
                      "pmid": 27222538
                    },
                    {
                      "citation": "Flaherty KT et al., 2012, Improved survival with MEK inhibition in BRAF-mutated melanoma., N Engl J Med",
                      "pmid": 22663011
                    },
                    {
                      "citation": "Salama AKS et al., 2020, Dabrafenib and Trametinib in Patients With Tumors With BRAF(V600E) Mutations: Results of the NCI-MATCH Trial Subprotocol H., J Clin Oncol",
                      "pmid": 32758030
                    },
                    {
                      "citation": "Lange F et al., 2014, Biological and molecular effects of small molecule kinase inhibitors on low-passage human colorectal cancer cell lines., Biomed Res Int",
                      "pmid": 25309914
                    },
                    {
                      "citation": "Klempner SJ et al., 2016, BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy., Cancer Discov",
                      "pmid": 27048246
                    },
                    {
                      "citation": "Schreuer M et al., 2017, Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF(V600)-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial., Lancet Oncol",
                      "pmid": 28268064
                    },
                    {
                      "citation": "Robert C et al., 2015, Improved overall survival in melanoma with combined dabrafenib and trametinib., N Engl J Med",
                      "pmid": 25399551
                    },
                    {
                      "citation": "Greger JG et al., 2012, Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations., Mol Cancer Ther",
                      "pmid": 22389471
                    },
                    {
                      "citation": "Butt SU et al., 2021, BRAF/MEK inhibitors for BRAF V600E-mutant cancers in non-approved setting: a case series., Cancer Chemother Pharmacol",
                      "pmid": 33537843
                    },
                    {
                      "citation": "Schreck KC et al., 2018, Concurrent BRAF/MEK Inhibitors in BRAF V600-Mutant High-Grade Primary Brain Tumors., J Natl Compr Canc Netw",
                      "pmid": 29632053
                    },
                    {
                      "citation": "Kanemaru Y et al., 2019, Dramatic response of BRAF V600E-mutant epithelioid glioblastoma to combination therapy with BRAF and MEK inhibitor: establishment and xenograft of a cell line to predict clinical efficacy., Acta Neuropathol Commun",
                      "pmid": 31345255
                    },
                    {
                      "citation": "Kushnirsky M et al., 2020, Prolonged Complete Response With Combined Dabrafenib and Trametinib After BRAF Inhibitor Failure in BRAF-Mutant Glioblastoma., JCO Precis Oncol",
                      "pmid": 32923904
                    },
                    {
                      "citation": "Woo PYM et al., 2019, Regression of BRAF (V600E) mutant adult glioblastoma after primary combined BRAF-MEK inhibitor targeted therapy: a report of two cases., Oncotarget",
                      "pmid": 31217909
                    },
                    {
                      "citation": "Wen PY et al., 2022, Dabrafenib plus trametinib in patients with BRAF(V600E)-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial., Lancet Oncol",
                      "pmid": 34838156
                    },
                    {
                      "citation": "Venkatesh A et al., 2021, Response to BRAF and MEK1/2 inhibition in a young adult with BRAF V600E mutant epithelioid glioblastoma multiforme: A Case Report and Literature Review., Curr Probl Cancer",
                      "pmid": 33461766
                    },
                    {
                      "citation": "Li HS et al., 2021, Remarkable response of BRAF (V600E)-mutated metastatic pancreatic cancer to BRAF/MEK inhibition: a case report., Gastroenterol Rep (Oxf)",
                      "pmid": 35382161
                    },
                    {
                      "citation": "Planchard D et al., 2016, Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial., Lancet Oncol",
                      "pmid": 27283860
                    },
                    {
                      "citation": "Planchard D et al., 2016, Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial., Lancet Oncol",
                      "pmid": 27080216
                    },
                    {
                      "citation": "Planchard D et al., 2017, Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial., Lancet Oncol",
                      "pmid": 28919011
                    },
                    {
                      "citation": "Brandenburg T et al., 2021, Therapeutic Effect of Combined Dabrafenib and Trametinib Treatment of BRAF V600E-Mutated Primary Squamous Cell Carcinoma of the Thyroid: A Case Report., Eur Thyroid J",
                      "pmid": 34956922
                    },
                    {
                      "citation": "Owen DH et al., 2019, KRAS G12V Mutation in Acquired Resistance to Combined BRAF and MEK Inhibition in Papillary Thyroid Cancer., J Natl Compr Canc Netw",
                      "pmid": 31085763
                    },
                    {
                      "citation": "Subbiah V et al., 2020, Dabrafenib plus trametinib in patients with BRAF(V600E)-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial., Lancet Oncol",
                      "pmid": 32818466
                    },
                    {
                      "citation": "Vogel A et al., 2023, Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up., Ann Oncol",
                      "pmid": 36372281
                    },
                    {
                      "citation": "Obasaju P et al., 2020, BRAF V600E-mutated metastatic pediatric Wilms tumor with complete response to targeted RAF/MEK inhibition., Cold Spring Harb Mol Case Stud",
                      "pmid": 32238401
                    },
                    {
                      "citation": "Jiang J et al., 2021, Case Report: Vemurafenib Treatment in Brain Metastases of BRAF(S365L) -Mutant Lung Papillary Cancer by Genetic Sequencing of Cerebrospinal Fluid Circulating Tumor DNA Detection., Front Oncol",
                      "pmid": 34178685
                    },
                    {
                      "citation": "Busch E et al., 2020, Successful BRAF/MEK inhibition in a patient with BRAF(V600E)-mutated extrapancreatic acinar cell carcinoma., Cold Spring Harb Mol Case Stud",
                      "pmid": 32843432
                    },
                    {
                      "citation": "Corcoran RB et al., 2015, Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer., J Clin Oncol",
                      "pmid": 26392102
                    },
                    {
                      "citation": "Oddo D et al., 2016, Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer., Cancer Res",
                      "pmid": 27312529
                    },
                    {
                      "citation": "Saijo K et al., 2022, BRAF and MEK Inhibitor Treatment for Metastatic Undifferentiated Sarcoma of the Spermatic Cord with BRAF V600E Mutation., Case Rep Oncol",
                      "pmid": 36157689
                    },
                    {
                      "citation": "Lin VTG et al., 2018, First-Line Treatment of Widely Metastatic BRAF-Mutated Salivary Duct Carcinoma With Combined BRAF and MEK Inhibition., J Natl Compr Canc Netw",
                      "pmid": 30323086
                    },
                    {
                      "citation": "Tholander B et al., 2020, Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma., Ups J Med Sci",
                      "pmid": 33043759
                    },
                    {
                      "citation": "Lima B et al., 2022, Impressive and durable clinical responses obtained with dabrafenib and trametinib in low-grade serous ovarian cancer harbouring a BRAF V600E mutation., Gynecol Oncol Rep",
                      "pmid": 35242981
                    },
                    {
                      "citation": "Lpez de S A et al., 2022, Case report: Clinical success targeting BRAF-mutated, hormone receptor positive, HER2- negative advanced breast cancer patient with BRAF-inhibitor plus MEK- inhibitor., Front Oncol",
                      "pmid": 36531075
                    },
                    {
                      "citation": "Agarwal R et al., 2016, Response to Targeted Therapy in BRAF Mutant Anaplastic Thyroid Cancer., J Natl Compr Canc Netw",
                      "pmid": 27697975
                    },
                    {
                      "citation": "Subbiah V et al., 2022, Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study., Ann Oncol",
                      "pmid": 35026411
                    },
                    {
                      "citation": "Filetti S et al., 2019, Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up., Ann Oncol",
                      "pmid": 31549998
                    },
                    {
                      "citation": "Filetti S et al., 2022, ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer., Ann Oncol",
                      "pmid": 35491008
                    },
                    {
                      "citation": "Brown NF et al., 2017, Dabrafenib and trametinib in BRAFV600E mutated glioma., CNS Oncol",
                      "pmid": 28984141
                    },
                    {
                      "citation": "Munjapara V et al., 2022, BRAF V600E-Mutant Glioblastoma with Extracranial Metastases Responsive to Combined BRAF and MEK Targeted Inhibition: A Case Report., Case Rep Oncol",
                      "pmid": 36825105
                    },
                    {
                      "citation": "Lin L et al., 2015, The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies., Nat Genet",
                      "pmid": 25665005
                    },
                    {
                      "citation": "Shattuck-Brandt RL et al., 2020, Metastatic Melanoma Patient-Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition., Clin Cancer Res",
                      "pmid": 32234759
                    },
                    {
                      "citation": "Corcoran RB et al., 2018, Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF(V600E)-Mutant Colorectal Cancer., Cancer Discov",
                      "pmid": 29431699
                    },
                    {
                      "citation": "Waizenegger IC et al., 2016, A Novel RAF Kinase Inhibitor with DFG-Out-Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation., Mol Cancer Ther",
                      "pmid": 26916115
                    },
                    {
                      "citation": "Wang Z et al., 2022, Vemurafenib Combined With Trametinib Significantly Benefits the Survival of a Patient With Stage IV Pancreatic Ductal Adenocarcinoma With BRAF V600E Mutation: A Case Report., Front Oncol",
                      "pmid": 35145907
                    },
                    {
                      "citation": "Peh J et al., 2016, The Combination of Vemurafenib and Procaspase-3 Activation Is Synergistic in Mutant BRAF Melanomas., Mol Cancer Ther",
                      "pmid": 27297867
                    },
                    {
                      "citation": "Tian J et al., 2023, Combined PD-1, BRAF and MEK inhibition in BRAF(V600E) colorectal cancer: a phase 2 trial., Nat Med",
                      "pmid": 36702949
                    },
                    {
                      "citation": "Xue Y et al., 2017, An approach to suppress the evolution of resistance in BRAF(V600E)-mutant cancer., Nat Med",
                      "pmid": 28714990
                    },
                    {
                      "citation": "Kinsey CG et al., 2019, Protective autophagy elicited by RAFMEKERK inhibition suggests a treatment strategy for RAS-driven cancers., Nat Med",
                      "pmid": 30833748
                    },
                    {
                      "citation": "Hitchman TD et al., 2021, Combined Inhibition of G(q) and MEK Enhances Therapeutic Efficacy in Uveal Melanoma., Clin Cancer Res",
                      "pmid": 33229459
                    },
                    {
                      "citation": "Hong A et al., 2021, Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity., Cancer Discov",
                      "pmid": 33318037
                    },
                    {
                      "citation": "Adamopoulos C et al., 2021, Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling., Cancer Discov",
                      "pmid": 33568355
                    },
                    {
                      "citation": "Sigaud R et al., 2023, The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma models., Neuro Oncol",
                      "pmid": 35882450
                    },
                    {
                      "citation": "Jenkins LJ et al., 2023, Genotype-Tailored ERK/MAPK Pathway and HDAC Inhibition Rewires the Apoptotic Rheostat to Trigger Colorectal Cancer Cell Death., Mol Cancer Ther",
                      "pmid": 36343387
                    },
                    {
                      "citation": "Ruiz-Saenz A et al., 2023, A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAF(V600E) colorectal tumors., Nat Cancer",
                      "pmid": 36759733
                    },
                    {
                      "citation": "Takano K et al., 2023, Discovery of a Novel ATP-Competitive MEK Inhibitor DS03090629 that Overcomes Resistance Conferred by BRAF Overexpression in BRAF-Mutated Melanoma., Mol Cancer Ther",
                      "pmid": 36622773
                    },
                    {
                      "citation": "Abravanel DL et al., 2018, An Acquired NRAS Q61K Mutation in BRAF V600E-Mutant Lung Adenocarcinoma Resistant toDabrafenib Plus Trametinib., J Thorac Oncol",
                      "pmid": 29631033
                    },
                    {
                      "citation": "Brady DC et al., 2017, Copper Chelation Inhibits BRAF(V600E)-Driven Melanomagenesis and Counters Resistance to BRAF(V600E) and MEK1/2 Inhibitors., Cancer Res",
                      "pmid": 28986383
                    },
                    {
                      "citation": "Mizuno S et al., 2023, High-Throughput Functional Evaluation of MAP2K1 Variants in Cancer., Mol Cancer Ther",
                      "pmid": 36442478
                    },
                    {
                      "citation": "Emery CM et al., 2017, BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity., Mol Cancer Res",
                      "pmid": 28655712
                    },
                    {
                      "citation": "Wagle N et al., 2014, MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition., Cancer Discov",
                      "pmid": 24265154
                    },
                    {
                      "citation": "Vellano CP et al., 2022, Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy., Nature",
                      "pmid": 35705814
                    },
                    {
                      "citation": "Van Allen EM et al., 2014, The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma., Cancer Discov",
                      "pmid": 24265153
                    },
                    {
                      "citation": "Gibson WJ et al., 2017, Genomic Heterogeneity and Exceptional Response to Dual Pathway Inhibition in Anaplastic Thyroid Cancer., Clin Cancer Res",
                      "pmid": 27797976
                    },
                    {
                      "citation": "Yu Y et al., 2015, Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092., PLoS One",
                      "pmid": 26469692
                    },
                    {
                      "citation": "Wang J et al., 2018, A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAF(V600E)-Mutant Brain Tumor., Cancer Discov",
                      "pmid": 29880583
                    },
                    {
                      "citation": "Persky NS et al., 2020, Defining the landscape of ATP-competitive inhibitor resistance residues in protein kinases., Nat Struct Mol Biol",
                      "pmid": 31925410
                    },
                    {
                      "citation": "Torresetti M et al., 2020, A case report of metastatic giant sarcomatoid melanoma with BRAF V600E mutation: a complete response to targeted therapy., Oncotarget",
                      "pmid": 32922664
                    },
                    {
                      "citation": "Sasankan S et al., 2020, Metastatic Pancreatic Cancer with BRAF and P53 Mutations: Case Report of Therapeutic Response to Doublet Targeted Therapy., Case Rep Oncol",
                      "pmid": 33250737
                    },
                    {
                      "citation": "Nassar KW et al., 2021, Targeting CDK4/6 Represents a Therapeutic Vulnerability in Acquired BRAF/MEK Inhibitor-Resistant Melanoma., Mol Cancer Ther",
                      "pmid": 34376578
                    },
                    {
                      "citation": "Facchinetti F et al., 2020, Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAF(V600E) non-small cell lung cancer., Eur J Cancer",
                      "pmid": 32388065
                    },
                    {
                      "citation": "Guo W et al., 2022, Lung adenocarcinoma harboring complex EML4-ALK fusion and BRAF V600E co-mutation responded to alectinib., Medicine (Baltimore)",
                      "pmid": 36221356
                    },
                    {
                      "citation": "Seto K et al., 2022, Sensitivity to dabrafenib and trametinib treatments in patients with non-small-cell cancer harboring BRAF compound mutations: A pooled analysis of BRAF p.V600E-positive advanced non-small-cell lung cancer., Cancer Genet",
                      "pmid": 35598548
                    },
                    {
                      "citation": "Carlino MS et al., 2015, Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients., Clin Cancer Res",
                      "pmid": 25370473
                    },
                    {
                      "citation": "Olbryt M et al., 2020, Genetic Profiling of Advanced Melanoma: Candidate Mutations for Predicting Sensitivity and Resistance to Targeted Therapy., Target Oncol",
                      "pmid": 31980996
                    },
                    {
                      "citation": "Peng SB et al., 2015, Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers., Cancer Cell",
                      "pmid": 26343583
                    },
                    {
                      "citation": "Johnson DB et al., 2020, Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131)., Clin Cancer Res",
                      "pmid": 31924734
                    },
                    {
                      "citation": "Noeparast A et al., 2016, Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib., Oncotarget",
                      "pmid": 28947956
                    },
                    {
                      "citation": "2016, Triple Therapy Improves Colorectal Cancer Response., Cancer Discov",
                      "pmid": 27770002
                    },
                    {
                      "citation": "Kotschy A et al., 2016, The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models., Nature",
                      "pmid": 27760111
                    },
                    {
                      "citation": "Algazi AP et al., 2020, Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial., Nat Med",
                      "pmid": 33020646
                    },
                    {
                      "citation": "Long GV et al., 2017, Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma., N Engl J Med",
                      "pmid": 28891408
                    },
                    {
                      "citation": "Joshi M et al., 2015, Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer., PLoS One",
                      "pmid": 25706985
                    },
                    {
                      "citation": "Negrao MV et al., 2020, Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations., J Thorac Oncol",
                      "pmid": 32540409
                    },
                    {
                      "citation": "Dagogo-Jack I, 2020, Durable Response to Dabrafenib Combined With Trametinib in a Patient With NSCLC Harboring a BRAF G469A Mutation., J Thorac Oncol",
                      "pmid": 32981611
                    },
                    {
                      "citation": "Dankner M et al., 2018, Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas., Clin Cancer Res",
                      "pmid": 29903896
                    },
                    {
                      "citation": "Melin A et al., 2019, BRAF exon 11 mutant melanoma and sensitivity to BRAF/MEK inhibition: Two case reports., Eur J Cancer",
                      "pmid": 31569065
                    },
                    {
                      "citation": "Reyes R et al., 2019, Clinical Benefit From BRAF/MEK Inhibition in a Double Non-V600E BRAF Mutant Lung Adenocarcinoma: A Case Report., Clin Lung Cancer",
                      "pmid": 30926357
                    },
                    {
                      "citation": "Drobysheva A et al., 2017, Targeted MAPK Pathway Inhibitors in Patients With Disseminated Pilocytic Astrocytomas., J Natl Compr Canc Netw",
                      "pmid": 28784858
                    },
                    {
                      "citation": "Comito F et al., 2022, Clinical characteristics and treatment outcomes of non-V600 E/K BRAF mutant melanoma patients: a single-institution experience., Melanoma Res",
                      "pmid": 36039514
                    },
                    {
                      "citation": "Allen A et al., 2019, Rare BRAF mutations in pancreatic neuroendocrine tumors may predict response to RAF and MEK inhibition., PLoS One",
                      "pmid": 31158244
                    },
                    {
                      "citation": "Marconcini R et al., 2017, Metastatic BRAF K601E-mutated melanoma reaches complete response to MEK inhibitor trametinib administered for over 36months., Exp Hematol Oncol",
                      "pmid": 28344857
                    },
                    {
                      "citation": "Kim KB et al., 2013, Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor., J Clin Oncol",
                      "pmid": 23248257
                    },
                    {
                      "citation": "Bowyer SE et al., 2014, Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma., Melanoma Res",
                      "pmid": 24933606
                    },
                    {
                      "citation": "Dahlman KB et al., 2012, BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors., Cancer Discov",
                      "pmid": 22798288
                    },
                    {
                      "citation": "Rogiers A et al., 2019, Dabrafenib plus trametinib in BRAF K601E-mutant melanoma., Br J Dermatol",
                      "pmid": 30248172
                    },
                    {
                      "citation": "Su PL et al., 2021, Durable Response to Combined Dabrafenib and Trametinib in a Patient With BRAF K601E Mutation-Positive Lung Adenocarcinoma: A Case Report., JTO Clin Res Rep",
                      "pmid": 34590045
                    },
                    {
                      "citation": "Yao Z et al., 2017, Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS., Nature",
                      "pmid": 28783719
                    },
                    {
                      "citation": "Lehtomaki KI et al., 2019, Clonal Evolution of MEK/MAPK Pathway Activating Mutations in a Metastatic Colorectal Cancer Case., Anticancer Res",
                      "pmid": 31704811
                    },
                    {
                      "citation": "Nebhan CA et al., 2021, Efficacy and Safety of Trametinib in Non-V600 BRAF Mutant Melanoma: A Phase II Study., Oncologist",
                      "pmid": 33861486
                    },
                    {
                      "citation": "Bouffet E et al., 2023, Efficacy and Safety of Trametinib Monotherapy or in Combination With Dabrafenib in Pediatric BRAF V600-Mutant Low-Grade Glioma., J Clin Oncol",
                      "pmid": 36375115
                    },
                    {
                      "citation": "Long GV et al., 2016, Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib., J Clin Oncol",
                      "pmid": 26811525
                    },
                    {
                      "citation": "Planchard D et al., 2018, Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up., Ann Oncol",
                      "pmid": 30285222
                    },
                    {
                      "citation": "Michielin O et al., 2019, Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up., Ann Oncol",
                      "pmid": 31566661
                    },
                    {
                      "citation": "Shi H et al., 2014, A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition., Cancer Discov",
                      "pmid": 24265152
                    },
                    {
                      "citation": "Dummer R et al., 2020, Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i., Nat Med",
                      "pmid": 33020648
                    },
                    {
                      "citation": "Mehnert JM et al., 2022, BAMM (BRAF Autophagy and MEK Inhibition in Melanoma): A Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Advanced BRAFV600-mutant Melanoma., Clin Cancer Res",
                      "pmid": 35022320
                    },
                    {
                      "citation": "Rogiers A et al., 2017, Response to targeted therapy in two patients with metastatic melanoma carrying rare BRAF exon 15 mutations: A598_T599insV and V600_K601delinsE., Melanoma Res",
                      "pmid": 28800030
                    },
                    {
                      "citation": "Bjursten S et al., 2019, Response to BRAF/MEK Inhibition in A598_T599insV BRAF Mutated Melanoma., Case Rep Oncol",
                      "pmid": 31824282
                    },
                    {
                      "citation": "Lampasona G et al., 2022, Locoregionally Advanced, BRAF V600L-Positive, Mucosal Melanoma of the Hypopharynx Treated With a Combination of BRAF and MEK Inhibitors., JCO Precis Oncol",
                      "pmid": 35709404
                    },
                    {
                      "citation": "Bernocchi O et al., 2021, Tumor Type Agnostic Therapy Carrying BRAF Mutation: Case Reports and Review of Literature., Pharmaceuticals (Basel)",
                      "pmid": 33669326
                    },
                    {
                      "citation": "Sasaki-Saito N et al., 2023, BRAF N581S and NRAS Q61R-mutated malignant melanoma and sensitivity to BRAF/MEK inhibitors., J Dermatol",
                      "pmid": 36217799
                    },
                    {
                      "citation": "Yap J et al., 2021, The stability of R-spine defines RAF inhibitor resistance: A comprehensive analysis of oncogenic BRAF mutants with in-frame insertion of C-4 loop., Sci Adv",
                      "pmid": 34108213
                    },
                    {
                      "citation": "Khater F et al., 2019, Recurrent somatic BRAF insertion (p.V504_R506dup): a tumor marker and a potential therapeutic target in pilocytic astrocytoma., Oncogene",
                      "pmid": 30575814
                    },
                    {
                      "citation": "Chen SH et al., 2016, Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120., Cancer Discov",
                      "pmid": 26732095
                    },
                    {
                      "citation": "Aguirre AJ et al., 2018, Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine., Cancer Discov",
                      "pmid": 29903880
                    },
                    {
                      "citation": "Pham NA et al., 2021, Patient-derived tumor xenograft and organoid models established from resected pancreatic, duodenal and biliary cancers., Sci Rep",
                      "pmid": 34011980
                    },
                    {
                      "citation": "Messinger YH et al., 2020, Langerhans cell histiocytosis with BRAF p.N486_P490del or MAP2K1 p.K57_G61del treated by the MEK inhibitor trametinib., Pediatr Blood Cancer",
                      "pmid": 32991018
                    },
                    {
                      "citation": "Shin JE et al., 2022, Efficacy of dabrafenib/trametinib in pancreatic ductal adenocarcinoma with BRAF NVTAP deletion: A case report., Front Oncol",
                      "pmid": 36505826
                    },
                    {
                      "citation": "Zhang S et al., 2023, BRAF L485-P490 deletion mutant metastatic melanoma sensitive to BRAF and MEK inhibition: A case report and literature review., Front Pharmacol",
                      "pmid": 36686670
                    },
                    {
                      "citation": "Marchand A et al., 2018, A rare BRAF T599dup mutation conferring sensitivity to BRAF inhibitor in a patient with metastatic melanoma., Br J Dermatol",
                      "pmid": 29494756
                    },
                    {
                      "citation": "Oberl M et al., 2022, Response to BRAF and MEK Inhibitors in BRAF Thr599dup-Mutated Melanoma., JCO Precis Oncol",
                      "pmid": 35319964
                    },
                    {
                      "citation": "Turshudzhyan A et al., 2020, A Rare p.T599dup BRAF Mutant NSCLC in a Non-Smoker., Curr Oncol",
                      "pmid": 33704186
                    },
                    {
                      "citation": "Lu H et al., 2017, Engineering and Functional Characterization of Fusion Genes Identifies Novel Oncogenic Drivers of Cancer., Cancer Res",
                      "pmid": 28512244
                    },
                    {
                      "citation": "Johnson DB et al., 2018, BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy., Pigment Cell Melanoma Res",
                      "pmid": 29171936
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "OncoKB"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "PharmGKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Alteration",
                  "value": "BRAF:V600E"
                },
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "resistant"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Indication",
                  "value": "colon cancer"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Indication",
                  "value": "glioblastoma"
                },
                {
                  "name": "Response Type",
                  "value": "decreased response"
                },
                {
                  "name": "Indication",
                  "value": "Advanced Solid Tumor"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical"
                },
                {
                  "name": "Combination Therapy",
                  "value": "PLX4720 + Selumetinib"
                },
                {
                  "name": "Indication",
                  "value": "high grade glioma"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Navitoclax + PLX4720"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Gefitinib + PLX4720"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Cediranib + PLX4720"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Cediranib + PLX4720 + Selumetinib"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                },
                {
                  "name": "Combination Therapy",
                  "value": "PLX4720 + Tivozanib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "PLX4720 + TAK-632"
                },
                {
                  "name": "Indication",
                  "value": "colorectal cancer"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Everolimus + PLX4720"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Imatinib + PLX4720"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Alpelisib + PLX4720"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Erlotinib + PLX4720"
                },
                {
                  "name": "Combination Therapy",
                  "value": "PLX4720 + Vorinostat"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Doxorubicin + PLX4720"
                },
                {
                  "name": "Combination Therapy",
                  "value": "BI2536 + PLX4720"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Cetuximab + PLX4720"
                },
                {
                  "name": "Combination Therapy",
                  "value": "PLX4720 + Ponatinib"
                },
                {
                  "name": "Indication",
                  "value": "thyroid gland cancer"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Dasatinib + Gefitinib + PLX4720"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Gefitinib + PLX4720 + Saracatinib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Pictilisib + PLX4720"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - resistant"
                }
              ],
              "drug": {
                "name": "PLX-4720",
                "approved": false
              },
              "interactionScore": 0.7869529663098288,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Tsai J et al., 2008, Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity., Proc Natl Acad Sci U S A",
                      "pmid": 18287029
                    },
                    {
                      "citation": "Lerner RG et al., 2015, Targeting a Plk1-Controlled Polarity Checkpoint in Therapy-Resistant Glioblastoma-Propagating Cells., Cancer Res",
                      "pmid": 26573800
                    },
                    {
                      "citation": "Whittaker S et al., 2010, Gatekeeper mutations mediate resistance to BRAF-targeted therapies., Sci Transl Med",
                      "pmid": 20538618
                    },
                    {
                      "citation": "Friedman AA et al., 2015, Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment., PLoS One",
                      "pmid": 26461489
                    },
                    {
                      "citation": "Olow A et al., 2016, BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas., Clin Cancer Res",
                      "pmid": 27217440
                    },
                    {
                      "citation": "Frederick DT et al., 2014, Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics., PLoS One",
                      "pmid": 24983357
                    },
                    {
                      "citation": "Girotti MR et al., 2013, Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma., Cancer Discov",
                      "pmid": 23242808
                    },
                    {
                      "citation": "Karoulia Z et al., 2016, An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling., Cancer Cell",
                      "pmid": 27523909
                    },
                    {
                      "citation": "Vinik A et al., 2016, Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial., Target Oncol",
                      "pmid": 27924459
                    },
                    {
                      "citation": "Prahallad A et al., 2012, Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR., Nature",
                      "pmid": 22281684
                    },
                    {
                      "citation": "Ghosh C et al., 2020, A Combinatorial Strategy for Targeting BRAF (V600E)-Mutant Cancers with BRAF(V600E) Inhibitor (PLX4720) and Tyrosine Kinase Inhibitor (Ponatinib)., Clin Cancer Res",
                      "pmid": 31937621
                    },
                    {
                      "citation": "Ruiz-Saenz A et al., 2023, A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAF(V600E) colorectal tumors., Nat Cancer",
                      "pmid": 36759733
                    },
                    {
                      "citation": "Wagle N et al., 2011, Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling., J Clin Oncol",
                      "pmid": 21383288
                    },
                    {
                      "citation": "Emery CM et al., 2009, MEK1 mutations confer resistance to MEK and B-RAF inhibition., Proc Natl Acad Sci U S A",
                      "pmid": 19915144
                    },
                    {
                      "citation": "Van Allen EM et al., 2014, The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma., Cancer Discov",
                      "pmid": 24265153
                    },
                    {
                      "citation": "Whittaker SR et al., 2015, Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors., Mol Cancer Ther",
                      "pmid": 26351322
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "CIViC"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "CGI"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "decreased response"
                },
                {
                  "name": "Approval Status",
                  "value": "Clinical Study"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Indication",
                  "value": "lung non-small cell carcinoma"
                },
                {
                  "name": "Response Type",
                  "value": "not predictive"
                },
                {
                  "name": "Approval Status",
                  "value": "Clinical Study - Cohort"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Dabrafenib + Pembrolizumab + Trametinib"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Phase II"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Cobimetinib + Pembrolizumab + Vemurafenib"
                },
                {
                  "name": "Response Type",
                  "value": "no benefit"
                },
                {
                  "name": "Approval Status",
                  "value": "Phase I"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical"
                },
                {
                  "name": "Combination Therapy",
                  "value": "GSK2636771 + Pembrolizumab"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Indication",
                  "value": "glioblastoma"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Binimetinib + Encorafenib + Pembrolizumab"
                }
              ],
              "drug": {
                "name": "PEMBROLIZUMAB",
                "approved": true
              },
              "interactionScore": 0.08283715434840302,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "FDA"
                  }
                },
                {
                  "publications": [
                    {
                      "citation": "Pires da Silva I et al., 2019, Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant Melanoma., Clin Cancer Res",
                      "pmid": 30630828
                    },
                    {
                      "citation": "Dudnik E et al., 2018, BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors., J Thorac Oncol",
                      "pmid": 29723688
                    },
                    {
                      "citation": "Peng W et al., 2016, Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy., Cancer Discov",
                      "pmid": 26645196
                    },
                    {
                      "citation": "Zhao J et al., 2019, Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma., Nat Med",
                      "pmid": 30742119
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "PharmGKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Combination Therapy",
                  "value": "Bevacizumab + Pegylated liposomal doxorubicin + Temsirolimus"
                },
                {
                  "name": "Indication",
                  "value": "ovarian carcinoma"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Case Reports/Case Series"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Indication",
                  "value": "Exclusion criteria: Prior immunotherapy with ipilimumab, vaccination, B-raf inhibitor."
                },
                {
                  "name": "Cancer Type",
                  "value": "Melanoma"
                },
                {
                  "name": "Clinical Trial ID",
                  "value": "NCT01614301"
                }
              ],
              "drug": {
                "name": "TEMSIROLIMUS",
                "approved": true
              },
              "interactionScore": 0.06626972347872241,
              "interactionTypes": [
                {
                  "type": "inhibitor"
                }
              ],
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "MyCancerGenomeClinicalTrial"
                  }
                },
                {
                  "publications": [
                    {
                      "citation": "Janku F et al., 2011, PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors., Mol Cancer Ther",
                      "pmid": 21216929
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Indication",
                  "value": "high grade glioma"
                },
                {
                  "name": "Response Type",
                  "value": "no benefit"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Patient cell culture"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Vemurafenib + ZM336372"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                }
              ],
              "drug": {
                "name": "ZM336372",
                "approved": false
              },
              "interactionScore": 0.110449539131204,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Schreck KC et al., 2021, Deconvoluting Mechanisms of Acquired Resistance to RAF Inhibitors in BRAF(V600E)-Mutant Human Glioma., Clin Cancer Res",
                      "pmid": 34433654
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Indication",
                  "value": "colorectal cancer"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Pdx"
                }
              ],
              "drug": {
                "name": "BRAFV600/PI3K INHIBITOR ASN003",
                "approved": false
              },
              "interactionScore": 0.220899078262408,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TTD"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Direct Interaction",
                  "value": "true"
                },
                {
                  "name": "Mechanism of Action",
                  "value": "Serine/threonine-protein kinase B-raf inhibitor"
                },
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                },
                {
                  "name": "Indication",
                  "value": "colorectal cancer"
                },
                {
                  "name": "Approval Status",
                  "value": "Phase I"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Binimetinib + Encorafenib"
                },
                {
                  "name": "Approval Status",
                  "value": "FDA approved - On Companion Diagnostic"
                },
                {
                  "name": "Indication",
                  "value": "skin melanoma"
                },
                {
                  "name": "Approval Status",
                  "value": "Guideline"
                },
                {
                  "name": "Indication",
                  "value": "multiple myeloma"
                },
                {
                  "name": "Approval Status",
                  "value": "Phase II"
                },
                {
                  "name": "Indication",
                  "value": "ovarian serous carcinoma"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Case Reports/Case Series"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Encorafenib + Ribociclib"
                },
                {
                  "name": "Approval Status",
                  "value": "Phase Ib/II"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Cetuximab + Encorafenib"
                },
                {
                  "name": "Indication",
                  "value": "colon cancer"
                },
                {
                  "name": "Indication",
                  "value": "rectum cancer"
                },
                {
                  "name": "Approval Status",
                  "value": "Clinical Study"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Alpelisib + Cetuximab + Encorafenib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Binimetinib + Cetuximab + Encorafenib"
                },
                {
                  "name": "Approval Status",
                  "value": "Phase III"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Encorafenib + Panitumumab"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Cetuximab + Encorafenib + Ulixertinib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Celecoxib + Encorafenib + Panitumumab"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Pdx"
                },
                {
                  "name": "Response Type",
                  "value": "resistant"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - resistant"
                },
                {
                  "name": "Indication",
                  "value": "Advanced Solid Tumor"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Buparlisib + Encorafenib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "CGM097 + Encorafenib"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical"
                },
                {
                  "name": "Combination Therapy",
                  "value": "AZD6482 + Encorafenib"
                },
                {
                  "name": "Response Type",
                  "value": "no benefit"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Encorafenib + GSK2636771"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Alpelisib + Encorafenib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Encorafenib + Pictilisib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "AZD6482 + Encorafenib + NVP-AEW541"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Alpelisib + AZD6482 + Encorafenib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Alpelisib + AZD6482 + Binimetinib + Encorafenib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "AZD6482 + Binimetinib + Encorafenib + NVP-AEW541"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Alpelisib + Encorafenib + GSK2636771"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Encorafenib + unspecified IGF-1R antibody"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Encorafenib + GSK2636771 + unspecified IGF-1R antibody"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Encorafenib + Trametinib"
                },
                {
                  "name": "Indication",
                  "value": "lung non-small cell carcinoma"
                },
                {
                  "name": "Indication",
                  "value": "lung adenocarcinoma"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Patient cell culture"
                },
                {
                  "name": "Indication",
                  "value": "gallbladder cancer"
                },
                {
                  "name": "Indication",
                  "value": "ampulla of Vater cancer"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Pdx & cell culture"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Binimetinib + Encorafenib + Pembrolizumab"
                },
                {
                  "name": "Cancer Type",
                  "value": "Melanoma"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Encorafenib + Binimetinib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Encorafenib + Binimetinib + Cetuximab"
                }
              ],
              "drug": {
                "name": "ENCORAFENIB",
                "approved": true
              },
              "interactionScore": 1.251761443486979,
              "interactionTypes": [
                {
                  "type": "inhibitor"
                }
              ],
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "ChEMBL"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "FDA"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "MyCancerGenome"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "OncoKB"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TTD"
                  }
                },
                {
                  "publications": [
                    {
                      "citation": "Yao Z et al., 2019, RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling., Nat Med",
                      "pmid": 30559419
                    },
                    {
                      "citation": "Dummer R et al., 2018, Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial., Lancet Oncol",
                      "pmid": 29573941
                    },
                    {
                      "citation": "Dummer R et al., 2018, Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial., Lancet Oncol",
                      "pmid": 30219628
                    },
                    {
                      "citation": "Coit DG et al., 2019, Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology., J Natl Compr Canc Netw",
                      "pmid": 30959471
                    },
                    {
                      "citation": "Giesen N et al., 2023, A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAFV600E-mutated multiple myeloma., Blood",
                      "pmid": 36608320
                    },
                    {
                      "citation": "Tholander B et al., 2020, Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma., Ups J Med Sci",
                      "pmid": 33043759
                    },
                    {
                      "citation": "Tripathy D et al., 2017, Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors., Clin Cancer Res",
                      "pmid": 28351928
                    },
                    {
                      "citation": "Cervantes A et al., 2023, Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up., Ann Oncol",
                      "pmid": 36307056
                    },
                    {
                      "citation": "Kopetz S et al., 2019, Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer., N Engl J Med",
                      "pmid": 31566309
                    },
                    {
                      "citation": "Oddo D et al., 2016, Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer., Cancer Res",
                      "pmid": 27312529
                    },
                    {
                      "citation": "Boccaccino A et al., 2022, Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience., ESMO Open",
                      "pmid": 35696748
                    },
                    {
                      "citation": "Van Cutsem E et al., 2023, ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated BRAF(V600E)-Mutant Metastatic Colorectal Cancer., J Clin Oncol",
                      "pmid": 36763936
                    },
                    {
                      "citation": "Ruiz-Saenz A et al., 2023, A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAF(V600E) colorectal tumors., Nat Cancer",
                      "pmid": 36759733
                    },
                    {
                      "citation": "Mizuno S et al., 2023, High-Throughput Functional Evaluation of MAP2K1 Variants in Cancer., Mol Cancer Ther",
                      "pmid": 36442478
                    },
                    {
                      "citation": "Yaeger R et al., 2017, Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition., Cancer Res",
                      "pmid": 28951457
                    },
                    {
                      "citation": "Delord JP et al., 2017, Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma., Clin Cancer Res",
                      "pmid": 28611198
                    },
                    {
                      "citation": "Niessner H et al., 2016, PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo., Clin Cancer Res",
                      "pmid": 27307593
                    },
                    {
                      "citation": "van Geel RMJM et al., 2017, A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer., Cancer Discov",
                      "pmid": 28363909
                    },
                    {
                      "citation": "Herkert B et al., 2016, Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition., Cancer Res",
                      "pmid": 26577700
                    },
                    {
                      "citation": "Dankner M et al., 2018, Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas., Clin Cancer Res",
                      "pmid": 29903896
                    },
                    {
                      "citation": "Negrao MV et al., 2020, Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations., J Thorac Oncol",
                      "pmid": 32540409
                    },
                    {
                      "citation": "Rajkumar S et al., 2022, Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy., Cell Rep",
                      "pmid": 35385748
                    },
                    {
                      "citation": "Michielin O et al., 2019, Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up., Ann Oncol",
                      "pmid": 31566661
                    },
                    {
                      "citation": "Oberl M et al., 2022, Response to BRAF and MEK Inhibitors in BRAF Thr599dup-Mutated Melanoma., JCO Precis Oncol",
                      "pmid": 35319964
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "CIViC"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "CancerCommons"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "PharmGKB"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TALC"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Indication",
                  "value": "glioblastoma"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Case Reports/Case Series"
                },
                {
                  "name": "Indication",
                  "value": "Advanced Solid Tumor"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical"
                },
                {
                  "name": "Response Type",
                  "value": "decreased response"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                },
                {
                  "name": "Indication",
                  "value": "colon cancer"
                },
                {
                  "name": "Indication",
                  "value": "lung adenocarcinoma"
                },
                {
                  "name": "Indication",
                  "value": "colorectal cancer"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Pdx"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Cetuximab + PLX8394"
                },
                {
                  "name": "Indication",
                  "value": "lung cancer"
                },
                {
                  "name": "Response Type",
                  "value": "resistant"
                },
                {
                  "name": "Indication",
                  "value": "prostate cancer"
                },
                {
                  "name": "Approval Status",
                  "value": "Phase Ib/II"
                },
                {
                  "name": "Indication",
                  "value": "chronic lymphocytic leukemia"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - resistant"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Biochemical"
                }
              ],
              "drug": {
                "name": "PLX8394",
                "approved": false
              },
              "interactionScore": 0.9940458521808363,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "OncoKB"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TTD"
                  }
                },
                {
                  "publications": [
                    {
                      "citation": "Yao Z et al., 2019, RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling., Nat Med",
                      "pmid": 30559419
                    },
                    {
                      "citation": "Kushnirsky M et al., 2020, Prolonged Complete Response With Combined Dabrafenib and Trametinib After BRAF Inhibitor Failure in BRAF-Mutant Glioblastoma., JCO Precis Oncol",
                      "pmid": 32923904
                    },
                    {
                      "citation": "Basile KJ et al., 2014, Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors., Pigment Cell Melanoma Res",
                      "pmid": 24422853
                    },
                    {
                      "citation": "Wang J et al., 2018, A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAF(V600E)-Mutant Brain Tumor., Cancer Discov",
                      "pmid": 29880583
                    },
                    {
                      "citation": "Okimoto RA et al., 2016, Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer., Proc Natl Acad Sci U S A",
                      "pmid": 27834212
                    },
                    {
                      "citation": "Yap J et al., 2021, The stability of R-spine defines RAF inhibitor resistance: A comprehensive analysis of oncogenic BRAF mutants with in-frame insertion of C-4 loop., Sci Adv",
                      "pmid": 34108213
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Indication",
                  "value": "lung cancer"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Case Reports/Case Series"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                },
                {
                  "name": "Indication",
                  "value": "glioblastoma"
                },
                {
                  "name": "Indication",
                  "value": "pancreatic ductal adenocarcinoma"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                },
                {
                  "name": "Indication",
                  "value": "central nervous system cancer"
                },
                {
                  "name": "Indication",
                  "value": "pleomorphic xanthoastrocytoma"
                },
                {
                  "name": "Indication",
                  "value": "colorectal cancer"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Trametinib + Ulixertinib"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Cetuximab + Encorafenib + Ulixertinib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Binimetinib + Ulixertinib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Selumetinib + Ulixertinib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Ulixertinib + Vinblastine"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Navitoclax + Ulixertinib"
                },
                {
                  "name": "Response Type",
                  "value": "decreased response"
                },
                {
                  "name": "Response Type",
                  "value": "conflicting"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Palbociclib + Ulixertinib"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Pdx"
                },
                {
                  "name": "Indication",
                  "value": "lung adenocarcinoma"
                },
                {
                  "name": "Response Type",
                  "value": "resistant"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Patient cell culture"
                },
                {
                  "name": "Indication",
                  "value": "small intestine carcinoma"
                },
                {
                  "name": "Indication",
                  "value": "head and neck cancer"
                },
                {
                  "name": "Indication",
                  "value": "high grade glioma"
                },
                {
                  "name": "Indication",
                  "value": "low grade glioma"
                },
                {
                  "name": "Indication",
                  "value": "gallbladder cancer"
                }
              ],
              "drug": {
                "name": "ULIXERTINIB",
                "approved": false
              },
              "interactionScore": 0.3681651304373468,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Sullivan RJ et al., 2018, First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study., Cancer Discov",
                      "pmid": 29247021
                    },
                    {
                      "citation": "Germann UA et al., 2017, Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)., Mol Cancer Ther",
                      "pmid": 28939558
                    },
                    {
                      "citation": "Sigaud R et al., 2023, The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma models., Neuro Oncol",
                      "pmid": 35882450
                    },
                    {
                      "citation": "Emery CM et al., 2017, BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity., Mol Cancer Res",
                      "pmid": 28655712
                    },
                    {
                      "citation": "Mizuno S et al., 2023, High-Throughput Functional Evaluation of MAP2K1 Variants in Cancer., Mol Cancer Ther",
                      "pmid": 36442478
                    },
                    {
                      "citation": "Nassar KW et al., 2021, Targeting CDK4/6 Represents a Therapeutic Vulnerability in Acquired BRAF/MEK Inhibitor-Resistant Melanoma., Mol Cancer Ther",
                      "pmid": 34376578
                    },
                    {
                      "citation": "Negrao MV et al., 2020, Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations., J Thorac Oncol",
                      "pmid": 32540409
                    },
                    {
                      "citation": "Wolfe Z et al., 2022, Case report: response to the ERK1/2 inhibitor ulixertinib in BRAF D594G cutaneous melanoma., Melanoma Res",
                      "pmid": 35551160
                    },
                    {
                      "citation": "Chang MT et al., 2018, Accelerating Discovery of Functional Mutant Alleles in Cancer., Cancer Discov",
                      "pmid": 29247016
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Indication",
                  "value": "colon adenocarcinoma"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Patient cell culture"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                }
              ],
              "drug": {
                "name": "SAPITINIB",
                "approved": false
              },
              "interactionScore": 0.165674308696806,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Lehtomaki KI et al., 2019, Clonal Evolution of MEK/MAPK Pathway Activating Mutations in a Metastatic Colorectal Cancer Case., Anticancer Res",
                      "pmid": 31704811
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Clinical Trial ID",
                  "value": "NCT01450384"
                },
                {
                  "name": "Cancer Type",
                  "value": "Gastric cancer"
                },
                {
                  "name": "Indication",
                  "value": "Purpose: Pemetrexed disodium and sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth."
                },
                {
                  "name": "Cancer Type",
                  "value": "Lung cancer"
                },
                {
                  "name": "Clinical Trial ID",
                  "value": "NCT01377025"
                },
                {
                  "name": "Cancer Type",
                  "value": "Melanoma"
                },
                {
                  "name": "Indication",
                  "value": "Purpose: sorafenib as inhibitor of b-Raf and Raf-1 (c-Raf or c-Raf-1), pro-angiogenic vascular endothelial growth factor receptor (VEGFR), and platelet-derived growth factor receptor (PDGFR)."
                },
                {
                  "name": "Alteration",
                  "value": "BRAF__."
                },
                {
                  "name": "Alteration",
                  "value": "BRAF:D594G,G469E"
                },
                {
                  "name": "Clinical Trial ID",
                  "value": "NCT01303341"
                },
                {
                  "name": "Cancer Type",
                  "value": "Colorectal cancer"
                },
                {
                  "name": "Indication",
                  "value": "Purpose: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth."
                },
                {
                  "name": "Clinical Trial ID",
                  "value": "NCT00326495"
                },
                {
                  "name": "Indication",
                  "value": "Purpose: BAY 43-9006 is both a Raf kinase inhibitor and an inhibitor of VEGF receptor (VEGFR2) tyrosine kinase. Therapies targeting EGFR, like cetuximab, have shown activity in the treatment of solid tumors like CRC. %Inclusion criteria: Tumor should express EGFR"
                },
                {
                  "name": "Cancer Type",
                  "value": "Ovarian cancer"
                },
                {
                  "name": "Approval Status",
                  "value": "preclinical"
                },
                {
                  "name": "Pathway",
                  "value": "activation"
                },
                {
                  "name": "Variant Effect",
                  "value": "gain-of-function (low activity)"
                },
                {
                  "name": "Direct Interaction",
                  "value": "true"
                },
                {
                  "name": "Mechanism of Action",
                  "value": "Serine/threonine-protein kinase B-raf inhibitor"
                },
                {
                  "name": "Mechanism of Action",
                  "value": "RAF, VEGFR2, and PDGFR-beta inhibitors"
                },
                {
                  "name": "Clinical Trial Name",
                  "value": "Nexavar"
                },
                {
                  "name": "Novel Drug Target",
                  "value": "Established target"
                },
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Patient cell culture"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Response Type",
                  "value": "no benefit"
                },
                {
                  "name": "Approval Status",
                  "value": "Phase II"
                },
                {
                  "name": "Indication",
                  "value": "colorectal cancer"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Pimasertib + Sorafenib"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Cetuximab + Sorafenib"
                },
                {
                  "name": "Indication",
                  "value": "colon cancer"
                },
                {
                  "name": "Approval Status",
                  "value": "Case Reports/Case Series"
                },
                {
                  "name": "Combination Therapy",
                  "value": "C6-ceramide nanoliposome + Sorafenib"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                },
                {
                  "name": "Indication",
                  "value": "Advanced Solid Tumor"
                },
                {
                  "name": "Response Type",
                  "value": "conflicting"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Denosumab + Sorafenib"
                },
                {
                  "name": "Indication",
                  "value": "thyroid gland papillary carcinoma"
                },
                {
                  "name": "Indication",
                  "value": "lung non-small cell carcinoma"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - resistant"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Biochemical"
                }
              ],
              "drug": {
                "name": "SORAFENIB",
                "approved": true
              },
              "interactionScore": 0.1277072796204546,
              "interactionTypes": [
                {
                  "type": "inhibitor"
                }
              ],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Palanisamy N et al., 2010, Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma., Nat Med",
                      "pmid": 20526349
                    },
                    {
                      "citation": "Nakaoku T et al., 2014, Druggable oncogene fusions in invasive mucinous lung adenocarcinoma., Clin Cancer Res",
                      "pmid": 24727320
                    }
                  ],
                  "source": {
                    "sourceDbName": "CGI"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "ChEMBL"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "ClearityFoundationClinicalTrial"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "MyCancerGenomeClinicalTrial"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "MyCancerGenomeClinicalTrial"
                  }
                },
                {
                  "publications": [
                    {
                      "citation": "Gong L et al., 2017, PharmGKB summary: sorafenib pathways., Pharmacogenet Genomics",
                      "pmid": 28362716
                    }
                  ],
                  "source": {
                    "sourceDbName": "PharmGKB"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TdgClinicalTrial"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TEND"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "CIViC"
                  }
                },
                {
                  "publications": [
                    {
                      "citation": "Bahadoran P et al., 2013, Major clinical response to a BRAF inhibitor in a patient with a BRAF L597R-mutated melanoma., J Clin Oncol",
                      "pmid": 23715574
                    },
                    {
                      "citation": "Mangana J et al., 2012, Sorafenib in melanoma., Expert Opin Investig Drugs",
                      "pmid": 22394203
                    },
                    {
                      "citation": "Eisen T et al., 2006, Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis., Br J Cancer",
                      "pmid": 16880785
                    },
                    {
                      "citation": "Hirschi B et al., 2014, Genetic targeting of B-RafV600E affects survival and proliferation and identifies selective agents against BRAF-mutant colorectal cancer cells., Mol Cancer",
                      "pmid": 24885690
                    },
                    {
                      "citation": "Martinelli E et al., 2013, Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells., Int J Cancer",
                      "pmid": 23629727
                    },
                    {
                      "citation": "Al-Marrawi MY et al., 2013, Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer., Cancer Biol Ther",
                      "pmid": 23792568
                    },
                    {
                      "citation": "Tran MA et al., 2008, Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development., Clin Cancer Res",
                      "pmid": 18519791
                    },
                    {
                      "citation": "Whittaker S et al., 2010, Gatekeeper mutations mediate resistance to BRAF-targeted therapies., Sci Transl Med",
                      "pmid": 20538618
                    },
                    {
                      "citation": "Smalley KS et al., 2009, CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations., Oncogene",
                      "pmid": 18794803
                    },
                    {
                      "citation": "Caterino M et al., 2022, Sorafenib in Metastatic Papillary Thyroid Carcinoma with BRAF K601E Mutation on Liquid Biopsy: A Case Report and Literature Review., Medicina (Kaunas)",
                      "pmid": 35630083
                    },
                    {
                      "citation": "Casadei Gardini A et al., 2016, Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report., BMC Cancer",
                      "pmid": 27388325
                    },
                    {
                      "citation": "Yap J et al., 2021, The stability of R-spine defines RAF inhibitor resistance: A comprehensive analysis of oncogenic BRAF mutants with in-frame insertion of C-4 loop., Sci Adv",
                      "pmid": 34108213
                    },
                    {
                      "citation": "Khater F et al., 2019, Recurrent somatic BRAF insertion (p.V504_R506dup): a tumor marker and a potential therapeutic target in pilocytic astrocytoma., Oncogene",
                      "pmid": 30575814
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "MyCancerGenome"
                  }
                },
                {
                  "publications": [
                    {
                      "citation": "Chang MT et al., 2016, Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity., Nat Biotechnol",
                      "pmid": 26619011
                    },
                    {
                      "citation": "Rizzo S et al., 2010, Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?, Cancer Treat Rev",
                      "pmid": 21129611
                    },
                    {
                      "citation": "Maldonado JL et al., 2003, Determinants of BRAF mutations in primary melanomas., J Natl Cancer Inst",
                      "pmid": 14679157
                    },
                    {
                      "citation": "De Roock W et al., 2010, Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis., Lancet Oncol",
                      "pmid": 20619739
                    },
                    {
                      "citation": "Davies H et al., 2002, Mutations of the BRAF gene in human cancer., Nature",
                      "pmid": 12068308
                    },
                    {
                      "citation": "De Roock W et al., 2009, Clinical biomarkers in oncology: focus on colorectal cancer., Mol Diagn Ther",
                      "pmid": 19537845
                    },
                    {
                      "citation": "Tejpar S et al., 2010, Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery., Oncologist",
                      "pmid": 20350999
                    },
                    {
                      "citation": "Bardelli A et al., 2012, The road to resistance: EGFR mutation and cetuximab., Nat Med",
                      "pmid": 22310681
                    },
                    {
                      "citation": "MacConaill LE et al., 2014, Prospective enterprise-level molecular genotyping of a cohort of cancer patients., J Mol Diagn",
                      "pmid": 25157968
                    },
                    {
                      "citation": "Smalley KS et al., 2009, CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations., Oncogene",
                      "pmid": 18794803
                    },
                    {
                      "citation": "Bentivegna S et al., 2008, Rapid identification of somatic mutations in colorectal and breast cancer tissues using mismatch repair detection (MRD)., Hum Mutat",
                      "pmid": 18186519
                    }
                  ],
                  "source": {
                    "sourceDbName": "DoCM"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Combination Therapy",
                  "value": "Selumetinib + ZSTK474"
                },
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Vemurafenib + ZSTK474"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical"
                }
              ],
              "drug": {
                "name": "ZSTK474",
                "approved": false
              },
              "interactionScore": 0.08283715434840302,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Sweetlove M et al., 2015, Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth., Front Oncol",
                      "pmid": 26137449
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Indication",
                  "value": "Advanced Solid Tumor"
                },
                {
                  "name": "Response Type",
                  "value": "no benefit"
                },
                {
                  "name": "Approval Status",
                  "value": "Phase I"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                }
              ],
              "drug": {
                "name": "ERK INHIBITOR CC-90003",
                "approved": false
              },
              "interactionScore": 0.165674308696806,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                }
              ],
              "drug": {
                "name": "MEK INHIBITOR RO4987655",
                "approved": false
              },
              "interactionScore": 0.1325394469574448,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Nakanishi Y et al., 2015, ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor., Mol Cancer Ther",
                      "pmid": 26438159
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Phase III"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Response Type",
                  "value": "decreased response"
                },
                {
                  "name": "Approval Status",
                  "value": "Clinical Study - Cohort"
                },
                {
                  "name": "Indication",
                  "value": "lung non-small cell carcinoma"
                },
                {
                  "name": "Response Type",
                  "value": "not predictive"
                },
                {
                  "name": "Indication",
                  "value": "glioblastoma"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Ipilimumab + Nivolumab"
                },
                {
                  "name": "Approval Status",
                  "value": "Clinical Study"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Dabrafenib + Nivolumab + Trametinib"
                },
                {
                  "name": "Approval Status",
                  "value": "Phase II"
                }
              ],
              "drug": {
                "name": "NIVOLUMAB",
                "approved": true
              },
              "interactionScore": 0.1355517071155685,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "FDA"
                  }
                },
                {
                  "publications": [
                    {
                      "citation": "Ascierto PA et al., 2019, Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial., JAMA Oncol",
                      "pmid": 30422243
                    },
                    {
                      "citation": "Pires da Silva I et al., 2019, Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant Melanoma., Clin Cancer Res",
                      "pmid": 30630828
                    },
                    {
                      "citation": "Dudnik E et al., 2018, BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors., J Thorac Oncol",
                      "pmid": 29723688
                    },
                    {
                      "citation": "Zhao J et al., 2019, Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma., Nat Med",
                      "pmid": 30742119
                    },
                    {
                      "citation": "Tarhini AA et al., 2021, A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma()., ESMO Open",
                      "pmid": 33556898
                    },
                    {
                      "citation": "van Not OJ et al., 2022, BRAF and NRAS Mutation Status and Response to Checkpoint Inhibition in Advanced Melanoma., JCO Precis Oncol",
                      "pmid": 36130145
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "PharmGKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                }
              ],
              "drug": {
                "name": "UPROSERTIB",
                "approved": false
              },
              "interactionScore": 0.09467103354103204,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Shi H et al., 2014, A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition., Cancer Discov",
                      "pmid": 24265152
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Response Type",
                  "value": "no benefit"
                },
                {
                  "name": "Approval Status",
                  "value": "Phase II"
                },
                {
                  "name": "Indication",
                  "value": "colorectal cancer"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Pimasertib + Regorafenib"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Dabrafenib + Regorafenib + Trametinib"
                },
                {
                  "name": "Indication",
                  "value": "colon adenocarcinoma"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Case Reports/Case Series"
                },
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Pdx & cell culture"
                },
                {
                  "name": "Response Type",
                  "value": "resistant"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Cetuximab + Regorafenib"
                },
                {
                  "name": "Clinical Trial ID",
                  "value": "NCT01298570"
                },
                {
                  "name": "Cancer Type",
                  "value": "Colorectal cancer"
                },
                {
                  "name": "Clinical Trial ID",
                  "value": "NCT01298584"
                },
                {
                  "name": "Indication",
                  "value": "Purpose:  in patients with mCRC and KRAS or BRAF mutant disease."
                },
                {
                  "name": "Clinical Trial ID",
                  "value": "NCT01300299"
                },
                {
                  "name": "Cancer Type",
                  "value": "Lung cancer"
                },
                {
                  "name": "Direct Interaction",
                  "value": "true"
                },
                {
                  "name": "Mechanism of Action",
                  "value": "Serine/threonine-protein kinase B-raf inhibitor"
                }
              ],
              "drug": {
                "name": "REGORAFENIB",
                "approved": true
              },
              "interactionScore": 0.09619798569491964,
              "interactionTypes": [
                {
                  "type": "inhibitor"
                }
              ],
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "ChEMBL"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "MyCancerGenome"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "MyCancerGenomeClinicalTrial"
                  }
                },
                {
                  "publications": [
                    {
                      "citation": "Wilhelm SM et al., 2011, Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity., Int J Cancer",
                      "pmid": 21170960
                    },
                    {
                      "citation": "Martinelli E et al., 2013, Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells., Int J Cancer",
                      "pmid": 23629727
                    },
                    {
                      "citation": "Adamopoulos C et al., 2021, Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling., Cancer Discov",
                      "pmid": 33568355
                    },
                    {
                      "citation": "Napolitano S et al., 2015, Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab., Clin Cancer Res",
                      "pmid": 25838391
                    },
                    {
                      "citation": "Garca-Alfonso P et al., 2018, Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial)., Oncologist",
                      "pmid": 30120161
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Indication",
                  "value": "glioblastoma"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Combination Therapy",
                  "value": "BI2536 + PLX4720"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                }
              ],
              "drug": {
                "name": "BI-2536",
                "approved": false
              },
              "interactionScore": 0.220899078262408,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Lerner RG et al., 2015, Targeting a Plk1-Controlled Polarity Checkpoint in Therapy-Resistant Glioblastoma-Propagating Cells., Cancer Res",
                      "pmid": 26573800
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Mechanism of Action",
                  "value": "Sensitivity"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Binimetinib + Buparlisib"
                },
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Indication",
                  "value": "colon neuroendocrine neoplasm"
                },
                {
                  "name": "Response Type",
                  "value": "no benefit"
                },
                {
                  "name": "Approval Status",
                  "value": "Case Reports/Case Series"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Binimetinib + Encorafenib"
                },
                {
                  "name": "Approval Status",
                  "value": "FDA approved - On Companion Diagnostic"
                },
                {
                  "name": "Indication",
                  "value": "skin melanoma"
                },
                {
                  "name": "Approval Status",
                  "value": "Guideline"
                },
                {
                  "name": "Indication",
                  "value": "multiple myeloma"
                },
                {
                  "name": "Approval Status",
                  "value": "Phase II"
                },
                {
                  "name": "Indication",
                  "value": "ovarian serous carcinoma"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Binimetinib + Cetuximab + Encorafenib"
                },
                {
                  "name": "Indication",
                  "value": "colorectal cancer"
                },
                {
                  "name": "Approval Status",
                  "value": "Phase III"
                },
                {
                  "name": "Approval Status",
                  "value": "Clinical Study"
                },
                {
                  "name": "Combination Therapy",
                  "value": "ABM-1310 + Binimetinib"
                },
                {
                  "name": "Indication",
                  "value": "colon cancer"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Binimetinib + Ulixertinib"
                },
                {
                  "name": "Indication",
                  "value": "pleomorphic xanthoastrocytoma"
                },
                {
                  "name": "Response Type",
                  "value": "resistant"
                },
                {
                  "name": "Approval Status",
                  "value": "Phase I"
                },
                {
                  "name": "Indication",
                  "value": "Advanced Solid Tumor"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Binimetinib + GSK2636771"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical"
                },
                {
                  "name": "Combination Therapy",
                  "value": "AZD6482 + Binimetinib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Alpelisib + Binimetinib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Binimetinib + Pictilisib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Alpelisib + AZD6482 + Binimetinib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "AZD6482 + Binimetinib + NVP-AEW541"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Alpelisib + AZD6482 + Binimetinib + Encorafenib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "AZD6482 + Binimetinib + Encorafenib + NVP-AEW541"
                },
                {
                  "name": "Approval Status",
                  "value": "Phase Ib/II"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Pdx"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Binimetinib + Panitumumab"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - resistant"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Binimetinib + Cetuximab"
                },
                {
                  "name": "Indication",
                  "value": "gallbladder cancer"
                },
                {
                  "name": "Indication",
                  "value": "ampulla of Vater cancer"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Pdx & cell culture"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Binimetinib + Encorafenib + Pembrolizumab"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Biochemical"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Encorafenib + Binimetinib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Encorafenib + Binimetinib + Cetuximab"
                }
              ],
              "drug": {
                "name": "BINIMETINIB",
                "approved": true
              },
              "interactionScore": 0.4883032256326915,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "ClearityFoundationBiomarkers"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "FDA"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "OncoKB"
                  }
                },
                {
                  "publications": [
                    {
                      "citation": "Niessner H et al., 2016, PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo., Clin Cancer Res",
                      "pmid": 27307593
                    },
                    {
                      "citation": "Burkart J et al., 2018, Targeting BRAF Mutations in High-Grade Neuroendocrine Carcinoma of the Colon., J Natl Compr Canc Netw",
                      "pmid": 30181415
                    },
                    {
                      "citation": "Dummer R et al., 2018, Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial., Lancet Oncol",
                      "pmid": 29573941
                    },
                    {
                      "citation": "Dummer R et al., 2018, Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial., Lancet Oncol",
                      "pmid": 30219628
                    },
                    {
                      "citation": "Coit DG et al., 2019, Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology., J Natl Compr Canc Netw",
                      "pmid": 30959471
                    },
                    {
                      "citation": "Giesen N et al., 2023, A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAFV600E-mutated multiple myeloma., Blood",
                      "pmid": 36608320
                    },
                    {
                      "citation": "Tholander B et al., 2020, Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma., Ups J Med Sci",
                      "pmid": 33043759
                    },
                    {
                      "citation": "Van Cutsem E et al., 2023, ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated BRAF(V600E)-Mutant Metastatic Colorectal Cancer., J Clin Oncol",
                      "pmid": 36763936
                    },
                    {
                      "citation": "Kopetz S et al., 2019, Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer., N Engl J Med",
                      "pmid": 31566309
                    },
                    {
                      "citation": "Boccaccino A et al., 2022, Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience., ESMO Open",
                      "pmid": 35696748
                    },
                    {
                      "citation": "Sigaud R et al., 2023, The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma models., Neuro Oncol",
                      "pmid": 35882450
                    },
                    {
                      "citation": "Mizuno S et al., 2023, High-Throughput Functional Evaluation of MAP2K1 Variants in Cancer., Mol Cancer Ther",
                      "pmid": 36442478
                    },
                    {
                      "citation": "Bendell JC et al., 2017, A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor., Br J Cancer",
                      "pmid": 28152546
                    },
                    {
                      "citation": "Herkert B et al., 2016, Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition., Cancer Res",
                      "pmid": 26577700
                    },
                    {
                      "citation": "Yan J et al., 2018, Analysis of NRAS gain in 657 patients with melanoma and evaluation of its sensitivity to a MEK inhibitor., Eur J Cancer",
                      "pmid": 29245078
                    },
                    {
                      "citation": "Dankner M et al., 2018, Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas., Clin Cancer Res",
                      "pmid": 29903896
                    },
                    {
                      "citation": "Gao Y et al., 2019, V211D Mutation in MEK1 Causes Resistance to MEK Inhibitors in Colon Cancer., Cancer Discov",
                      "pmid": 31227518
                    },
                    {
                      "citation": "Rajkumar S et al., 2022, Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy., Cell Rep",
                      "pmid": 35385748
                    },
                    {
                      "citation": "Ascierto PA et al., 2013, MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study., Lancet Oncol",
                      "pmid": 23414587
                    },
                    {
                      "citation": "Michielin O et al., 2019, Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up., Ann Oncol",
                      "pmid": 31566661
                    },
                    {
                      "citation": "Oberl M et al., 2022, Response to BRAF and MEK Inhibitors in BRAF Thr599dup-Mutated Melanoma., JCO Precis Oncol",
                      "pmid": 35319964
                    },
                    {
                      "citation": "Yap J et al., 2021, The stability of R-spine defines RAF inhibitor resistance: A comprehensive analysis of oncogenic BRAF mutants with in-frame insertion of C-4 loop., Sci Adv",
                      "pmid": 34108213
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "CIViC"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "PharmGKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Combination Therapy",
                  "value": "CGM097 + Dabrafenib + Navitoclax + PF-04217903"
                },
                {
                  "name": "Indication",
                  "value": "colorectal cancer"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                }
              ],
              "drug": {
                "name": "PF-04217903",
                "approved": false
              },
              "interactionScore": 0.220899078262408,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Horn T et al., 2016, High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells., Cancer Res",
                      "pmid": 27659046
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - resistant"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Pdx"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Dabrafenib + KRT-232 + Trametinib"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                },
                {
                  "name": "Combination Therapy",
                  "value": "KRT-232 + Navitoclax"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                },
                {
                  "name": "Approval Status",
                  "value": "Phase I"
                }
              ],
              "drug": {
                "name": "NAVTEMADLIN",
                "approved": false
              },
              "interactionScore": 0.1988091704361672,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Shattuck-Brandt RL et al., 2020, Metastatic Melanoma Patient-Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition., Clin Cancer Res",
                      "pmid": 32234759
                    },
                    {
                      "citation": "Canon J et al., 2015, The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents., Mol Cancer Ther",
                      "pmid": 25567130
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Response Type",
                  "value": "resistant"
                }
              ],
              "drug": {
                "name": "U0126",
                "approved": false
              },
              "interactionScore": 0.165674308696806,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "CIViC"
                  }
                },
                {
                  "publications": [
                    {
                      "citation": "Smalley KS et al., 2009, CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations., Oncogene",
                      "pmid": 18794803
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Combination Therapy",
                  "value": "Lapatinib + Vemurafenib"
                },
                {
                  "name": "Indication",
                  "value": "thyroid gland cancer"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Lapatinib + Panobinostat"
                },
                {
                  "name": "Indication",
                  "value": "colorectal cancer"
                }
              ],
              "drug": {
                "name": "LAPATINIB",
                "approved": true
              },
              "interactionScore": 0.03823253277618601,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Montero-Conde C et al., 2013, Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas., Cancer Discov",
                      "pmid": 23365119
                    },
                    {
                      "citation": "LaBonte MJ et al., 2011, The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models., Cancer Res",
                      "pmid": 21464044
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Combination Therapy",
                  "value": "Ipilimumab + Nivolumab"
                },
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Clinical Study"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Approval Status",
                  "value": "Clinical Study - Cohort"
                }
              ],
              "drug": {
                "name": "IPILIMUMAB",
                "approved": true
              },
              "interactionScore": 0.08283715434840302,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Tarhini AA et al., 2021, A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma()., ESMO Open",
                      "pmid": 33556898
                    },
                    {
                      "citation": "van Not OJ et al., 2022, BRAF and NRAS Mutation Status and Response to Checkpoint Inhibition in Advanced Melanoma., JCO Precis Oncol",
                      "pmid": 36130145
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Case Reports/Case Series"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Indication",
                  "value": "cholangiocarcinoma"
                },
                {
                  "name": "Indication",
                  "value": "ovarian serous carcinoma"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                }
              ],
              "drug": {
                "name": "BRAF INHIBITOR BGB-3245",
                "approved": false
              },
              "interactionScore": 0.3313486173936121,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Wang J et al., 2018, A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAF(V600E)-Mutant Brain Tumor., Cancer Discov",
                      "pmid": 29880583
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Mechanism of Action",
                  "value": "Sensitivity"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Biochemical"
                },
                {
                  "name": "Approval Status",
                  "value": "FDA approved"
                },
                {
                  "name": "Approval Status",
                  "value": "Phase Ib/II"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Atezolizumab + Cobimetinib + Vemurafenib"
                },
                {
                  "name": "Approval Status",
                  "value": "Phase III"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Belvarafenib + Cobimetinib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Cobimetinib + Gemcitabine + Nab-paclitaxel"
                },
                {
                  "name": "Approval Status",
                  "value": "Phase I"
                },
                {
                  "name": "Response Type",
                  "value": "no benefit"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Cobimetinib + Pembrolizumab + Vemurafenib"
                },
                {
                  "name": "Indication",
                  "value": "high grade glioma"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - resistant"
                },
                {
                  "name": "Indication",
                  "value": "refractory hairy cell leukemia"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                },
                {
                  "name": "Response Type",
                  "value": "resistant"
                },
                {
                  "name": "Indication",
                  "value": "colon adenocarcinoma"
                },
                {
                  "name": "Indication",
                  "value": "Advanced Solid Tumor"
                },
                {
                  "name": "Indication",
                  "value": "low grade glioma"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                },
                {
                  "name": "Approval Status",
                  "value": "Phase II"
                },
                {
                  "name": "Indication",
                  "value": "colorectal cancer"
                },
                {
                  "name": "Indication",
                  "value": "skin melanoma"
                },
                {
                  "name": "Indication",
                  "value": "anaplastic oligodendroglioma"
                },
                {
                  "name": "Indication",
                  "value": "ganglioglioma"
                },
                {
                  "name": "Indication",
                  "value": "cholangiocarcinoma"
                },
                {
                  "name": "Indication",
                  "value": "pleomorphic xanthoastrocytoma"
                },
                {
                  "name": "Indication",
                  "value": "pilocytic astrocytoma"
                },
                {
                  "name": "Indication",
                  "value": "large cell carcinoma"
                },
                {
                  "name": "Indication",
                  "value": "pancreatic ductal adenocarcinoma"
                },
                {
                  "name": "Indication",
                  "value": "anaplastic astrocytoma"
                },
                {
                  "name": "Approval Status",
                  "value": "Guideline"
                },
                {
                  "name": "Indication",
                  "value": "glioblastoma"
                },
                {
                  "name": "Indication",
                  "value": "ovarian cancer"
                },
                {
                  "name": "Approval Status",
                  "value": "FDA approved - On Companion Diagnostic"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Indication",
                  "value": "breast cancer"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Cobimetinib + Vemurafenib"
                },
                {
                  "name": "Indication",
                  "value": "lymphatic system cancer"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Approval Status",
                  "value": "Case Reports/Case Series"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                },
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Vemurafenib + Cobimetinib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Vemurafenib;Cobimetinib"
                },
                {
                  "name": "Alteration",
                  "value": "BRAF:V600E,V600K"
                }
              ],
              "drug": {
                "name": "COBIMETINIB",
                "approved": true
              },
              "interactionScore": 0.6212786576130227,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "CGI"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "PharmGKB"
                  }
                },
                {
                  "publications": [
                    {
                      "citation": "Rosen LS et al., 2016, A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors., Invest New Drugs",
                      "pmid": 27424159
                    },
                    {
                      "citation": "Diamond EL et al., 2019, Efficacy of MEK inhibition in patients with histiocytic neoplasms., Nature",
                      "pmid": 30867592
                    },
                    {
                      "citation": "Ascierto PA et al., 2016, Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial., Lancet Oncol",
                      "pmid": 27480103
                    },
                    {
                      "citation": "Woo PYM et al., 2019, Regression of BRAF (V600E) mutant adult glioblastoma after primary combined BRAF-MEK inhibitor targeted therapy: a report of two cases., Oncotarget",
                      "pmid": 31217909
                    },
                    {
                      "citation": "Li HS et al., 2021, Remarkable response of BRAF (V600E)-mutated metastatic pancreatic cancer to BRAF/MEK inhibition: a case report., Gastroenterol Rep (Oxf)",
                      "pmid": 35382161
                    },
                    {
                      "citation": "Hoes LR et al., 2022, Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment., Clin Cancer Res",
                      "pmid": 35046062
                    },
                    {
                      "citation": "Bernocchi O et al., 2021, Tumor Type Agnostic Therapy Carrying BRAF Mutation: Case Reports and Review of Literature., Pharmaceuticals (Basel)",
                      "pmid": 33669326
                    },
                    {
                      "citation": "Klute KA et al., 2022, Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study., JCO Precis Oncol",
                      "pmid": 36409971
                    },
                    {
                      "citation": "Kirouac DC et al., 2017, Clinical responses to ERK inhibition in BRAF(V600E)-mutant colorectal cancer predicted using a computational model., NPJ Syst Biol Appl",
                      "pmid": 28649441
                    },
                    {
                      "citation": "Ardalan B et al., 2021, Potential benefit of treatment with MEK inhibitors and chemotherapy in BRAF-mutated KRAS wild-type pancreatic ductal adenocarcinoma patients: a case report., Cold Spring Harb Mol Case Stud",
                      "pmid": 34667063
                    },
                    {
                      "citation": "Mizuno S et al., 2023, High-Throughput Functional Evaluation of MAP2K1 Variants in Cancer., Mol Cancer Ther",
                      "pmid": 36442478
                    },
                    {
                      "citation": "Caeser R et al., 2019, Targeting MEK in vemurafenib-resistant hairy cell leukemia., Leukemia",
                      "pmid": 30341394
                    },
                    {
                      "citation": "Nassar KW et al., 2021, Targeting CDK4/6 Represents a Therapeutic Vulnerability in Acquired BRAF/MEK Inhibitor-Resistant Melanoma., Mol Cancer Ther",
                      "pmid": 34376578
                    },
                    {
                      "citation": "Schreck KC et al., 2021, Deconvoluting Mechanisms of Acquired Resistance to RAF Inhibitors in BRAF(V600E)-Mutant Human Glioma., Clin Cancer Res",
                      "pmid": 34433654
                    },
                    {
                      "citation": "Yen I et al., 2021, ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma., Nature",
                      "pmid": 33953400
                    },
                    {
                      "citation": "Dankner M et al., 2018, Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas., Clin Cancer Res",
                      "pmid": 29903896
                    },
                    {
                      "citation": "Hoeflich KP et al., 2012, Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition., Cancer Res",
                      "pmid": 22084396
                    },
                    {
                      "citation": "Michielin O et al., 2019, Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up., Ann Oncol",
                      "pmid": 31566661
                    },
                    {
                      "citation": "Sullivan RJ et al., 2019, Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients., Nat Med",
                      "pmid": 31171876
                    },
                    {
                      "citation": "Gutzmer R et al., 2020, Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF(V600) mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial., Lancet",
                      "pmid": 32534646
                    },
                    {
                      "citation": "Foster SA et al., 2016, Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2., Cancer Cell",
                      "pmid": 26996308
                    },
                    {
                      "citation": "Lobo-Martins S et al., 2021, BRAF L597K mutation: an opportunity to treat., Dermatol Online J",
                      "pmid": 33560788
                    },
                    {
                      "citation": "Yap J et al., 2021, The stability of R-spine defines RAF inhibitor resistance: A comprehensive analysis of oncogenic BRAF mutants with in-frame insertion of C-4 loop., Sci Adv",
                      "pmid": 34108213
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "CIViC"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "FDA"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "ClearityFoundationBiomarkers"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "OncoKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Clinical Trial Name",
                  "value": "CHIR-265"
                },
                {
                  "name": "Novel Drug Target",
                  "value": "Established target"
                },
                {
                  "name": "Cancer Type",
                  "value": "Melanoma"
                }
              ],
              "drug": {
                "name": "CHIR-265",
                "approved": false
              },
              "interactionScore": 0.165674308696806,
              "interactionTypes": [
                {
                  "type": "inhibitor"
                }
              ],
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "CancerCommons"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TdgClinicalTrial"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Pdx"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Indication",
                  "value": "colorectal cancer"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical"
                }
              ],
              "drug": {
                "name": "CCT241161",
                "approved": false
              },
              "interactionScore": 0.6626972347872242,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Girotti MR et al., 2015, Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma., Cancer Cell",
                      "pmid": 25500121
                    },
                    {
                      "citation": "Jarry A et al., 2004, Real-time allele-specific amplification for sensitive detection of the BRAF mutation V600E., Mol Cell Probes",
                      "pmid": 15294323
                    },
                    {
                      "citation": "Gray-Schopfer VC et al., 2007, Tumor necrosis factor-alpha blocks apoptosis in melanoma cells when BRAF signaling is inhibited., Cancer Res",
                      "pmid": 17210691
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Combination Therapy",
                  "value": "PLX4720 + Vorinostat"
                },
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Trametinib + Vorinostat"
                },
                {
                  "name": "Indication",
                  "value": "colorectal cancer"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                }
              ],
              "drug": {
                "name": "VORINOSTAT",
                "approved": true
              },
              "interactionScore": 0.02160969243871383,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Vinik A et al., 2016, Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial., Target Oncol",
                      "pmid": 27924459
                    },
                    {
                      "citation": "Jenkins LJ et al., 2023, Genotype-Tailored ERK/MAPK Pathway and HDAC Inhibition Rewires the Apoptotic Rheostat to Trigger Colorectal Cancer Cell Death., Mol Cancer Ther",
                      "pmid": 36343387
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Direct Interaction",
                  "value": "true"
                },
                {
                  "name": "Mechanism of Action",
                  "value": "Serine/threonine-protein kinase B-raf inhibitor"
                }
              ],
              "drug": {
                "name": "RG-7256",
                "approved": false
              },
              "interactionScore": 0.6626972347872242,
              "interactionTypes": [
                {
                  "type": "inhibitor"
                }
              ],
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TTD"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "ChEMBL"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Saracatinib + Vemurafenib"
                },
                {
                  "name": "Indication",
                  "value": "colorectal cancer"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Gefitinib + PLX4720 + Saracatinib"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                }
              ],
              "drug": {
                "name": "SARACATINIB",
                "approved": false
              },
              "interactionScore": 0.09940458521808361,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Girotti MR et al., 2013, Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma., Cancer Discov",
                      "pmid": 23242808
                    },
                    {
                      "citation": "Ruiz-Saenz A et al., 2023, A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAF(V600E) colorectal tumors., Nat Cancer",
                      "pmid": 36759733
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Approval Status",
                  "value": "Case Reports/Case Series"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Pdx & cell culture"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                },
                {
                  "name": "Indication",
                  "value": "colorectal cancer"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Ganetespib + TAK-733"
                }
              ],
              "drug": {
                "name": "TAK-733",
                "approved": false
              },
              "interactionScore": 0.2650788939148897,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Acquaviva J et al., 2014, Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib., Mol Cancer Ther",
                      "pmid": 24398428
                    },
                    {
                      "citation": "Lieu CH et al., 2015, Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts., Oncotarget",
                      "pmid": 26439693
                    },
                    {
                      "citation": "Dahlman KB et al., 2012, BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors., Cancer Discov",
                      "pmid": 22798288
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Combination Therapy",
                  "value": "Dabrafenib + Rabeprazole + Rifampin + Trametinib"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Approval Status",
                  "value": "Case Reports/Case Series"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                },
                {
                  "name": "Indication",
                  "value": "endometrial adenocarcinoma"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Dabrafenib + Rabeprazole + Rifampin"
                }
              ],
              "drug": {
                "name": "RABEPRAZOLE",
                "approved": true
              },
              "interactionScore": 0.02548835518412401,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Butt SU et al., 2021, BRAF/MEK inhibitors for BRAF V600E-mutant cancers in non-approved setting: a case series., Cancer Chemother Pharmacol",
                      "pmid": 33537843
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                },
                {
                  "name": "Indication",
                  "value": "melanoma"
                }
              ],
              "drug": {
                "name": "TINLORAFENIB",
                "approved": false
              },
              "interactionScore": 0.3313486173936121,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Approval Status",
                  "value": "Preclinical"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Indication",
                  "value": "colorectal cancer"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - resistant"
                },
                {
                  "name": "Indication",
                  "value": "high grade glioma"
                }
              ],
              "drug": {
                "name": "NERATINIB",
                "approved": true
              },
              "interactionScore": 0.08283715434840302,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Schreck KC et al., 2021, Deconvoluting Mechanisms of Acquired Resistance to RAF Inhibitors in BRAF(V600E)-Mutant Human Glioma., Clin Cancer Res",
                      "pmid": 34433654
                    },
                    {
                      "citation": "Kavuri SM et al., 2015, HER2 activating mutations are targets for colorectal cancer treatment., Cancer Discov",
                      "pmid": 26243863
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Combination Therapy",
                  "value": "Axitinib + Vemurafenib"
                },
                {
                  "name": "Indication",
                  "value": "colorectal cancer"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                }
              ],
              "drug": {
                "name": "AXITINIB",
                "approved": true
              },
              "interactionScore": 0.03681651304373468,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Tran KB et al., 2022, Response to BRAF-targeted Therapy Is Enhanced by Cotargeting VEGFRs or WNT/-Catenin Signaling in BRAF-mutant Colorectal Cancer Models., Mol Cancer Ther",
                      "pmid": 36198029
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [],
              "drug": {
                "name": "MITOGEN-ACTIVATED PROTEIN KINASE KINASE INHIBITOR",
                "approved": false
              },
              "interactionScore": 0.05522476956560202,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "CIViC"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Combination Therapy",
                  "value": "Denosumab + Sorafenib"
                },
                {
                  "name": "Indication",
                  "value": "thyroid gland papillary carcinoma"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Case Reports/Case Series"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                }
              ],
              "drug": {
                "name": "DENOSUMAB",
                "approved": true
              },
              "interactionScore": 0.220899078262408,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Caterino M et al., 2022, Sorafenib in Metastatic Papillary Thyroid Carcinoma with BRAF K601E Mutation on Liquid Biopsy: A Case Report and Literature Review., Medicina (Kaunas)",
                      "pmid": 35630083
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Venetoclax + VX-11e"
                },
                {
                  "name": "Indication",
                  "value": "colorectal cancer"
                },
                {
                  "name": "Response Type",
                  "value": "no benefit"
                },
                {
                  "name": "Combination Therapy",
                  "value": "VX-11e + WEHI-539"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                }
              ],
              "drug": {
                "name": "VTX-11E",
                "approved": false
              },
              "interactionScore": 0.6626972347872242,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Van Allen EM et al., 2014, The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma., Cancer Discov",
                      "pmid": 24265153
                    },
                    {
                      "citation": "Carlino MS et al., 2015, Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients., Clin Cancer Res",
                      "pmid": 25370473
                    },
                    {
                      "citation": "Anderson GR et al., 2016, PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation., Sci Transl Med",
                      "pmid": 27974663
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Combination Therapy",
                  "value": "Ruxolitinib + Vemurafenib"
                },
                {
                  "name": "Indication",
                  "value": "hairy cell leukemia"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Phase II"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                }
              ],
              "drug": {
                "name": "RUXOLITINIB",
                "approved": true
              },
              "interactionScore": 0.05097671036824802,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Tiacci E et al., 2021, Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia., N Engl J Med",
                      "pmid": 33979489
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Pdx & cell culture"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Indication",
                  "value": "colorectal cancer"
                },
                {
                  "name": "Indication",
                  "value": "diffuse large B-cell lymphoma"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                }
              ],
              "drug": {
                "name": "ERK1/2 INHIBITOR ERAS-007",
                "approved": false
              },
              "interactionScore": 0.220899078262408,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Portelinha A et al., 2021, ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors., Cell Rep Med",
                      "pmid": 34337566
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Indication",
                  "value": "colon cancer"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "conflicting"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                },
                {
                  "name": "Indication",
                  "value": "glioblastoma"
                },
                {
                  "name": "Response Type",
                  "value": "decreased response"
                },
                {
                  "name": "Indication",
                  "value": "colorectal cancer"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Palbociclib + PD-0325901"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Lifirafenib + PD-0325901"
                },
                {
                  "name": "Indication",
                  "value": "lung non-small cell carcinoma"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Phase I"
                },
                {
                  "name": "Response Type",
                  "value": "resistant"
                },
                {
                  "name": "Combination Therapy",
                  "value": "PD-0325901 + Sapanisertib"
                },
                {
                  "name": "Indication",
                  "value": "ovarian cancer"
                }
              ],
              "drug": {
                "name": "MIRDAMETINIB",
                "approved": false
              },
              "interactionScore": 0.1767192626099264,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Solit DB et al., 2006, BRAF mutation predicts sensitivity to MEK inhibition., Nature",
                      "pmid": 16273091
                    },
                    {
                      "citation": "Teh JL et al., 2016, An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma., Cancer Res",
                      "pmid": 27488531
                    },
                    {
                      "citation": "Herrero A et al., 2015, Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes., Cancer Cell",
                      "pmid": 26267534
                    },
                    {
                      "citation": "Wada M et al., 2014, The dual RAF/MEK inhibitor CH5126766/RO5126766 may be a potential therapy for RAS-mutated tumor cells., PLoS One",
                      "pmid": 25422890
                    },
                    {
                      "citation": "Lerner RG et al., 2015, Targeting a Plk1-Controlled Polarity Checkpoint in Therapy-Resistant Glioblastoma-Propagating Cells., Cancer Res",
                      "pmid": 26573800
                    },
                    {
                      "citation": "Garca-Garca C et al., 2015, MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer., Clin Cancer Res",
                      "pmid": 26272063
                    },
                    {
                      "citation": "Foster SA et al., 2016, Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2., Cancer Cell",
                      "pmid": 26996308
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Indication",
                  "value": "colorectal adenocarcinoma"
                },
                {
                  "name": "Combination Therapy",
                  "value": "ASTX029 + Vemurafenib"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                }
              ],
              "drug": {
                "name": "ASTX029",
                "approved": false
              },
              "interactionScore": 0.220899078262408,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Munck JM et al., 2021, ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK., Mol Cancer Ther",
                      "pmid": 34330842
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Combination Therapy",
                  "value": "PD-0325901 + Sapanisertib"
                },
                {
                  "name": "Indication",
                  "value": "colorectal cancer"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                }
              ],
              "drug": {
                "name": "SAPANISERTIB",
                "approved": true
              },
              "interactionScore": 0.03898219028160143,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Garca-Garca C et al., 2015, MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer., Clin Cancer Res",
                      "pmid": 26272063
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Indication",
                  "value": "colon cancer"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                }
              ],
              "drug": {
                "name": "GEDATOLISIB",
                "approved": false
              },
              "interactionScore": 0.03976183408723344,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Ahmed D et al., 2013, Epigenetic and genetic features of 24 colon cancer cell lines., Oncogenesis",
                      "pmid": 24042735
                    },
                    {
                      "citation": "Mallon R et al., 2011, Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor., Clin Cancer Res",
                      "pmid": 21325073
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "no benefit"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                }
              ],
              "drug": {
                "name": "IDELALISIB",
                "approved": true
              },
              "interactionScore": 0.1325394469574448,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Sweetlove M et al., 2015, Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth., Front Oncol",
                      "pmid": 26137449
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Combination Therapy",
                  "value": "Chloroquine + Trametinib"
                },
                {
                  "name": "Indication",
                  "value": "colorectal cancer"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Pdx"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                }
              ],
              "drug": {
                "name": "CHLOROQUINE",
                "approved": true
              },
              "interactionScore": 0.04733551677051602,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Kinsey CG et al., 2019, Protective autophagy elicited by RAFMEKERK inhibition suggests a treatment strategy for RAS-driven cancers., Nat Med",
                      "pmid": 30833748
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Combination Therapy",
                  "value": "BI 882370 + Trametinib"
                },
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Indication",
                  "value": "colorectal cancer"
                },
                {
                  "name": "Combination Therapy",
                  "value": "BI 882370 + Cetuximab"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Afatinib + BI 882370"
                }
              ],
              "drug": {
                "name": "PAN-RAF INHIBITOR XP-102",
                "approved": false
              },
              "interactionScore": 0.6626972347872242,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Waizenegger IC et al., 2016, A Novel RAF Kinase Inhibitor with DFG-Out-Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation., Mol Cancer Ther",
                      "pmid": 26916115
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Combination Therapy",
                  "value": "unspecified PD-1 antibody + VE800"
                },
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                }
              ],
              "drug": {
                "name": "COMMENSAL BACTERIAL STRAIN FORMULATION VE800",
                "approved": false
              },
              "interactionScore": 0.3313486173936121,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Tanoue T et al., 2019, A defined commensal consortium elicits CD8 T cells and anti-cancer immunity., Nature",
                      "pmid": 30675064
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "no benefit"
                },
                {
                  "name": "Approval Status",
                  "value": "Phase II"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Everolimus + Selumetinib"
                },
                {
                  "name": "Indication",
                  "value": "high grade glioma"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                },
                {
                  "name": "Indication",
                  "value": "thyroid gland cancer"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                },
                {
                  "name": "Indication",
                  "value": "pilocytic astrocytoma"
                },
                {
                  "name": "Approval Status",
                  "value": "Guideline"
                },
                {
                  "name": "Indication",
                  "value": "childhood pilocytic astrocytoma"
                },
                {
                  "name": "Approval Status",
                  "value": "Phase I"
                },
                {
                  "name": "Indication",
                  "value": "colorectal cancer"
                },
                {
                  "name": "Indication",
                  "value": "Advanced Solid Tumor"
                },
                {
                  "name": "Approval Status",
                  "value": "Clinical Study - Cohort"
                },
                {
                  "name": "Combination Therapy",
                  "value": "PLX4720 + Selumetinib"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Cediranib + PLX4720 + Selumetinib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Cetuximab + Selumetinib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Dasatinib + Selumetinib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Selumetinib + Ulixertinib"
                },
                {
                  "name": "Indication",
                  "value": "pleomorphic xanthoastrocytoma"
                },
                {
                  "name": "Response Type",
                  "value": "decreased response"
                },
                {
                  "name": "Response Type",
                  "value": "resistant"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Patient cell culture"
                },
                {
                  "name": "Indication",
                  "value": "colon cancer"
                },
                {
                  "name": "Approval Status",
                  "value": "Case Reports/Case Series"
                },
                {
                  "name": "Combination Therapy",
                  "value": "AZ628 + Selumetinib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "SAR260301 + Selumetinib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Dactolisib + Selumetinib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Selumetinib + ZSTK474"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Selumetinib + Vemurafenib"
                },
                {
                  "name": "Indication",
                  "value": "colon adenocarcinoma"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Buparlisib + Selumetinib"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Biochemical"
                },
                {
                  "name": "Alteration",
                  "value": "BRAF__."
                },
                {
                  "name": "Alteration",
                  "value": "BRAF:V600E"
                },
                {
                  "name": "Alteration",
                  "value": "NF1:.;BRAF:."
                },
                {
                  "name": "Alteration",
                  "value": "NF1:del;BRAF:."
                },
                {
                  "name": "Mechanism of Action",
                  "value": "Sensitivity"
                }
              ],
              "drug": {
                "name": "SELUMETINIB",
                "approved": true
              },
              "interactionScore": 0.2692207516323098,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "CGI"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "ClearityFoundationBiomarkers"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "PharmGKB"
                  }
                },
                {
                  "publications": [
                    {
                      "citation": "Kirkwood JM et al., 2012, Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma., Clin Cancer Res",
                      "pmid": 22048237
                    },
                    {
                      "citation": "Olow A et al., 2016, BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas., Clin Cancer Res",
                      "pmid": 27217440
                    },
                    {
                      "citation": "Beadnell TC et al., 2016, The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer., Mol Cancer Ther",
                      "pmid": 27222538
                    },
                    {
                      "citation": "Fangusaro J et al., 2019, Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial., Lancet Oncol",
                      "pmid": 31151904
                    },
                    {
                      "citation": "Beloueche-Babari M et al., 2013, Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI., Br J Cancer",
                      "pmid": 23942066
                    },
                    {
                      "citation": "Friedman AA et al., 2015, Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment., PLoS One",
                      "pmid": 26461489
                    },
                    {
                      "citation": "Oddo D et al., 2016, Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer., Cancer Res",
                      "pmid": 27312529
                    },
                    {
                      "citation": "Sigaud R et al., 2023, The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma models., Neuro Oncol",
                      "pmid": 35882450
                    },
                    {
                      "citation": "Narita Y et al., 2014, Novel ATP-competitive MEK inhibitor E6201 is effective against vemurafenib-resistant melanoma harboring the MEK1-C121S mutation in a preclinical model., Mol Cancer Ther",
                      "pmid": 24448821
                    },
                    {
                      "citation": "Emery CM et al., 2009, MEK1 mutations confer resistance to MEK and B-RAF inhibition., Proc Natl Acad Sci U S A",
                      "pmid": 19915144
                    },
                    {
                      "citation": "Nikolaev SI et al., 2011, Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma., Nat Genet",
                      "pmid": 22197931
                    },
                    {
                      "citation": "McNew KL et al., 2016, MEK and TAK1 Regulate Apoptosis in Colon Cancer Cells with KRAS-Dependent Activation of Proinflammatory Signaling., Mol Cancer Res",
                      "pmid": 27655129
                    },
                    {
                      "citation": "Ho AL et al., 2013, Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer., N Engl J Med",
                      "pmid": 23406027
                    },
                    {
                      "citation": "Whittaker SR et al., 2015, Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors., Mol Cancer Ther",
                      "pmid": 26351322
                    },
                    {
                      "citation": "Bonnevaux H et al., 2016, Concomitant Inhibition of PI3K and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3K-Selective Inhibitor., Mol Cancer Ther",
                      "pmid": 27196754
                    },
                    {
                      "citation": "Sweetlove M et al., 2015, Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth., Front Oncol",
                      "pmid": 26137449
                    },
                    {
                      "citation": "Lehtomaki KI et al., 2019, Clonal Evolution of MEK/MAPK Pathway Activating Mutations in a Metastatic Colorectal Cancer Case., Anticancer Res",
                      "pmid": 31704811
                    },
                    {
                      "citation": "Shi H et al., 2014, A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition., Cancer Discov",
                      "pmid": 24265152
                    },
                    {
                      "citation": "Peng SB et al., 2015, Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers., Cancer Cell",
                      "pmid": 26343583
                    },
                    {
                      "citation": "Yap J et al., 2021, The stability of R-spine defines RAF inhibitor resistance: A comprehensive analysis of oncogenic BRAF mutants with in-frame insertion of C-4 loop., Sci Adv",
                      "pmid": 34108213
                    },
                    {
                      "citation": "Nakai C et al., 2023, Regulation of MEK inhibitor selumetinib sensitivity by AKT phosphorylation in the novel BRAF L525R mutant., Int J Clin Oncol",
                      "pmid": 36856908
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "CIViC"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Combination Therapy",
                  "value": "Alpelisib + Dabrafenib + Erlotinib + Navitoclax"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Alpelisib + Encorafenib + GSK2636771"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Alpelisib + AZD6482 + Binimetinib + Encorafenib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Alpelisib + AZD6482 + Encorafenib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Alpelisib + AZD6482 + Binimetinib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Alpelisib + Encorafenib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Alpelisib + NVP-AEW541"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Alpelisib + GSK2636771"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Alpelisib + AZD6482"
                },
                {
                  "name": "Response Type",
                  "value": "no benefit"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Alpelisib + Binimetinib"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical"
                },
                {
                  "name": "Response Type",
                  "value": "decreased response"
                },
                {
                  "name": "Approval Status",
                  "value": "Phase Ib/II"
                },
                {
                  "name": "Approval Status",
                  "value": "Case Reports/Case Series"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - resistant"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                },
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Alpelisib + PLX4720"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Indication",
                  "value": "colorectal cancer"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Alpelisib + Cetuximab + Encorafenib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Panitumumab;Dabrafenib;BYL719"
                },
                {
                  "name": "Alteration",
                  "value": "BRAF:V600."
                }
              ],
              "drug": {
                "name": "ALPELISIB",
                "approved": true
              },
              "interactionScore": 0.0931917986419534,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Oddo D et al., 2016, Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer., Cancer Res",
                      "pmid": 27312529
                    },
                    {
                      "citation": "Vinik A et al., 2016, Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial., Target Oncol",
                      "pmid": 27924459
                    },
                    {
                      "citation": "Yaeger R et al., 2017, Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition., Cancer Res",
                      "pmid": 28951457
                    },
                    {
                      "citation": "van Geel RMJM et al., 2017, A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer., Cancer Discov",
                      "pmid": 28363909
                    },
                    {
                      "citation": "Herkert B et al., 2016, Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition., Cancer Res",
                      "pmid": 26577700
                    },
                    {
                      "citation": "Horn T et al., 2016, High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells., Cancer Res",
                      "pmid": 27659046
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "CGI"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "CIViC"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Indication",
                  "value": "melanoma"
                }
              ],
              "drug": {
                "name": "TUBASTATIN A",
                "approved": false
              },
              "interactionScore": 0.220899078262408,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Woan KV et al., 2015, Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation., Mol Oncol",
                      "pmid": 25957812
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Combination Therapy",
                  "value": "Irinotecan;Vemurafenib;Cetuximab"
                },
                {
                  "name": "Alteration",
                  "value": "BRAF:V600."
                },
                {
                  "name": "Alteration",
                  "value": "BRAF:V600E"
                },
                {
                  "name": "Approval Status",
                  "value": "late trials"
                },
                {
                  "name": "Pathway",
                  "value": "activation"
                },
                {
                  "name": "Variant Effect",
                  "value": "gain-of-function"
                },
                {
                  "name": "Indication",
                  "value": "colon cancer"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Guideline"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Indication",
                  "value": "rectum cancer"
                },
                {
                  "name": "Response Type",
                  "value": "resistant"
                },
                {
                  "name": "Indication",
                  "value": "colorectal cancer"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Cetuximab + Irinotecan + Vemurafenib"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Phase II"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Cetuximab + Vemurafenib"
                },
                {
                  "name": "Approval Status",
                  "value": "Case Reports/Case Series"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Cetuximab + Encorafenib"
                },
                {
                  "name": "Approval Status",
                  "value": "FDA approved - On Companion Diagnostic"
                },
                {
                  "name": "Approval Status",
                  "value": "Clinical Study"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Alpelisib + Cetuximab + Encorafenib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "BI 882370 + Cetuximab"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Cetuximab + Dabrafenib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Cetuximab + Selumetinib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Cetuximab + Dabrafenib + Trametinib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Cetuximab + Dabrafenib + SCH772984"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Cetuximab + SCH772984"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Cetuximab + Lifirafenib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Binimetinib + Cetuximab + Encorafenib"
                },
                {
                  "name": "Approval Status",
                  "value": "Phase III"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Cetuximab + PLX4720"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Cetuximab + Sorafenib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "ABM-1310 + Cetuximab"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Cetuximab + Encorafenib + Ulixertinib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Cetuximab + Regorafenib"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - resistant"
                },
                {
                  "name": "Combination Therapy",
                  "value": "BGB659 + Cetuximab"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Pdx"
                },
                {
                  "name": "Approval Status",
                  "value": "Phase Ib/II"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Cetuximab + LSN3074753"
                },
                {
                  "name": "Response Type",
                  "value": "not predictive"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Cetuximab + Irinotecan"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Cetuximab + Fluorouracil + Irinotecan + Leucovorin"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Cetuximab + PLX8394"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Binimetinib + Cetuximab"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Cetuximab + Trametinib"
                },
                {
                  "name": "Indication",
                  "value": "colon adenocarcinoma"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Patient cell culture"
                },
                {
                  "name": "Response Type",
                  "value": "decreased response"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Encorafenib + Binimetinib + Cetuximab"
                }
              ],
              "drug": {
                "name": "CETUXIMAB",
                "approved": true
              },
              "interactionScore": 1.072010232744039,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "De Roock W et al., 2010, Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis., Lancet Oncol",
                      "pmid": 20619739
                    },
                    {
                      "citation": "De Roock W et al., 2011, KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer., Lancet Oncol",
                      "pmid": 21163703
                    },
                    {
                      "citation": "Peeters M et al., 2013, Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer., Clin Cancer Res",
                      "pmid": 23325582
                    }
                  ],
                  "source": {
                    "sourceDbName": "CGI"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "OncoKB"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "CIViC"
                  }
                },
                {
                  "publications": [
                    {
                      "citation": "Davies H et al., 2002, Mutations of the BRAF gene in human cancer., Nature",
                      "pmid": 12068308
                    },
                    {
                      "citation": "Gautschi O et al., 2012, A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib., J Thorac Oncol",
                      "pmid": 22743296
                    },
                    {
                      "citation": "Xing M et al., 2014, BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence., J Clin Oncol",
                      "pmid": 25024077
                    },
                    {
                      "citation": "Naoki K et al., 2002, Missense mutations of the BRAF gene in human lung adenocarcinoma., Cancer Res",
                      "pmid": 12460919
                    },
                    {
                      "citation": "Paik PK et al., 2011, Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations., J Clin Oncol",
                      "pmid": 21483012
                    },
                    {
                      "citation": "Falchook GS et al., 2012, Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial., Lancet",
                      "pmid": 22608338
                    },
                    {
                      "citation": "Ohashi K et al., 2012, Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1., Proc Natl Acad Sci U S A",
                      "pmid": 22773810
                    },
                    {
                      "citation": "Flaherty KT et al., 2010, Inhibition of mutated, activated BRAF in metastatic melanoma., N Engl J Med",
                      "pmid": 20818844
                    },
                    {
                      "citation": "Chen D et al., 2014, BRAFV600E mutation and its association with clinicopathological features of colorectal cancer: a systematic review and meta-analysis., PLoS One",
                      "pmid": 24594804
                    },
                    {
                      "citation": "MacConaill LE et al., 2014, Prospective enterprise-level molecular genotyping of a cohort of cancer patients., J Mol Diagn",
                      "pmid": 25157968
                    },
                    {
                      "citation": "Andrulis M et al., 2013, Targeting the BRAF V600E mutation in multiple myeloma., Cancer Discov",
                      "pmid": 23612012
                    },
                    {
                      "citation": "Falchook GS et al., 2012, Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial., Lancet Oncol",
                      "pmid": 22805292
                    },
                    {
                      "citation": "Kurman RJ et al., 2011, Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm., Hum Pathol",
                      "pmid": 21683865
                    },
                    {
                      "citation": "Coffee EM et al., 2013, Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer., Clin Cancer Res",
                      "pmid": 23549875
                    },
                    {
                      "citation": "Flaherty KT et al., 2012, Improved survival with MEK inhibition in BRAF-mutated melanoma., N Engl J Med",
                      "pmid": 22663011
                    },
                    {
                      "citation": "Wan PT et al., 2004, Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF., Cell",
                      "pmid": 15035987
                    },
                    {
                      "citation": "De Roock W et al., 2011, KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer., Lancet Oncol",
                      "pmid": 21163703
                    },
                    {
                      "citation": "Ascierto PA et al., 2013, Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma., J Clin Oncol",
                      "pmid": 23918947
                    },
                    {
                      "citation": "Chang MT et al., 2016, Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity., Nat Biotechnol",
                      "pmid": 26619011
                    },
                    {
                      "citation": "Hayes DN et al., 2012, Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements., Clin Cancer Res",
                      "pmid": 22241789
                    },
                    {
                      "citation": "Zecchin D et al., 2013, BRAF V600E is a determinant of sensitivity to proteasome inhibitors., Mol Cancer Ther",
                      "pmid": 24107445
                    },
                    {
                      "citation": "Nissan MH et al., 2014, Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence., Cancer Res",
                      "pmid": 24576830
                    },
                    {
                      "citation": "Lam ET et al., 2010, Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer., J Clin Oncol",
                      "pmid": 20368568
                    },
                    {
                      "citation": "Patel SP et al., 2013, Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma., Cancer",
                      "pmid": 22972589
                    },
                    {
                      "citation": "Sen B et al., 2012, Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib., Sci Transl Med",
                      "pmid": 22649091
                    },
                    {
                      "citation": "Morris EJ et al., 2013, Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors., Cancer Discov",
                      "pmid": 23614898
                    },
                    {
                      "citation": "Tol J et al., 2010, Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab., Eur J Cancer",
                      "pmid": 20413299
                    },
                    {
                      "citation": "Chapman PB et al., 2011, Improved survival with vemurafenib in melanoma with BRAF V600E mutation., N Engl J Med",
                      "pmid": 21639808
                    },
                    {
                      "citation": "Sarker D et al., 2015, First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors., Clin Cancer Res",
                      "pmid": 25370471
                    },
                    {
                      "citation": "Crescenzi A et al., 2014, Immunohistochemistry for BRAF(V600E) antibody VE1 performed in core needle biopsy samples identifies mutated papillary thyroid cancers., Horm Metab Res",
                      "pmid": 24570209
                    },
                    {
                      "citation": "Dienstmann R et al., 2011, BRAF as a target for cancer therapy., Anticancer Agents Med Chem",
                      "pmid": 21426297
                    },
                    {
                      "citation": "Kim KB et al., 2013, Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation., Thyroid",
                      "pmid": 23489023
                    },
                    {
                      "citation": "Rubinstein JC et al., 2010, Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032., J Transl Med",
                      "pmid": 20630094
                    },
                    {
                      "citation": "Rudin CM et al., 2013, Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer., J Thorac Oncol",
                      "pmid": 23524406
                    },
                    {
                      "citation": "Boulalas I et al., 2009, Mutational analysis of the BRAF gene in transitional cell carcinoma of the bladder., Int J Biol Markers",
                      "pmid": 19404918
                    },
                    {
                      "citation": "Prahallad A et al., 2012, Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR., Nature",
                      "pmid": 22281684
                    },
                    {
                      "citation": "Hauschild A et al., 2012, Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial., Lancet",
                      "pmid": 22735384
                    },
                    {
                      "citation": "Gandhi J et al., 2009, Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines., PLoS One",
                      "pmid": 19238210
                    },
                    {
                      "citation": "Jalili A et al., 2012, Dual suppression of the cyclin-dependent kinase inhibitors CDKN2C and CDKN1A in human melanoma., J Natl Cancer Inst",
                      "pmid": 22997239
                    },
                    {
                      "citation": "Flaherty KT et al., 2012, Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations., N Engl J Med",
                      "pmid": 23020132
                    },
                    {
                      "citation": "Greger JG et al., 2012, Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations., Mol Cancer Ther",
                      "pmid": 22389471
                    },
                    {
                      "citation": "Cardarella S et al., 2013, Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer., Clin Cancer Res",
                      "pmid": 23833300
                    },
                    {
                      "citation": "Meckbach D et al., 2014, BRAF-V600 mutations have no prognostic impact in stage IV melanoma patients treated with monochemotherapy., PLoS One",
                      "pmid": 24586605
                    },
                    {
                      "citation": "Kirkwood JM et al., 2012, Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma., Clin Cancer Res",
                      "pmid": 22048237
                    },
                    {
                      "citation": "Paraiso KH et al., 2012, The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms., Clin Cancer Res",
                      "pmid": 22351686
                    },
                    {
                      "citation": "Ponti G et al., 2012, Overwhelming response to Dabrafenib in a patient with double BRAF mutation (V600E; V600M) metastatic malignant melanoma., J Hematol Oncol",
                      "pmid": 23031422
                    },
                    {
                      "citation": "Kloos RT et al., 2009, Phase II trial of sorafenib in metastatic thyroid cancer., J Clin Oncol",
                      "pmid": 19255327
                    },
                    {
                      "citation": "Agaimy A et al., 2009, V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours., J Clin Pathol",
                      "pmid": 19561230
                    },
                    {
                      "citation": "Faber AC et al., 2014, mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1., Cancer Discov",
                      "pmid": 24163374
                    },
                    {
                      "citation": "Howell GM et al., 2011, Both BRAF V600E mutation and older age ( 65 years) are associated with recurrent papillary thyroid cancer., Ann Surg Oncol",
                      "pmid": 21594703
                    },
                    {
                      "citation": "Tejpar S et al., 2010, Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery., Oncologist",
                      "pmid": 20350999
                    },
                    {
                      "citation": "Corcoran RB et al., 2012, EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib., Cancer Discov",
                      "pmid": 22448344
                    },
                    {
                      "citation": "De Roock W et al., 2010, Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis., Lancet Oncol",
                      "pmid": 20619739
                    },
                    {
                      "citation": "Tiacci E et al., 2011, BRAF mutations in hairy-cell leukemia., N Engl J Med",
                      "pmid": 21663470
                    },
                    {
                      "citation": "Haldar K et al., 2011, Epidermal growth factor receptor blockers for the treatment of ovarian cancer., Cochrane Database Syst Rev",
                      "pmid": 21975775
                    },
                    {
                      "citation": "Rowland A et al., 2015, Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer., Br J Cancer",
                      "pmid": 25989278
                    },
                    {
                      "citation": "De Roock W et al., 2009, Clinical biomarkers in oncology: focus on colorectal cancer., Mol Diagn Ther",
                      "pmid": 19537845
                    },
                    {
                      "citation": "Rad R et al., 2013, A genetic progression model of Braf(V600E)-induced intestinal tumorigenesis reveals targets for therapeutic intervention., Cancer Cell",
                      "pmid": 23845441
                    },
                    {
                      "citation": "Mao C et al., 2011, BRAF V600E mutation and resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer: a meta-analysis., Mol Biol Rep",
                      "pmid": 20857202
                    },
                    {
                      "citation": "McArthur GA et al., 2014, Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study., Lancet Oncol",
                      "pmid": 24508103
                    },
                    {
                      "citation": "Yang H et al., 2012, Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer., Cancer Res",
                      "pmid": 22180495
                    },
                    {
                      "citation": "Pratilas CA et al., 2008, Genetic predictors of MEK dependence in non-small cell lung cancer., Cancer Res",
                      "pmid": 19010912
                    },
                    {
                      "citation": "Peeters M et al., 2013, Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer., Clin Cancer Res",
                      "pmid": 23325582
                    },
                    {
                      "citation": "Hatzivassiliou G et al., 2013, Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers., Nature",
                      "pmid": 23934108
                    },
                    {
                      "citation": "Huillard E et al., 2012, Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy., Proc Natl Acad Sci U S A",
                      "pmid": 22586120
                    },
                    {
                      "citation": "Nakayama N et al., 2008, KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer., Br J Cancer",
                      "pmid": 19018267
                    },
                    {
                      "citation": "Mao M et al., 2013, Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents., Clin Cancer Res",
                      "pmid": 23251002
                    },
                    {
                      "citation": "Falchook GS et al., 2013, BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance., Oncotarget",
                      "pmid": 23470635
                    },
                    {
                      "citation": "Di Nicolantonio F et al., 2008, Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer., J Clin Oncol",
                      "pmid": 19001320
                    },
                    {
                      "citation": "Lovly CM et al., 2012, Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials., PLoS One",
                      "pmid": 22536370
                    },
                    {
                      "citation": "Rizzo S et al., 2010, Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?, Cancer Treat Rev",
                      "pmid": 21129611
                    },
                    {
                      "citation": "Ji Z et al., 2013, Vemurafenib synergizes with nutlin-3 to deplete survivin and suppresses melanoma viability and tumor growth., Clin Cancer Res",
                      "pmid": 23812671
                    },
                    {
                      "citation": "Ho AL et al., 2013, Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer., N Engl J Med",
                      "pmid": 23406027
                    },
                    {
                      "citation": "Gupta-Abramson V et al., 2008, Phase II trial of sorafenib in advanced thyroid cancer., J Clin Oncol",
                      "pmid": 18541894
                    },
                    {
                      "citation": "Menzies AM et al., 2014, Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma., Clin Cancer Res",
                      "pmid": 24583796
                    },
                    {
                      "citation": "Brose MS et al., 2002, BRAF and RAS mutations in human lung cancer and melanoma., Cancer Res",
                      "pmid": 12460918
                    },
                    {
                      "citation": "Sosman JA et al., 2012, Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib., N Engl J Med",
                      "pmid": 22356324
                    },
                    {
                      "citation": "Villanueva J et al., 2010, Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K., Cancer Cell",
                      "pmid": 21156289
                    },
                    {
                      "citation": "Maldonado JL et al., 2003, Determinants of BRAF mutations in primary melanomas., J Natl Cancer Inst",
                      "pmid": 14679157
                    },
                    {
                      "citation": "Nagore E et al., 2014, Prognostic value of BRAF mutations in localized cutaneous melanoma., J Am Acad Dermatol",
                      "pmid": 24388723
                    },
                    {
                      "citation": "Hoftijzer H et al., 2009, Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma., Eur J Endocrinol",
                      "pmid": 19773371
                    },
                    {
                      "citation": "He G et al., 2014, Prognostic value of the BRAF V600E mutation in papillary thyroid carcinoma., Oncol Lett",
                      "pmid": 24396464
                    },
                    {
                      "citation": "Walczyk A et al., 2014, The BRAF(V600E) mutation in papillary thyroid microcarcinoma: does the mutation have an impact on clinical outcome?, Clin Endocrinol (Oxf)",
                      "pmid": 24354346
                    },
                    {
                      "citation": "Nicolaides TP et al., 2011, Targeted therapy for BRAFV600E malignant astrocytoma., Clin Cancer Res",
                      "pmid": 22038996
                    },
                    {
                      "citation": "Penna I et al., 2016, Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade., Oncotarget",
                      "pmid": 26678033
                    }
                  ],
                  "source": {
                    "sourceDbName": "DoCM"
                  }
                },
                {
                  "publications": [
                    {
                      "citation": "Cervantes A et al., 2023, Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up., Ann Oncol",
                      "pmid": 36307056
                    },
                    {
                      "citation": "Kopetz S et al., 2021, Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406)., J Clin Oncol",
                      "pmid": 33356422
                    },
                    {
                      "citation": "Yang H et al., 2012, Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer., Cancer Res",
                      "pmid": 22180495
                    },
                    {
                      "citation": "Connolly K et al., 2014, Anticancer activity of combination targeted therapy using cetuximab plus vemurafenib for refractory BRAF (V600E)-mutant metastatic colorectal carcinoma., Curr Oncol",
                      "pmid": 24523613
                    },
                    {
                      "citation": "Oddo D et al., 2016, Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer., Cancer Res",
                      "pmid": 27312529
                    },
                    {
                      "citation": "Kopetz S et al., 2019, Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer., N Engl J Med",
                      "pmid": 31566309
                    },
                    {
                      "citation": "Boccaccino A et al., 2022, Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience., ESMO Open",
                      "pmid": 35696748
                    },
                    {
                      "citation": "Waizenegger IC et al., 2016, A Novel RAF Kinase Inhibitor with DFG-Out-Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation., Mol Cancer Ther",
                      "pmid": 26916115
                    },
                    {
                      "citation": "Tang Z et al., 2015, BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers., Mol Cancer Ther",
                      "pmid": 26208524
                    },
                    {
                      "citation": "Van Cutsem E et al., 2023, ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated BRAF(V600E)-Mutant Metastatic Colorectal Cancer., J Clin Oncol",
                      "pmid": 36763936
                    },
                    {
                      "citation": "Prahallad A et al., 2012, Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR., Nature",
                      "pmid": 22281684
                    },
                    {
                      "citation": "Al-Marrawi MY et al., 2013, Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer., Cancer Biol Ther",
                      "pmid": 23792568
                    },
                    {
                      "citation": "Napolitano S et al., 2015, Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab., Clin Cancer Res",
                      "pmid": 25838391
                    },
                    {
                      "citation": "Yaeger R et al., 2017, Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition., Cancer Res",
                      "pmid": 28951457
                    },
                    {
                      "citation": "van Geel RMJM et al., 2017, A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer., Cancer Discov",
                      "pmid": 28363909
                    },
                    {
                      "citation": "Yao YM et al., 2017, Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations., Clin Cancer Res",
                      "pmid": 28611205
                    },
                    {
                      "citation": "Yaeger R et al., 2019, Response to Anti-EGFR Therapy in Patients with BRAF non-V600-Mutant Metastatic Colorectal Cancer., Clin Cancer Res",
                      "pmid": 31515458
                    },
                    {
                      "citation": "Yao Z et al., 2019, RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling., Nat Med",
                      "pmid": 30559419
                    },
                    {
                      "citation": "Gao Y et al., 2019, V211D Mutation in MEK1 Causes Resistance to MEK Inhibitors in Colon Cancer., Cancer Discov",
                      "pmid": 31227518
                    },
                    {
                      "citation": "Yao Z et al., 2017, Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS., Nature",
                      "pmid": 28783719
                    },
                    {
                      "citation": "Lehtomaki KI et al., 2019, Clonal Evolution of MEK/MAPK Pathway Activating Mutations in a Metastatic Colorectal Cancer Case., Anticancer Res",
                      "pmid": 31704811
                    },
                    {
                      "citation": "Hyman DM et al., 2015, Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations., N Engl J Med",
                      "pmid": 26287849
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Approval Status",
                  "value": "Case Reports/Case Series"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - resistant"
                },
                {
                  "name": "Indication",
                  "value": "acute myeloid leukemia"
                }
              ],
              "drug": {
                "name": "GILTERITINIB",
                "approved": true
              },
              "interactionScore": 0.06024520316247492,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "McMahon CM et al., 2019, Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia., Cancer Discov",
                      "pmid": 31088841
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Cancer Type",
                  "value": "Melanoma"
                }
              ],
              "drug": {
                "name": "BRAF(V600E) KINASE INHIBITOR RO5212054",
                "approved": false
              },
              "interactionScore": 0.6626972347872242,
              "interactionTypes": [
                {
                  "type": "inhibitor"
                }
              ],
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "CancerCommons"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "MyCancerGenome"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Indication",
                  "value": "colorectal cancer"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Pyrvinium + Vemurafenib"
                }
              ],
              "drug": {
                "name": "PYRVINIUM",
                "approved": false
              },
              "interactionScore": 0.3313486173936121,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Tran KB et al., 2022, Response to BRAF-targeted Therapy Is Enhanced by Cotargeting VEGFRs or WNT/-Catenin Signaling in BRAF-mutant Colorectal Cancer Models., Mol Cancer Ther",
                      "pmid": 36198029
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Combination Therapy",
                  "value": "PLX4720 + Ponatinib"
                },
                {
                  "name": "Indication",
                  "value": "thyroid gland cancer"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Ponatinib + Vemurafenib"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                }
              ],
              "drug": {
                "name": "PONATINIB",
                "approved": true
              },
              "interactionScore": 0.03487880183090653,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Ghosh C et al., 2020, A Combinatorial Strategy for Targeting BRAF (V600E)-Mutant Cancers with BRAF(V600E) Inhibitor (PLX4720) and Tyrosine Kinase Inhibitor (Ponatinib)., Clin Cancer Res",
                      "pmid": 31937621
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Combination Therapy",
                  "value": "DT01 + Fluorouracil + Oxaliplatin"
                },
                {
                  "name": "Indication",
                  "value": "colorectal cancer"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Cetuximab + Fluorouracil + Irinotecan + Leucovorin"
                },
                {
                  "name": "Response Type",
                  "value": "not predictive"
                },
                {
                  "name": "Approval Status",
                  "value": "Case Reports/Case Series"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Fluorouracil + Leucovorin + Oxaliplatin + Panitumumab"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Fluorouracil + Irinotecan + Leucovorin + Panitumumab"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - resistant"
                }
              ],
              "drug": {
                "name": "FLUOROURACIL",
                "approved": true
              },
              "interactionScore": 0.009377791058309775,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Herath NI et al., 2016, The DNA Repair Inhibitor DT01 as a Novel Therapeutic Strategy for Chemosensitization of Colorectal Liver Metastasis., Mol Cancer Ther",
                      "pmid": 26637369
                    },
                    {
                      "citation": "Yaeger R et al., 2019, Response to Anti-EGFR Therapy in Patients with BRAF non-V600-Mutant Metastatic Colorectal Cancer., Clin Cancer Res",
                      "pmid": 31515458
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Indication",
                  "value": "lung cancer"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                }
              ],
              "drug": {
                "name": "CFT1946",
                "approved": false
              },
              "interactionScore": 0.3313486173936121,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Indication",
                  "value": "Advanced Solid Tumor"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                }
              ],
              "drug": {
                "name": "OBATOCLAX",
                "approved": false
              },
              "interactionScore": 0.1325394469574448,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Garnett MJ et al., 2012, Systematic identification of genomic markers of drug sensitivity in cancer cells., Nature",
                      "pmid": 22460902
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Combination Therapy",
                  "value": "Entinostat + Trametinib"
                },
                {
                  "name": "Indication",
                  "value": "colorectal cancer"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                }
              ],
              "drug": {
                "name": "ENTINOSTAT",
                "approved": false
              },
              "interactionScore": 0.03898219028160143,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Jenkins LJ et al., 2023, Genotype-Tailored ERK/MAPK Pathway and HDAC Inhibition Rewires the Apoptotic Rheostat to Trigger Colorectal Cancer Cell Death., Mol Cancer Ther",
                      "pmid": 36343387
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Indication",
                  "value": "colorectal cancer"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Dabrafenib + JSI-1187"
                }
              ],
              "drug": {
                "name": "ERK1/2 INHIBITOR JSI-1187",
                "approved": false
              },
              "interactionScore": 0.3313486173936121,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Combination Therapy",
                  "value": "Romidepsin + Trametinib"
                },
                {
                  "name": "Indication",
                  "value": "colorectal cancer"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                }
              ],
              "drug": {
                "name": "ROMIDEPSIN",
                "approved": true
              },
              "interactionScore": 0.03313486173936121,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Jenkins LJ et al., 2023, Genotype-Tailored ERK/MAPK Pathway and HDAC Inhibition Rewires the Apoptotic Rheostat to Trigger Colorectal Cancer Cell Death., Mol Cancer Ther",
                      "pmid": 36343387
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Indication",
                  "value": "colorectal cancer"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical"
                }
              ],
              "drug": {
                "name": "REFAMETINIB",
                "approved": false
              },
              "interactionScore": 0.06024520316247492,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Iverson C et al., 2009, RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer., Cancer Res",
                      "pmid": 19706763
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Combination Therapy",
                  "value": "SAR260301 + Vemurafenib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "SAR260301 + Selumetinib"
                }
              ],
              "drug": {
                "name": "SAR260301",
                "approved": false
              },
              "interactionScore": 0.220899078262408,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Bonnevaux H et al., 2016, Concomitant Inhibition of PI3K and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3K-Selective Inhibitor., Mol Cancer Ther",
                      "pmid": 27196754
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Indication",
                  "value": "lung adenocarcinoma"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Case Reports/Case Series"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - resistant"
                }
              ],
              "drug": {
                "name": "ALECTINIB",
                "approved": true
              },
              "interactionScore": 0.165674308696806,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Guo W et al., 2022, Lung adenocarcinoma harboring complex EML4-ALK fusion and BRAF V600E co-mutation responded to alectinib., Medicine (Baltimore)",
                      "pmid": 36221356
                    },
                    {
                      "citation": "Pasau T et al., 2022, Case report: BRAF A598-T599insV mutation as a potential resistance mechanism to alectinib in ALK-rearranged lung adenocarcinoma., Front Oncol",
                      "pmid": 36419902
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Approval Status",
                  "value": "case report"
                },
                {
                  "name": "Pathway",
                  "value": "activation"
                },
                {
                  "name": "Variant Effect",
                  "value": "reduced kinase activity"
                },
                {
                  "name": "Approval Status",
                  "value": "preclinical"
                },
                {
                  "name": "Alteration",
                  "value": "BRAF:G466V"
                },
                {
                  "name": "Alteration",
                  "value": "BRAF:Y472C"
                },
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Indication",
                  "value": "lung carcinoma"
                },
                {
                  "name": "Response Type",
                  "value": "resistant"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Dasatinib + Trametinib"
                },
                {
                  "name": "Indication",
                  "value": "thyroid gland cancer"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Dasatinib + Selumetinib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Dasatinib + SCH772984"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Dasatinib + Vemurafenib"
                },
                {
                  "name": "Indication",
                  "value": "colorectal cancer"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Dasatinib + Gefitinib + Vemurafenib"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Pdx & cell culture"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Dasatinib + Gefitinib + PLX4720"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                },
                {
                  "name": "Indication",
                  "value": "lung non-small cell carcinoma"
                },
                {
                  "name": "Clinical Trial ID",
                  "value": "NCT01514864"
                },
                {
                  "name": "Cancer Type",
                  "value": "Lung cancer"
                },
                {
                  "name": "Indication",
                  "value": "Purpose: patients with malignancy harboring a Discoidin Domain Receptor 2 (DDR2) mutation or an inactivating B-RAF mutation will respond to Dasatinib. %Official title: Dasatinib in Subjects With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation. %Inclusion criteria: Malignancy of other histology with DDR2 mutation or inactivating B-RAF mutation."
                }
              ],
              "drug": {
                "name": "DASATINIB ANHYDROUS",
                "approved": true
              },
              "interactionScore": 0.1026714025726685,
              "interactionTypes": [
                {
                  "type": "inhibitor"
                }
              ],
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "MyCancerGenomeClinicalTrial"
                  }
                },
                {
                  "publications": [
                    {
                      "citation": "Girotti MR et al., 2013, Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma., Cancer Discov",
                      "pmid": 23242808
                    },
                    {
                      "citation": "Sen B et al., 2012, Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib., Sci Transl Med",
                      "pmid": 22649091
                    },
                    {
                      "citation": "Beadnell TC et al., 2016, The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer., Mol Cancer Ther",
                      "pmid": 27222538
                    },
                    {
                      "citation": "Ruiz-Saenz A et al., 2023, A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAF(V600E) colorectal tumors., Nat Cancer",
                      "pmid": 36759733
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                },
                {
                  "publications": [
                    {
                      "citation": "Pratilas CA et al., 2008, Genetic predictors of MEK dependence in non-small cell lung cancer., Cancer Res",
                      "pmid": 19010912
                    },
                    {
                      "citation": "Cardarella S et al., 2013, Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer., Clin Cancer Res",
                      "pmid": 23833300
                    },
                    {
                      "citation": "Davies H et al., 2002, Mutations of the BRAF gene in human cancer., Nature",
                      "pmid": 12068308
                    },
                    {
                      "citation": "Sen B et al., 2012, Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib., Sci Transl Med",
                      "pmid": 22649091
                    },
                    {
                      "citation": "Gandhi J et al., 2009, Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines., PLoS One",
                      "pmid": 19238210
                    },
                    {
                      "citation": "Paik PK et al., 2011, Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations., J Clin Oncol",
                      "pmid": 21483012
                    },
                    {
                      "citation": "Brose MS et al., 2002, BRAF and RAS mutations in human lung cancer and melanoma., Cancer Res",
                      "pmid": 12460918
                    },
                    {
                      "citation": "Naoki K et al., 2002, Missense mutations of the BRAF gene in human lung adenocarcinoma., Cancer Res",
                      "pmid": 12460919
                    },
                    {
                      "citation": "Chang MT et al., 2016, Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity., Nat Biotechnol",
                      "pmid": 26619011
                    },
                    {
                      "citation": "Bentivegna S et al., 2008, Rapid identification of somatic mutations in colorectal and breast cancer tissues using mismatch repair detection (MRD)., Hum Mutat",
                      "pmid": 18186519
                    },
                    {
                      "citation": "De Roock W et al., 2009, Clinical biomarkers in oncology: focus on colorectal cancer., Mol Diagn Ther",
                      "pmid": 19537845
                    },
                    {
                      "citation": "MacConaill LE et al., 2014, Prospective enterprise-level molecular genotyping of a cohort of cancer patients., J Mol Diagn",
                      "pmid": 25157968
                    },
                    {
                      "citation": "Bardelli A et al., 2012, The road to resistance: EGFR mutation and cetuximab., Nat Med",
                      "pmid": 22310681
                    },
                    {
                      "citation": "Rizzo S et al., 2010, Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?, Cancer Treat Rev",
                      "pmid": 21129611
                    },
                    {
                      "citation": "Tejpar S et al., 2010, Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery., Oncologist",
                      "pmid": 20350999
                    }
                  ],
                  "source": {
                    "sourceDbName": "DoCM"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "CGI"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                },
                {
                  "name": "Indication",
                  "value": "high grade glioma"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Patient cell culture"
                },
                {
                  "name": "Combination Therapy",
                  "value": "LY3009120 + Vemurafenib"
                },
                {
                  "name": "Indication",
                  "value": "Advanced Solid Tumor"
                },
                {
                  "name": "Response Type",
                  "value": "no benefit"
                },
                {
                  "name": "Approval Status",
                  "value": "Case Reports/Case Series"
                },
                {
                  "name": "Indication",
                  "value": "hematologic cancer"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - resistant"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Biochemical"
                },
                {
                  "name": "Indication",
                  "value": "ovarian cancer"
                },
                {
                  "name": "Indication",
                  "value": "pancreatic ductal adenocarcinoma"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Pdx & cell culture"
                },
                {
                  "name": "Combination Therapy",
                  "value": "LY3009120 + Trametinib"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Pdx"
                },
                {
                  "name": "Indication",
                  "value": "pancreatic cancer"
                },
                {
                  "name": "Indication",
                  "value": "lung non-small cell carcinoma"
                }
              ],
              "drug": {
                "name": "LY3009120",
                "approved": false
              },
              "interactionScore": 0.4970229260904181,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Peng SB et al., 2015, Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers., Cancer Cell",
                      "pmid": 26343583
                    },
                    {
                      "citation": "Yao Z et al., 2019, RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling., Nat Med",
                      "pmid": 30559419
                    },
                    {
                      "citation": "Schreck KC et al., 2021, Deconvoluting Mechanisms of Acquired Resistance to RAF Inhibitors in BRAF(V600E)-Mutant Human Glioma., Clin Cancer Res",
                      "pmid": 34433654
                    },
                    {
                      "citation": "Sullivan RJ et al., 2020, A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer., Mol Cancer Ther",
                      "pmid": 31645440
                    },
                    {
                      "citation": "Dankner M et al., 2018, Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas., Clin Cancer Res",
                      "pmid": 29903896
                    },
                    {
                      "citation": "Chen SH et al., 2016, Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120., Cancer Discov",
                      "pmid": 26732095
                    },
                    {
                      "citation": "Yap J et al., 2021, The stability of R-spine defines RAF inhibitor resistance: A comprehensive analysis of oncogenic BRAF mutants with in-frame insertion of C-4 loop., Sci Adv",
                      "pmid": 34108213
                    },
                    {
                      "citation": "Pham NA et al., 2021, Patient-derived tumor xenograft and organoid models established from resected pancreatic, duodenal and biliary cancers., Sci Rep",
                      "pmid": 34011980
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [],
              "drug": {
                "name": "PAN-RAF INHIBITOR LY3009120",
                "approved": false
              },
              "interactionScore": 0.3313486173936121,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "CIViC"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Combination Therapy",
                  "value": "GSK2126458 + Trametinib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Dabrafenib + GSK2126458"
                },
                {
                  "name": "Response Type",
                  "value": "decreased response"
                },
                {
                  "name": "Response Type",
                  "value": "no benefit"
                },
                {
                  "name": "Response Type",
                  "value": "conflicting"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                }
              ],
              "drug": {
                "name": "OMIPALISIB",
                "approved": false
              },
              "interactionScore": 0.03313486173936121,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Greger JG et al., 2012, Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations., Mol Cancer Ther",
                      "pmid": 22389471
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Mechanism of Action",
                  "value": "Serine/threonine-protein kinase B-raf inhibitor"
                },
                {
                  "name": "Direct Interaction",
                  "value": "true"
                }
              ],
              "drug": {
                "name": "ARQ-736",
                "approved": false
              },
              "interactionScore": 0.3313486173936121,
              "interactionTypes": [
                {
                  "type": "inhibitor"
                }
              ],
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "ChEMBL"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TTD"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Indication",
                  "value": "intrahepatic cholangiocarcinoma"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - resistant"
                },
                {
                  "name": "Approval Status",
                  "value": "Case Reports/Case Series"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                }
              ],
              "drug": {
                "name": "FUTIBATINIB",
                "approved": true
              },
              "interactionScore": 0.110449539131204,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Cleary JM et al., 2021, FGFR2 Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma., Cancer Discov",
                      "pmid": 33926920
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Combination Therapy",
                  "value": "Trametinib + YM-254890"
                },
                {
                  "name": "Indication",
                  "value": "skin melanoma"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                },
                {
                  "name": "Response Type",
                  "value": "no benefit"
                },
                {
                  "name": "Indication",
                  "value": "uveal melanoma"
                }
              ],
              "drug": {
                "name": "YM-254890",
                "approved": false
              },
              "interactionScore": 0.3313486173936121,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Hitchman TD et al., 2021, Combined Inhibition of G(q) and MEK Enhances Therapeutic Efficacy in Uveal Melanoma., Clin Cancer Res",
                      "pmid": 33229459
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Combination Therapy",
                  "value": "Dabrafenib + Rabeprazole + Rifampin + Trametinib"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Approval Status",
                  "value": "Case Reports/Case Series"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                },
                {
                  "name": "Indication",
                  "value": "endometrial adenocarcinoma"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Dabrafenib + Rabeprazole + Rifampin"
                }
              ],
              "drug": {
                "name": "RIFAMPIN",
                "approved": true
              },
              "interactionScore": 0.02881292325161844,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Butt SU et al., 2021, BRAF/MEK inhibitors for BRAF V600E-mutant cancers in non-approved setting: a case series., Cancer Chemother Pharmacol",
                      "pmid": 33537843
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Indication",
                  "value": "ovarian cancer"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Biochemical"
                },
                {
                  "name": "Indication",
                  "value": "Advanced Solid Tumor"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                },
                {
                  "name": "Combination Therapy",
                  "value": "GDC0879 + Pictilisib"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Pdx"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Indication",
                  "value": "colon cancer"
                },
                {
                  "name": "Indication",
                  "value": "lung non-small cell carcinoma"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Pdx & cell culture"
                },
                {
                  "name": "Response Type",
                  "value": "resistant"
                },
                {
                  "name": "Indication",
                  "value": "melanoma"
                }
              ],
              "drug": {
                "name": "GDC-0879",
                "approved": false
              },
              "interactionScore": 0.248511463045209,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Hoeflich KP et al., 2009, Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression., Cancer Res",
                      "pmid": 19276360
                    },
                    {
                      "citation": "Foster SA et al., 2016, Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2., Cancer Cell",
                      "pmid": 26996308
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                }
              ],
              "drug": {
                "name": "ABEMACICLIB",
                "approved": true
              },
              "interactionScore": 0.04141857717420151,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Yadav V et al., 2014, The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation., Mol Cancer Ther",
                      "pmid": 25122067
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Combination Therapy",
                  "value": "Irinotecan;Vemurafenib;Cetuximab"
                },
                {
                  "name": "Alteration",
                  "value": "BRAF:V600."
                },
                {
                  "name": "Combination Therapy",
                  "value": "Cetuximab + Irinotecan + Vemurafenib"
                },
                {
                  "name": "Indication",
                  "value": "colorectal cancer"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Phase II"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Irinotecan + Vemurafenib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Cetuximab + Irinotecan"
                },
                {
                  "name": "Response Type",
                  "value": "not predictive"
                },
                {
                  "name": "Approval Status",
                  "value": "Case Reports/Case Series"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Cetuximab + Fluorouracil + Irinotecan + Leucovorin"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Irinotecan + Panitumumab"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Fluorouracil + Irinotecan + Leucovorin + Panitumumab"
                }
              ],
              "drug": {
                "name": "IRINOTECAN HYDROCHLORIDE",
                "approved": true
              },
              "interactionScore": 0.03931254782636075,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "CGI"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "CIViC"
                  }
                },
                {
                  "publications": [
                    {
                      "citation": "Kopetz S et al., 2021, Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406)., J Clin Oncol",
                      "pmid": 33356422
                    },
                    {
                      "citation": "Yang H et al., 2012, Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer., Cancer Res",
                      "pmid": 22180495
                    },
                    {
                      "citation": "Yaeger R et al., 2019, Response to Anti-EGFR Therapy in Patients with BRAF non-V600-Mutant Metastatic Colorectal Cancer., Clin Cancer Res",
                      "pmid": 31515458
                    },
                    {
                      "citation": "Yao Z et al., 2017, Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS., Nature",
                      "pmid": 28783719
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Combination Therapy",
                  "value": "Dabrafenib + Enzalutamide + Trametinib"
                },
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                }
              ],
              "drug": {
                "name": "ENZALUTAMIDE",
                "approved": true
              },
              "interactionScore": 0.08283715434840302,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Vellano CP et al., 2022, Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy., Nature",
                      "pmid": 35705814
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Indication",
                  "value": "lung adenocarcinoma"
                },
                {
                  "name": "Response Type",
                  "value": "resistant"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Patient cell culture"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                }
              ],
              "drug": {
                "name": "MK-8353",
                "approved": false
              },
              "interactionScore": 0.1325394469574448,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Negrao MV et al., 2020, Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations., J Thorac Oncol",
                      "pmid": 32540409
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Combination Therapy",
                  "value": "E6201 + LY294002"
                },
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                }
              ],
              "drug": {
                "name": "PI3K/BET INHIBITOR LY294002",
                "approved": false
              },
              "interactionScore": 0.110449539131204,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Byron SA et al., 2012, Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status., Mol Cancer",
                      "pmid": 23039341
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Combination Therapy",
                  "value": "PF-00477736 + PF3644022"
                },
                {
                  "name": "Indication",
                  "value": "Advanced Solid Tumor"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Indication",
                  "value": "colon cancer"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                },
                {
                  "name": "Indication",
                  "value": "lung adenocarcinoma"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Patient cell culture"
                }
              ],
              "drug": {
                "name": "PF-00477736",
                "approved": false
              },
              "interactionScore": 0.165674308696806,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Dietlein F et al., 2015, A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer., Cell",
                      "pmid": 26140595
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Combination Therapy",
                  "value": "PX-866 + Vemurafenib"
                },
                {
                  "name": "Indication",
                  "value": "Advanced Solid Tumor"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Phase I"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                }
              ],
              "drug": {
                "name": "SONOLISIB",
                "approved": false
              },
              "interactionScore": 0.03681651304373468,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Yam C et al., 2018, A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid Tumors., Clin Cancer Res",
                      "pmid": 29051322
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Indication",
                  "value": "colorectal cancer"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Pimasertib + Sorafenib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Everolimus + Pimasertib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Pimasertib + Regorafenib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Pimasertib + SAR405838"
                },
                {
                  "name": "Indication",
                  "value": "Advanced Solid Tumor"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Phase I"
                },
                {
                  "name": "Mechanism of Action",
                  "value": "Sensitivity"
                }
              ],
              "drug": {
                "name": "PIMASERTIB",
                "approved": false
              },
              "interactionScore": 0.165674308696806,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "ClearityFoundationBiomarkers"
                  }
                },
                {
                  "publications": [
                    {
                      "citation": "Martinelli E et al., 2013, Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells., Int J Cancer",
                      "pmid": 23629727
                    },
                    {
                      "citation": "de Weger VA et al., 2019, A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours., Br J Cancer",
                      "pmid": 30585255
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [],
              "drug": {
                "name": "TAK-733",
                "approved": false
              },
              "interactionScore": 0.3313486173936121,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "CIViC"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Combination Therapy",
                  "value": "Bevacizumab + Pegylated liposomal doxorubicin + Temsirolimus"
                },
                {
                  "name": "Indication",
                  "value": "ovarian carcinoma"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Case Reports/Case Series"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                }
              ],
              "drug": {
                "name": "DOXORUBICIN LIPOSOME",
                "approved": true
              },
              "interactionScore": 0.220899078262408,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Janku F et al., 2011, PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors., Mol Cancer Ther",
                      "pmid": 21216929
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Response Type",
                  "value": "no benefit"
                }
              ],
              "drug": {
                "name": "TGX-221",
                "approved": false
              },
              "interactionScore": 0.248511463045209,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Herkert B et al., 2016, Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition., Cancer Res",
                      "pmid": 26577700
                    },
                    {
                      "citation": "Sweetlove M et al., 2015, Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth., Front Oncol",
                      "pmid": 26137449
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Indication",
                  "value": "colorectal adenocarcinoma"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Pdx"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                }
              ],
              "drug": {
                "name": "DEL-22379",
                "approved": false
              },
              "interactionScore": 0.220899078262408,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Herrero A et al., 2015, Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes., Cancer Cell",
                      "pmid": 26267534
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Combination Therapy",
                  "value": "Everolimus + Selumetinib"
                },
                {
                  "name": "Indication",
                  "value": "high grade glioma"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Everolimus + Pimasertib"
                },
                {
                  "name": "Indication",
                  "value": "colorectal cancer"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Everolimus + PLX4720"
                },
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - resistant"
                },
                {
                  "name": "Approval Status",
                  "value": "Case Reports/Case Series"
                },
                {
                  "name": "Indication",
                  "value": "thyroid gland carcinoma"
                },
                {
                  "name": "Response Type",
                  "value": "resistant"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Dabrafenib + Everolimus + Trametinib"
                }
              ],
              "drug": {
                "name": "EVEROLIMUS",
                "approved": true
              },
              "interactionScore": 0.05847328542240213,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Olow A et al., 2016, BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas., Clin Cancer Res",
                      "pmid": 27217440
                    },
                    {
                      "citation": "Martinelli E et al., 2013, Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells., Int J Cancer",
                      "pmid": 23629727
                    },
                    {
                      "citation": "Di Nicolantonio F et al., 2010, Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus., J Clin Invest",
                      "pmid": 20664172
                    },
                    {
                      "citation": "Gibson WJ et al., 2017, Genomic Heterogeneity and Exceptional Response to Dual Pathway Inhibition in Anaplastic Thyroid Cancer., Clin Cancer Res",
                      "pmid": 27797976
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "CIViC"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Approval Status",
                  "value": "Phase III"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                },
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Approval Status",
                  "value": "Phase II"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Indication",
                  "value": "colorectal cancer"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Dabrafenib + Spartalizumab + Trametinib"
                }
              ],
              "drug": {
                "name": "SPARTALIZUMAB",
                "approved": false
              },
              "interactionScore": 0.4970229260904181,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Tian J et al., 2023, Combined PD-1, BRAF and MEK inhibition in BRAF(V600E) colorectal cancer: a phase 2 trial., Nat Med",
                      "pmid": 36702949
                    },
                    {
                      "citation": "Dummer R et al., 2020, Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i., Nat Med",
                      "pmid": 33020648
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Indication",
                  "value": "melanoma"
                }
              ],
              "drug": {
                "name": "TIZATERKIB",
                "approved": false
              },
              "interactionScore": 0.165674308696806,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Flemington V et al., 2021, AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS-Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib., Mol Cancer Ther",
                      "pmid": 33273059
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Combination Therapy",
                  "value": "Doxorubicin + PLX4720"
                },
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                }
              ],
              "drug": {
                "name": "DOXORUBICIN HYDROCHLORIDE",
                "approved": true
              },
              "interactionScore": 0.004602064130466836,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Vinik A et al., 2016, Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial., Target Oncol",
                      "pmid": 27924459
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Combination Therapy",
                  "value": "PF-00477736 + PF3644022"
                },
                {
                  "name": "Indication",
                  "value": "Advanced Solid Tumor"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Indication",
                  "value": "colon cancer"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                },
                {
                  "name": "Indication",
                  "value": "lung adenocarcinoma"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Patient cell culture"
                }
              ],
              "drug": {
                "name": "(10R)-10-METHYL-3-(6-METHYLPYRIDIN-3-YL)-9,10,11,12-TETRAHYDRO-8H-[1,4]DIAZEPINO[5',6':4,5]THIENO[3,2-F]QUINOLIN-8-ONE",
                "approved": false
              },
              "interactionScore": 0.3313486173936121,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Dietlein F et al., 2015, A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer., Cell",
                      "pmid": 26140595
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Combination Therapy",
                  "value": "TW-37 + Vemurafenib"
                },
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Indication",
                  "value": "lung non-small cell carcinoma"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Trametinib + TW-37"
                }
              ],
              "drug": {
                "name": "TW-37",
                "approved": false
              },
              "interactionScore": 0.6626972347872242,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Lin L et al., 2015, The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies., Nat Genet",
                      "pmid": 25665005
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Indication",
                  "value": "lung non-small cell carcinoma"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - resistant"
                },
                {
                  "name": "Approval Status",
                  "value": "Case Reports/Case Series"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                }
              ],
              "drug": {
                "name": "OSIMERTINIB",
                "approved": true
              },
              "interactionScore": 0.0903678047437124,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "CIViC"
                  }
                },
                {
                  "publications": [
                    {
                      "citation": "Zhao J et al., 2020, Next-generation sequencing based mutation profiling reveals heterogeneity of clinical response and resistance to osimertinib., Lung Cancer",
                      "pmid": 31839416
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Indication",
                  "value": "thyroid gland papillary carcinoma"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical"
                },
                {
                  "name": "Indication",
                  "value": "colorectal adenocarcinoma"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                }
              ],
              "drug": {
                "name": "AVUTOMETINIB",
                "approved": false
              },
              "interactionScore": 0.1840825652186734,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Wada M et al., 2014, The dual RAF/MEK inhibitor CH5126766/RO5126766 may be a potential therapy for RAS-mutated tumor cells., PLoS One",
                      "pmid": 25422890
                    },
                    {
                      "citation": "Nakanishi Y et al., 2015, ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor., Mol Cancer Ther",
                      "pmid": 26438159
                    },
                    {
                      "citation": "Nagarajah J et al., 2016, Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine., J Clin Invest",
                      "pmid": 27669459
                    },
                    {
                      "citation": "Ishii N et al., 2013, Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of RAF activity., Cancer Res",
                      "pmid": 23667175
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - resistant"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Indication",
                  "value": "colorectal cancer"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                }
              ],
              "drug": {
                "name": "BI-3406",
                "approved": false
              },
              "interactionScore": 0.3313486173936121,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Hofmann MH et al., 2021, BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition., Cancer Discov",
                      "pmid": 32816843
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Combination Therapy",
                  "value": "Capecitabine + Vemurafenib"
                },
                {
                  "name": "Indication",
                  "value": "colorectal cancer"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Bevacizumab + Capecitabine + Vemurafenib"
                }
              ],
              "drug": {
                "name": "CAPECITABINE",
                "approved": true
              },
              "interactionScore": 0.01949109514080071,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Yang H et al., 2012, Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer., Cancer Res",
                      "pmid": 22180495
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Indication",
                  "value": "ovarian cancer"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Indication",
                  "value": "Advanced Solid Tumor"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical"
                },
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "resistant"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                }
              ],
              "drug": {
                "name": "CI-1040",
                "approved": false
              },
              "interactionScore": 0.07796438056320286,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Nakayama N et al., 2008, KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer., Br J Cancer",
                      "pmid": 19018267
                    },
                    {
                      "citation": "Whittaker S et al., 2010, Gatekeeper mutations mediate resistance to BRAF-targeted therapies., Sci Transl Med",
                      "pmid": 20538618
                    },
                    {
                      "citation": "Emery CM et al., 2009, MEK1 mutations confer resistance to MEK and B-RAF inhibition., Proc Natl Acad Sci U S A",
                      "pmid": 19915144
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Direct Interaction",
                  "value": "true"
                },
                {
                  "name": "Mechanism of Action",
                  "value": "Serine/threonine-protein kinase B-raf inhibitor"
                }
              ],
              "drug": {
                "name": "RAF-265",
                "approved": false
              },
              "interactionScore": 0.165674308696806,
              "interactionTypes": [
                {
                  "type": "inhibitor"
                }
              ],
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "ChEMBL"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Combination Therapy",
                  "value": "Binimetinib + Buparlisib"
                },
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Buparlisib + Encorafenib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Buparlisib + Vemurafenib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Buparlisib + Trametinib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Buparlisib + Selumetinib"
                }
              ],
              "drug": {
                "name": "BUPARLISIB",
                "approved": false
              },
              "interactionScore": 0.0451839023718562,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Niessner H et al., 2016, PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo., Clin Cancer Res",
                      "pmid": 27307593
                    },
                    {
                      "citation": "Shi H et al., 2014, A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition., Cancer Discov",
                      "pmid": 24265152
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [],
              "drug": {
                "name": "BMS-908662",
                "approved": false
              },
              "interactionScore": 0.3313486173936121,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TTD"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Combination Therapy",
                  "value": "AZD6482 + NVP-AEW541"
                },
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "no benefit"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Combination Therapy",
                  "value": "AZD6482 + Encorafenib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "AZD6482 + Binimetinib"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Alpelisib + AZD6482"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Alpelisib + AZD6482 + Binimetinib"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                },
                {
                  "name": "Combination Therapy",
                  "value": "AZD6482 + Binimetinib + NVP-AEW541"
                },
                {
                  "name": "Combination Therapy",
                  "value": "AZD6482 + Encorafenib + NVP-AEW541"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Alpelisib + AZD6482 + Encorafenib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Alpelisib + AZD6482 + Binimetinib + Encorafenib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "AZD6482 + Binimetinib + Encorafenib + NVP-AEW541"
                }
              ],
              "drug": {
                "name": "AZD6482",
                "approved": false
              },
              "interactionScore": 0.1325394469574448,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Herkert B et al., 2016, Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition., Cancer Res",
                      "pmid": 26577700
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Combination Therapy",
                  "value": "Pictilisib + PLX4720"
                },
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Combination Therapy",
                  "value": "GDC0879 + Pictilisib"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                },
                {
                  "name": "Combination Therapy",
                  "value": "NVP-AEW541 + Pictilisib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Binimetinib + Pictilisib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Encorafenib + Pictilisib"
                }
              ],
              "drug": {
                "name": "PICTILISIB",
                "approved": false
              },
              "interactionScore": 0.04570325757153271,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Van Allen EM et al., 2014, The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma., Cancer Discov",
                      "pmid": 24265153
                    },
                    {
                      "citation": "Hoeflich KP et al., 2009, Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression., Cancer Res",
                      "pmid": 19276360
                    },
                    {
                      "citation": "Herkert B et al., 2016, Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition., Cancer Res",
                      "pmid": 26577700
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Direct Interaction",
                  "value": "true"
                },
                {
                  "name": "Mechanism of Action",
                  "value": "Serine/threonine-protein kinase B-raf inhibitor"
                }
              ],
              "drug": {
                "name": "XL-281",
                "approved": false
              },
              "interactionScore": 0.165674308696806,
              "interactionTypes": [
                {
                  "type": "inhibitor"
                }
              ],
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "ChEMBL"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Indication",
                  "value": "thyroid gland cancer"
                },
                {
                  "name": "Indication",
                  "value": "colorectal cancer"
                },
                {
                  "name": "Combination Therapy",
                  "value": "PLX4720 + TAK-632"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                },
                {
                  "name": "Response Type",
                  "value": "decreased response"
                },
                {
                  "name": "Indication",
                  "value": "lung non-small cell carcinoma"
                }
              ],
              "drug": {
                "name": "TAK-632",
                "approved": false
              },
              "interactionScore": 0.6626972347872242,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Karoulia Z et al., 2016, An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling., Cancer Cell",
                      "pmid": 27523909
                    },
                    {
                      "citation": "Yao Z et al., 2019, RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling., Nat Med",
                      "pmid": 30559419
                    },
                    {
                      "citation": "Wang J et al., 2018, A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAF(V600E)-Mutant Brain Tumor., Cancer Discov",
                      "pmid": 29880583
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Combination Therapy",
                  "value": "Ulixertinib + Vinblastine"
                },
                {
                  "name": "Indication",
                  "value": "pleomorphic xanthoastrocytoma"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                }
              ],
              "drug": {
                "name": "VINBLASTINE",
                "approved": true
              },
              "interactionScore": 0.02008173438749164,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Sigaud R et al., 2023, The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma models., Neuro Oncol",
                      "pmid": 35882450
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Combination Therapy",
                  "value": "Miransertib + Trametinib"
                },
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Pdx"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                }
              ],
              "drug": {
                "name": "MIRANSERTIB",
                "approved": false
              },
              "interactionScore": 0.110449539131204,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Yu Y et al., 2015, Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092., PLoS One",
                      "pmid": 26469692
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Indication",
                  "value": "colorectal cancer"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - resistant"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Pdx"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                }
              ],
              "drug": {
                "name": "FUTUXIMAB/MODOTUXIMAB MIXTURE",
                "approved": false
              },
              "interactionScore": 0.220899078262408,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Montagut C et al., 2018, Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial., JAMA Oncol",
                      "pmid": 29423521
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Combination Therapy",
                  "value": "DT01 + Fluorouracil + Oxaliplatin"
                },
                {
                  "name": "Indication",
                  "value": "colorectal cancer"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                }
              ],
              "drug": {
                "name": "DNA-DEPENDENT PROTEIN KINASE-TARGETING SIDNA DT01",
                "approved": false
              },
              "interactionScore": 0.6626972347872242,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Herath NI et al., 2016, The DNA Repair Inhibitor DT01 as a Novel Therapeutic Strategy for Chemosensitization of Colorectal Liver Metastasis., Mol Cancer Ther",
                      "pmid": 26637369
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Phase I"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                }
              ],
              "drug": {
                "name": "LENVATINIB",
                "approved": true
              },
              "interactionScore": 0.05522476956560202,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Hong DS et al., 2015, Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma., Clin Cancer Res",
                      "pmid": 26169970
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Combination Therapy",
                  "value": "ABM-1310 + Cetuximab"
                },
                {
                  "name": "Indication",
                  "value": "colon cancer"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Combination Therapy",
                  "value": "ABM-1310 + Binimetinib"
                }
              ],
              "drug": {
                "name": "BRAF(V600E) KINASE INHIBITOR ABM-1310",
                "approved": false
              },
              "interactionScore": 0.3313486173936121,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Combination Therapy",
                  "value": "Mocetinostat + Trametinib"
                },
                {
                  "name": "Indication",
                  "value": "colorectal cancer"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                }
              ],
              "drug": {
                "name": "MOCETINOSTAT",
                "approved": false
              },
              "interactionScore": 0.05097671036824802,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Jenkins LJ et al., 2023, Genotype-Tailored ERK/MAPK Pathway and HDAC Inhibition Rewires the Apoptotic Rheostat to Trigger Colorectal Cancer Cell Death., Mol Cancer Ther",
                      "pmid": 36343387
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Indication",
                  "value": "Advanced Solid Tumor"
                },
                {
                  "name": "Response Type",
                  "value": "decreased response"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical"
                }
              ],
              "drug": {
                "name": "PILARALISIB",
                "approved": false
              },
              "interactionScore": 0.03898219028160143,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Foster P et al., 2015, The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models., Mol Cancer Ther",
                      "pmid": 25637314
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [],
              "drug": {
                "name": "TUNLAMETINIB",
                "approved": false
              },
              "interactionScore": 0.165674308696806,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "CIViC"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Pdx"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Indication",
                  "value": "colorectal cancer"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical"
                }
              ],
              "drug": {
                "name": "CCT196969",
                "approved": false
              },
              "interactionScore": 0.6626972347872242,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Girotti MR et al., 2015, Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma., Cancer Cell",
                      "pmid": 25500121
                    },
                    {
                      "citation": "Jarry A et al., 2004, Real-time allele-specific amplification for sensitive detection of the BRAF mutation V600E., Mol Cell Probes",
                      "pmid": 15294323
                    },
                    {
                      "citation": "Gray-Schopfer VC et al., 2007, Tumor necrosis factor-alpha blocks apoptosis in melanoma cells when BRAF signaling is inhibited., Cancer Res",
                      "pmid": 17210691
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Indication",
                  "value": "skin melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Ganetespib + TAK-733"
                },
                {
                  "name": "Indication",
                  "value": "melanoma"
                }
              ],
              "drug": {
                "name": "GANETESPIB",
                "approved": false
              },
              "interactionScore": 0.08283715434840302,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Acquaviva J et al., 2014, Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib., Mol Cancer Ther",
                      "pmid": 24398428
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Combination Therapy",
                  "value": "CGM097 + Encorafenib"
                },
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Combination Therapy",
                  "value": "CGM097 + Dabrafenib + Navitoclax + PF-04217903"
                },
                {
                  "name": "Indication",
                  "value": "colorectal cancer"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                }
              ],
              "drug": {
                "name": "P53/HDM2 INTERACTION INHIBITOR CGM097",
                "approved": false
              },
              "interactionScore": 0.220899078262408,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Horn T et al., 2016, High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells., Cancer Res",
                      "pmid": 27659046
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Combination Therapy",
                  "value": "LTT462 + LXH 254"
                },
                {
                  "name": "Indication",
                  "value": "lung non-small cell carcinoma"
                },
                {
                  "name": "Approval Status",
                  "value": "Case Reports/Case Series"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Dabrafenib + LXH 254 + Trametinib"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                },
                {
                  "name": "Indication",
                  "value": "colorectal cancer"
                },
                {
                  "name": "Indication",
                  "value": "Advanced Solid Tumor"
                },
                {
                  "name": "Indication",
                  "value": "lung adenocarcinoma"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Patient cell culture"
                },
                {
                  "name": "Response Type",
                  "value": "decreased response"
                }
              ],
              "drug": {
                "name": "NAPORAFENIB",
                "approved": false
              },
              "interactionScore": 0.4417981565248161,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Monaco KA et al., 2021, LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors., Clin Cancer Res",
                      "pmid": 33355204
                    },
                    {
                      "citation": "Adamopoulos C et al., 2021, Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling., Cancer Discov",
                      "pmid": 33568355
                    },
                    {
                      "citation": "Negrao MV et al., 2020, Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations., J Thorac Oncol",
                      "pmid": 32540409
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Combination Therapy",
                  "value": "Lapatinib + Panobinostat"
                },
                {
                  "name": "Indication",
                  "value": "colorectal cancer"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Panobinostat + Trametinib"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Panobinostat + Vemurafenib"
                }
              ],
              "drug": {
                "name": "PANOBINOSTAT",
                "approved": true
              },
              "interactionScore": 0.03976183408723344,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "LaBonte MJ et al., 2011, The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models., Cancer Res",
                      "pmid": 21464044
                    },
                    {
                      "citation": "Jenkins LJ et al., 2023, Genotype-Tailored ERK/MAPK Pathway and HDAC Inhibition Rewires the Apoptotic Rheostat to Trigger Colorectal Cancer Cell Death., Mol Cancer Ther",
                      "pmid": 36343387
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Direct Interaction",
                  "value": "true"
                },
                {
                  "name": "Mechanism of Action",
                  "value": "Serine/threonine-protein kinase B-raf inhibitor"
                }
              ],
              "drug": {
                "name": "PLX-8394",
                "approved": false
              },
              "interactionScore": 0.3313486173936121,
              "interactionTypes": [
                {
                  "type": "inhibitor"
                }
              ],
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "ChEMBL"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Combination Therapy",
                  "value": "Gefitinib + Vemurafenib"
                },
                {
                  "name": "Indication",
                  "value": "colorectal cancer"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Gefitinib + PLX4720"
                },
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Dasatinib + Gefitinib + Vemurafenib"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Pdx & cell culture"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Celecoxib + Gefitinib + Trametinib + Vemurafenib"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Dasatinib + Gefitinib + PLX4720"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Gefitinib + PLX4720 + Saracatinib"
                }
              ],
              "drug": {
                "name": "GEFITINIB",
                "approved": true
              },
              "interactionScore": 0.02172777818974505,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Corcoran RB et al., 2012, EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib., Cancer Discov",
                      "pmid": 22448344
                    },
                    {
                      "citation": "Girotti MR et al., 2013, Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma., Cancer Discov",
                      "pmid": 23242808
                    },
                    {
                      "citation": "Ruiz-Saenz A et al., 2023, A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAF(V600E) colorectal tumors., Nat Cancer",
                      "pmid": 36759733
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Mechanism of Action",
                  "value": "B-raf/RAF proto-oncogene serine/threonine-protein kinase inhibitor"
                },
                {
                  "name": "Direct Interaction",
                  "value": "true"
                }
              ],
              "drug": {
                "name": "LXH254",
                "approved": false
              },
              "interactionScore": 0.165674308696806,
              "interactionTypes": [
                {
                  "type": "inhibitor"
                }
              ],
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "ChEMBL"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Response Type",
                  "value": "predicted - resistant"
                },
                {
                  "name": "Approval Status",
                  "value": "Case Reports/Case Series"
                },
                {
                  "name": "Response Type",
                  "value": "no benefit"
                },
                {
                  "name": "Indication",
                  "value": "intrahepatic cholangiocarcinoma"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Patient cell culture"
                },
                {
                  "name": "Indication",
                  "value": "lung adenocarcinoma"
                },
                {
                  "name": "Response Type",
                  "value": "resistant"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                },
                {
                  "name": "Indication",
                  "value": "colorectal cancer"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Indication",
                  "value": "melanoma"
                }
              ],
              "drug": {
                "name": "TEMUTERKIB",
                "approved": false
              },
              "interactionScore": 0.189342067082064,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Bhagwat SV et al., 2020, ERK Inhibitor LY3214996 Targets ERK Pathway-Driven Cancers: A Therapeutic Approach Toward Precision Medicine., Mol Cancer Ther",
                      "pmid": 31744895
                    },
                    {
                      "citation": "Negrao MV et al., 2020, Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations., J Thorac Oncol",
                      "pmid": 32540409
                    },
                    {
                      "citation": "Cleary JM et al., 2021, FGFR2 Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma., Cancer Discov",
                      "pmid": 33926920
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Indication",
                  "value": "Advanced Solid Tumor"
                },
                {
                  "name": "Indication",
                  "value": "colorectal cancer"
                },
                {
                  "name": "Indication",
                  "value": "stomach carcinoma"
                },
                {
                  "name": "Indication",
                  "value": "lung non-small cell carcinoma"
                },
                {
                  "name": "Indication",
                  "value": "cervix carcinoma"
                },
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Pdx"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                },
                {
                  "name": "Indication",
                  "value": "pancreatic cancer"
                }
              ],
              "drug": {
                "name": "KO-947",
                "approved": false
              },
              "interactionScore": 0.06626972347872243,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Combination Therapy",
                  "value": "GSK2636771 + unspecified PD-1 antibody"
                },
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Response Type",
                  "value": "no benefit"
                },
                {
                  "name": "Combination Therapy",
                  "value": "GSK2636771 + Pembrolizumab"
                },
                {
                  "name": "Combination Therapy",
                  "value": "GSK2636771 + NVP-AEW541"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Binimetinib + GSK2636771"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Encorafenib + GSK2636771"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Alpelisib + GSK2636771"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Alpelisib + Encorafenib + GSK2636771"
                },
                {
                  "name": "Combination Therapy",
                  "value": "GSK2636771 + unspecified IGF-1R antibody"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Encorafenib + GSK2636771 + unspecified IGF-1R antibody"
                }
              ],
              "drug": {
                "name": "GSK-2636771",
                "approved": false
              },
              "interactionScore": 0.06212786576130227,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Peng W et al., 2016, Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy., Cancer Discov",
                      "pmid": 26645196
                    },
                    {
                      "citation": "Herkert B et al., 2016, Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition., Cancer Res",
                      "pmid": 26577700
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                }
              ],
              "drug": {
                "name": "MEK INHIBITOR IMM-1-104",
                "approved": false
              },
              "interactionScore": 0.165674308696806,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Mechanism of Action",
                  "value": "Sensitivity"
                }
              ],
              "drug": {
                "name": "MIRDAMETINIB",
                "approved": false
              },
              "interactionScore": 0.03313486173936121,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "ClearityFoundationBiomarkers"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Direct Interaction",
                  "value": "true"
                },
                {
                  "name": "Mechanism of Action",
                  "value": "Serine/threonine-protein kinase B-raf inhibitor"
                }
              ],
              "drug": {
                "name": "LGX-806",
                "approved": false
              },
              "interactionScore": 0.165674308696806,
              "interactionTypes": [
                {
                  "type": "inhibitor"
                }
              ],
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "ChEMBL"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Combination Therapy",
                  "value": "AZD6482 + NVP-AEW541"
                },
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "no benefit"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Combination Therapy",
                  "value": "GSK2636771 + NVP-AEW541"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Combination Therapy",
                  "value": "NVP-AEW541 + Pictilisib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Alpelisib + NVP-AEW541"
                },
                {
                  "name": "Combination Therapy",
                  "value": "AZD6482 + Binimetinib + NVP-AEW541"
                },
                {
                  "name": "Combination Therapy",
                  "value": "AZD6482 + Encorafenib + NVP-AEW541"
                },
                {
                  "name": "Combination Therapy",
                  "value": "AZD6482 + Binimetinib + Encorafenib + NVP-AEW541"
                }
              ],
              "drug": {
                "name": "NVP-AEW541",
                "approved": false
              },
              "interactionScore": 0.165674308696806,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Herkert B et al., 2016, Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition., Cancer Res",
                      "pmid": 26577700
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Indication",
                  "value": "colorectal cancer"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Case Reports/Case Series"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "decreased response"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                },
                {
                  "name": "Indication",
                  "value": "lung adenocarcinoma"
                },
                {
                  "name": "Response Type",
                  "value": "resistant"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Patient cell culture"
                }
              ],
              "drug": {
                "name": "RAVOXERTINIB",
                "approved": false
              },
              "interactionScore": 0.3313486173936121,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Varga A et al., 2020, A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors., Clin Cancer Res",
                      "pmid": 31848189
                    },
                    {
                      "citation": "Mizuno S et al., 2023, High-Throughput Functional Evaluation of MAP2K1 Variants in Cancer., Mol Cancer Ther",
                      "pmid": 36442478
                    },
                    {
                      "citation": "Negrao MV et al., 2020, Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations., J Thorac Oncol",
                      "pmid": 32540409
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Combination Therapy",
                  "value": "PAC-1 + Trametinib + Vemurafenib"
                },
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Combination Therapy",
                  "value": "PAC-1 + Vemurafenib"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                }
              ],
              "drug": {
                "name": "PAC-1",
                "approved": false
              },
              "interactionScore": 0.220899078262408,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Peh J et al., 2016, The Combination of Vemurafenib and Procaspase-3 Activation Is Synergistic in Mutant BRAF Melanomas., Mol Cancer Ther",
                      "pmid": 27297867
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Combination Therapy",
                  "value": "Vemurafenib + Voruciclib"
                },
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Phase I"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                }
              ],
              "drug": {
                "name": "VORUCICLIB",
                "approved": false
              },
              "interactionScore": 0.165674308696806,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Indication",
                  "value": "lung non-small cell carcinoma"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                }
              ],
              "drug": {
                "name": "NVP-TAE 226",
                "approved": false
              },
              "interactionScore": 0.220899078262408,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Otani H et al., 2015, TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells., PLoS One",
                      "pmid": 26090892
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Indication",
                  "value": "neuroblastoma"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - resistant"
                },
                {
                  "name": "Approval Status",
                  "value": "Case Reports/Case Series"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                }
              ],
              "drug": {
                "name": "LORLATINIB",
                "approved": true
              },
              "interactionScore": 0.06626972347872243,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Berko ER et al., 2023, Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma., Nat Commun",
                      "pmid": 37147298
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Combination Therapy",
                  "value": "Dactolisib + Selumetinib"
                },
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Dactolisib + Vemurafenib"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical"
                },
                {
                  "name": "Indication",
                  "value": "Advanced Solid Tumor"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                }
              ],
              "drug": {
                "name": "DACTOLISIB",
                "approved": false
              },
              "interactionScore": 0.0225919511859281,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Sweetlove M et al., 2015, Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth., Front Oncol",
                      "pmid": 26137449
                    },
                    {
                      "citation": "Nakai C et al., 2023, Regulation of MEK inhibitor selumetinib sensitivity by AKT phosphorylation in the novel BRAF L525R mutant., Int J Clin Oncol",
                      "pmid": 36856908
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Combination Therapy",
                  "value": "Venetoclax + VX-11e"
                },
                {
                  "name": "Indication",
                  "value": "colorectal cancer"
                },
                {
                  "name": "Response Type",
                  "value": "no benefit"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                }
              ],
              "drug": {
                "name": "VENETOCLAX",
                "approved": true
              },
              "interactionScore": 0.04141857717420151,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Anderson GR et al., 2016, PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation., Sci Transl Med",
                      "pmid": 27974663
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [],
              "drug": {
                "name": "BRAF INHIBITOR",
                "approved": false
              },
              "interactionScore": 0.3313486173936121,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "CIViC"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Case Reports/Case Series"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical"
                },
                {
                  "name": "Combination Therapy",
                  "value": "E6201 + LY294002"
                },
                {
                  "name": "Response Type",
                  "value": "decreased response"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                }
              ],
              "drug": {
                "name": "E6201",
                "approved": false
              },
              "interactionScore": 0.220899078262408,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Babiker HM et al., 2019, E6201, an intravenous MEK1 inhibitor, achieves an exceptional response in BRAF V600E-mutated metastatic malignant melanoma with brain metastases., Invest New Drugs",
                      "pmid": 30264293
                    },
                    {
                      "citation": "Narita Y et al., 2014, Novel ATP-competitive MEK inhibitor E6201 is effective against vemurafenib-resistant melanoma harboring the MEK1-C121S mutation in a preclinical model., Mol Cancer Ther",
                      "pmid": 24448821
                    },
                    {
                      "citation": "Byron SA et al., 2012, Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status., Mol Cancer",
                      "pmid": 23039341
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Combination Therapy",
                  "value": "Cobimetinib + Gemcitabine + Nab-paclitaxel"
                },
                {
                  "name": "Indication",
                  "value": "pancreatic ductal adenocarcinoma"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Case Reports/Case Series"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                }
              ],
              "drug": {
                "name": "GEMCITABINE",
                "approved": true
              },
              "interactionScore": 0.007282387195464003,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Ardalan B et al., 2021, Potential benefit of treatment with MEK inhibitors and chemotherapy in BRAF-mutated KRAS wild-type pancreatic ductal adenocarcinoma patients: a case report., Cold Spring Harb Mol Case Stud",
                      "pmid": 34667063
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Palbociclib + Trametinib"
                },
                {
                  "name": "Response Type",
                  "value": "decreased response"
                },
                {
                  "name": "Response Type",
                  "value": "no benefit"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Palbociclib + PD-0325901"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Palbociclib + Vemurafenib"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - resistant"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Pdx"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Palbociclib + Ulixertinib"
                },
                {
                  "name": "Approval Status",
                  "value": "Phase Ib/II"
                }
              ],
              "drug": {
                "name": "PALBOCICLIB",
                "approved": true
              },
              "interactionScore": 0.02704886672600915,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Teh JL et al., 2016, An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma., Cancer Res",
                      "pmid": 27488531
                    },
                    {
                      "citation": "Louveau B et al., 2021, Phase I-II Open-Label Multicenter Study of Palbociclib + Vemurafenib in BRAF (V600MUT) Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism., Clin Cancer Res",
                      "pmid": 33947696
                    },
                    {
                      "citation": "Nassar KW et al., 2021, Targeting CDK4/6 Represents a Therapeutic Vulnerability in Acquired BRAF/MEK Inhibitor-Resistant Melanoma., Mol Cancer Ther",
                      "pmid": 34376578
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Combination Therapy",
                  "value": "Trametinib + Valproic acid"
                },
                {
                  "name": "Indication",
                  "value": "colorectal cancer"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                }
              ],
              "drug": {
                "name": "VALPROIC ACID",
                "approved": true
              },
              "interactionScore": 0.011833879192629,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Jenkins LJ et al., 2023, Genotype-Tailored ERK/MAPK Pathway and HDAC Inhibition Rewires the Apoptotic Rheostat to Trigger Colorectal Cancer Cell Death., Mol Cancer Ther",
                      "pmid": 36343387
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Combination Therapy",
                  "value": "Bosutinib + Vemurafenib"
                },
                {
                  "name": "Indication",
                  "value": "colorectal cancer"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                }
              ],
              "drug": {
                "name": "BOSUTINIB",
                "approved": true
              },
              "interactionScore": 0.08283715434840302,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Ruiz-Saenz A et al., 2023, A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAF(V600E) colorectal tumors., Nat Cancer",
                      "pmid": 36759733
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Combination Therapy",
                  "value": "Erlotinib + Vemurafenib"
                },
                {
                  "name": "Indication",
                  "value": "colorectal cancer"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Phase Ib/II"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                },
                {
                  "name": "Indication",
                  "value": "Advanced Solid Tumor"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Case Reports/Case Series"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Erlotinib + PLX4720"
                },
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Alpelisib + Dabrafenib + Erlotinib + Navitoclax"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                }
              ],
              "drug": {
                "name": "ERLOTINIB",
                "approved": true
              },
              "interactionScore": 0.03976183408723344,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Tan L et al., 2023, A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study., Clin Cancer Res",
                      "pmid": 36638198
                    },
                    {
                      "citation": "Corcoran RB et al., 2012, EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib., Cancer Discov",
                      "pmid": 22448344
                    },
                    {
                      "citation": "Yang H et al., 2012, Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer., Cancer Res",
                      "pmid": 22180495
                    },
                    {
                      "citation": "Vinik A et al., 2016, Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial., Target Oncol",
                      "pmid": 27924459
                    },
                    {
                      "citation": "Horn T et al., 2016, High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells., Cancer Res",
                      "pmid": 27659046
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Phase I"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical"
                },
                {
                  "name": "Approval Status",
                  "value": "Case Reports/Case Series"
                },
                {
                  "name": "Indication",
                  "value": "Advanced Solid Tumor"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Response Type",
                  "value": "resistant"
                }
              ],
              "drug": {
                "name": "B-RAF/VEGFR-2 INHIBITOR RAF265",
                "approved": false
              },
              "interactionScore": 0.3313486173936121,
              "interactionTypes": [
                {
                  "type": "inhibitor"
                }
              ],
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "MyCancerGenome"
                  }
                },
                {
                  "publications": [
                    {
                      "citation": "Izar B et al., 2017, A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status., Cancer Med",
                      "pmid": 28719152
                    },
                    {
                      "citation": "Su Y et al., 2012, RAF265 inhibits the growth of advanced human melanoma tumors., Clin Cancer Res",
                      "pmid": 22351689
                    },
                    {
                      "citation": "Whittaker S et al., 2010, Gatekeeper mutations mediate resistance to BRAF-targeted therapies., Sci Transl Med",
                      "pmid": 20538618
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Vemurafenib + XL888"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Phase I"
                }
              ],
              "drug": {
                "name": "HSP90 INHIBITOR XL888",
                "approved": false
              },
              "interactionScore": 0.248511463045209,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Paraiso KH et al., 2012, The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms., Clin Cancer Res",
                      "pmid": 22351686
                    },
                    {
                      "citation": "Eroglu Z et al., 2018, Combined BRAF and HSP90 Inhibition in Patients with Unresectable BRAF (V600E)-Mutant Melanoma., Clin Cancer Res",
                      "pmid": 29674508
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Combination Therapy",
                  "value": "DT01 + Fluorouracil + Oxaliplatin"
                },
                {
                  "name": "Indication",
                  "value": "colorectal cancer"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Fluorouracil + Leucovorin + Oxaliplatin + Panitumumab"
                },
                {
                  "name": "Response Type",
                  "value": "not predictive"
                },
                {
                  "name": "Approval Status",
                  "value": "Case Reports/Case Series"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - resistant"
                }
              ],
              "drug": {
                "name": "OXALIPLATIN",
                "approved": true
              },
              "interactionScore": 0.04141857717420151,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "CIViC"
                  }
                },
                {
                  "publications": [
                    {
                      "citation": "Herath NI et al., 2016, The DNA Repair Inhibitor DT01 as a Novel Therapeutic Strategy for Chemosensitization of Colorectal Liver Metastasis., Mol Cancer Ther",
                      "pmid": 26637369
                    },
                    {
                      "citation": "Yaeger R et al., 2019, Response to Anti-EGFR Therapy in Patients with BRAF non-V600-Mutant Metastatic Colorectal Cancer., Clin Cancer Res",
                      "pmid": 31515458
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Indication",
                  "value": "colorectal cancer"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Cetuximab + Dabrafenib + SCH772984"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Cetuximab + SCH772984"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Dabrafenib + SCH772984"
                },
                {
                  "name": "Indication",
                  "value": "thyroid gland cancer"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Dasatinib + SCH772984"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Dabrafenib + SCH772984 + Trametinib"
                },
                {
                  "name": "Response Type",
                  "value": "decreased response"
                },
                {
                  "name": "Response Type",
                  "value": "resistant"
                },
                {
                  "name": "Indication",
                  "value": "lung adenocarcinoma"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Patient cell culture"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Pdx"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                }
              ],
              "drug": {
                "name": "SCH772984",
                "approved": false
              },
              "interactionScore": 0.4638880643510569,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Herrero A et al., 2015, Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes., Cancer Cell",
                      "pmid": 26267534
                    },
                    {
                      "citation": "Oddo D et al., 2016, Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer., Cancer Res",
                      "pmid": 27312529
                    },
                    {
                      "citation": "Hicks HM et al., 2021, Inhibition of BRAF and ERK1/2 has synergistic effects on thyroid cancer growth in vitro and in vivo., Mol Carcinog",
                      "pmid": 33595872
                    },
                    {
                      "citation": "Beadnell TC et al., 2016, The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer., Mol Cancer Ther",
                      "pmid": 27222538
                    },
                    {
                      "citation": "Xue Y et al., 2017, An approach to suppress the evolution of resistance in BRAF(V600E)-mutant cancer., Nat Med",
                      "pmid": 28714990
                    },
                    {
                      "citation": "Wang J et al., 2018, A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAF(V600E)-Mutant Brain Tumor., Cancer Discov",
                      "pmid": 29880583
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Combination Therapy",
                  "value": "Cediranib + PLX4720"
                },
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Cediranib + PLX4720 + Selumetinib"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                }
              ],
              "drug": {
                "name": "CEDIRANIB",
                "approved": false
              },
              "interactionScore": 0.0138061923914005,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Friedman AA et al., 2015, Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment., PLoS One",
                      "pmid": 26461489
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Combination Therapy",
                  "value": "Navitoclax + Vemurafenib"
                },
                {
                  "name": "Indication",
                  "value": "pleomorphic xanthoastrocytoma"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Navitoclax + Ulixertinib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Alpelisib + Dabrafenib + Erlotinib + Navitoclax"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                },
                {
                  "name": "Indication",
                  "value": "colorectal cancer"
                },
                {
                  "name": "Combination Therapy",
                  "value": "CGM097 + Dabrafenib + Navitoclax + PF-04217903"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Pdx"
                },
                {
                  "name": "Combination Therapy",
                  "value": "KRT-232 + Navitoclax"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Navitoclax + PLX4720"
                },
                {
                  "name": "Indication",
                  "value": "lung non-small cell carcinoma"
                },
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Indication",
                  "value": "colon cancer"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Navitoclax + Trametinib"
                }
              ],
              "drug": {
                "name": "NAVITOCLAX",
                "approved": false
              },
              "interactionScore": 0.142006550311548,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Lin L et al., 2015, The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies., Nat Genet",
                      "pmid": 25665005
                    },
                    {
                      "citation": "Frederick DT et al., 2014, Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics., PLoS One",
                      "pmid": 24983357
                    },
                    {
                      "citation": "Shattuck-Brandt RL et al., 2020, Metastatic Melanoma Patient-Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition., Clin Cancer Res",
                      "pmid": 32234759
                    },
                    {
                      "citation": "Sigaud R et al., 2023, The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma models., Neuro Oncol",
                      "pmid": 35882450
                    },
                    {
                      "citation": "Horn T et al., 2016, High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells., Cancer Res",
                      "pmid": 27659046
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Indication",
                  "value": "Advanced Solid Tumor"
                },
                {
                  "name": "Approval Status",
                  "value": "Case Reports/Case Series"
                },
                {
                  "name": "Indication",
                  "value": "pancreatic cancer"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                }
              ],
              "drug": {
                "name": "EXARAFENIB",
                "approved": false
              },
              "interactionScore": 0.165674308696806,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Combination Therapy",
                  "value": "Afatinib + BI 882370"
                },
                {
                  "name": "Indication",
                  "value": "colorectal cancer"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                }
              ],
              "drug": {
                "name": "AFATINIB",
                "approved": true
              },
              "interactionScore": 0.05522476956560202,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Waizenegger IC et al., 2016, A Novel RAF Kinase Inhibitor with DFG-Out-Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation., Mol Cancer Ther",
                      "pmid": 26916115
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Combination Therapy",
                  "value": "AZ628 + Selumetinib"
                },
                {
                  "name": "Indication",
                  "value": "colorectal cancer"
                },
                {
                  "name": "Indication",
                  "value": "lung non-small cell carcinoma"
                },
                {
                  "name": "Indication",
                  "value": "ovarian cancer"
                }
              ],
              "drug": {
                "name": "AZ628",
                "approved": false
              },
              "interactionScore": 0.6626972347872242,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Karoulia Z et al., 2016, An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling., Cancer Cell",
                      "pmid": 27523909
                    },
                    {
                      "citation": "Whittaker SR et al., 2015, Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors., Mol Cancer Ther",
                      "pmid": 26351322
                    },
                    {
                      "citation": "Foster SA et al., 2016, Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2., Cancer Cell",
                      "pmid": 26996308
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                },
                {
                  "publications": [
                    {
                      "citation": "Vasbinder MM et al., 2013, Discovery and optimization of a novel series of potent mutant B-Raf(V600E) selective kinase inhibitors., J Med Chem",
                      "pmid": 23398453
                    }
                  ],
                  "source": {
                    "sourceDbName": "DTC"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Combination Therapy",
                  "value": "Cobimetinib + Gemcitabine + Nab-paclitaxel"
                },
                {
                  "name": "Indication",
                  "value": "pancreatic ductal adenocarcinoma"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Case Reports/Case Series"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Nab-paclitaxel + Vemurafenib"
                },
                {
                  "name": "Indication",
                  "value": "triple-receptor negative breast cancer"
                }
              ],
              "drug": {
                "name": "NAB-PACLITAXEL",
                "approved": false
              },
              "interactionScore": 0.3313486173936121,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Ardalan B et al., 2021, Potential benefit of treatment with MEK inhibitors and chemotherapy in BRAF-mutated KRAS wild-type pancreatic ductal adenocarcinoma patients: a case report., Cold Spring Harb Mol Case Stud",
                      "pmid": 34667063
                    },
                    {
                      "citation": "Wang L et al., 2022, BRAF V600E Mutation in Triple-Negative Breast Cancer: A Case Report and Literature Review., Oncol Res Treat",
                      "pmid": 34818649
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Indication",
                  "value": "colon cancer"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Pdx"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                }
              ],
              "drug": {
                "name": "MAP855",
                "approved": false
              },
              "interactionScore": 0.3313486173936121,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Gao Y et al., 2019, V211D Mutation in MEK1 Causes Resistance to MEK Inhibitors in Colon Cancer., Cancer Discov",
                      "pmid": 31227518
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Mechanism of Action",
                  "value": "Serine/threonine-protein kinase B-raf inhibitor"
                },
                {
                  "name": "Direct Interaction",
                  "value": "true"
                }
              ],
              "drug": {
                "name": "AGERAFENIB",
                "approved": false
              },
              "interactionScore": 0.220899078262408,
              "interactionTypes": [
                {
                  "type": "inhibitor"
                }
              ],
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TTD"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "ChEMBL"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Combination Therapy",
                  "value": "LTT462 + LXH 254"
                },
                {
                  "name": "Indication",
                  "value": "lung non-small cell carcinoma"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Case Reports/Case Series"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                }
              ],
              "drug": {
                "name": "RINETERKIB",
                "approved": false
              },
              "interactionScore": 0.165674308696806,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Combination Therapy",
                  "value": "Bevacizumab + Capecitabine + Vemurafenib"
                },
                {
                  "name": "Indication",
                  "value": "colorectal cancer"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Bevacizumab + Vemurafenib"
                },
                {
                  "name": "Indication",
                  "value": "lung papillary adenocarcinoma"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Case Reports/Case Series"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Bevacizumab + Pegylated liposomal doxorubicin + Temsirolimus"
                },
                {
                  "name": "Indication",
                  "value": "ovarian carcinoma"
                }
              ],
              "drug": {
                "name": "BEVACIZUMAB-AWWB",
                "approved": true
              },
              "interactionScore": 0.04602064130466835,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Yang H et al., 2012, Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer., Cancer Res",
                      "pmid": 22180495
                    },
                    {
                      "citation": "Jiang J et al., 2021, Case Report: Vemurafenib Treatment in Brain Metastases of BRAF(S365L) -Mutant Lung Papillary Cancer by Genetic Sequencing of Cerebrospinal Fluid Circulating Tumor DNA Detection., Front Oncol",
                      "pmid": 34178685
                    },
                    {
                      "citation": "Janku F et al., 2011, PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors., Mol Cancer Ther",
                      "pmid": 21216929
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "CIViC"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Combination Therapy",
                  "value": "PLX4720 + Tivozanib"
                },
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                }
              ],
              "drug": {
                "name": "TIVOZANIB",
                "approved": true
              },
              "interactionScore": 0.110449539131204,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Friedman AA et al., 2015, Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment., PLoS One",
                      "pmid": 26461489
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Indication",
                  "value": "colorectal cancer"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Pdx"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                }
              ],
              "drug": {
                "name": "SY-5609",
                "approved": false
              },
              "interactionScore": 0.3313486173936121,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Indication",
                  "value": "colorectal cancer"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Combination Therapy",
                  "value": "MK2206 + Vemurafenib"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                },
                {
                  "name": "Combination Therapy",
                  "value": "MK2206 + Trametinib"
                }
              ],
              "drug": {
                "name": "AKT INHIBITOR MK2206",
                "approved": false
              },
              "interactionScore": 0.06626972347872241,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Yang H et al., 2012, Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer., Cancer Res",
                      "pmid": 22180495
                    },
                    {
                      "citation": "Shi H et al., 2014, A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition., Cancer Discov",
                      "pmid": 24265152
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Cancer Type",
                  "value": "Melanoma"
                },
                {
                  "name": "Alteration",
                  "value": "BRAF:V600E"
                },
                {
                  "name": "Alteration",
                  "value": "BRAF:V600R"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Dabrafenib;Trametinib"
                },
                {
                  "name": "Alteration",
                  "value": "BRAF:V600E,V600K"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Panitumumab;Dabrafenib;BYL719"
                },
                {
                  "name": "Alteration",
                  "value": "BRAF:V600."
                },
                {
                  "name": "Combination Therapy",
                  "value": "Panitumumab;Dabrafenib;Trametinib"
                },
                {
                  "name": "Indication",
                  "value": "melanoma"
                },
                {
                  "name": "Response Type",
                  "value": "no benefit"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Patient cell culture"
                },
                {
                  "name": "Evidence Type",
                  "value": "Actionable"
                },
                {
                  "name": "Response Type",
                  "value": "sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "FDA approved - On Companion Diagnostic"
                },
                {
                  "name": "Indication",
                  "value": "glioblastoma"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - sensitive"
                },
                {
                  "name": "Approval Status",
                  "value": "Case Reports/Case Series"
                },
                {
                  "name": "Indication",
                  "value": "lung non-small cell carcinoma"
                },
                {
                  "name": "Approval Status",
                  "value": "Phase II"
                },
                {
                  "name": "Approval Status",
                  "value": "Guideline"
                },
                {
                  "name": "Indication",
                  "value": "thyroid gland follicular carcinoma"
                },
                {
                  "name": "Indication",
                  "value": "thyroid gland carcinoma"
                },
                {
                  "name": "Indication",
                  "value": "thyroid gland papillary carcinoma"
                },
                {
                  "name": "Approval Status",
                  "value": "Clinical Study - Cohort"
                },
                {
                  "name": "Indication",
                  "value": "colon neuroendocrine neoplasm"
                },
                {
                  "name": "Indication",
                  "value": "Erdheim-Chester disease"
                },
                {
                  "name": "Indication",
                  "value": "pilocytic astrocytoma"
                },
                {
                  "name": "Indication",
                  "value": "ganglioglioma"
                },
                {
                  "name": "Indication",
                  "value": "skin melanoma"
                },
                {
                  "name": "Indication",
                  "value": "gastrointestinal stromal tumor"
                },
                {
                  "name": "Indication",
                  "value": "colorectal cancer"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Dabrafenib + Trametinib"
                },
                {
                  "name": "Indication",
                  "value": "neuroendocrine tumor"
                },
                {
                  "name": "Indication",
                  "value": "hairy cell leukemia"
                },
                {
                  "name": "Indication",
                  "value": "ovary epithelial cancer"
                },
                {
                  "name": "Indication",
                  "value": "basal cell carcinoma"
                },
                {
                  "name": "Indication",
                  "value": "high grade glioma"
                },
                {
                  "name": "Indication",
                  "value": "brain glioblastoma multiforme"
                },
                {
                  "name": "Indication",
                  "value": "anaplastic astrocytoma"
                },
                {
                  "name": "Indication",
                  "value": "pancreatic ductal adenocarcinoma"
                },
                {
                  "name": "Indication",
                  "value": "ampulla of Vater adenocarcinoma"
                },
                {
                  "name": "Indication",
                  "value": "esophagus squamous cell carcinoma"
                },
                {
                  "name": "Indication",
                  "value": "pancreatic adenocarcinoma"
                },
                {
                  "name": "Indication",
                  "value": "biliary tract cancer"
                },
                {
                  "name": "Indication",
                  "value": "pleomorphic xanthoastrocytoma"
                },
                {
                  "name": "Indication",
                  "value": "esophagus adenocarcinoma"
                },
                {
                  "name": "Indication",
                  "value": "intrahepatic cholangiocarcinoma"
                },
                {
                  "name": "Indication",
                  "value": "gastroesophageal junction adenocarcinoma"
                },
                {
                  "name": "Indication",
                  "value": "cholangiocarcinoma"
                },
                {
                  "name": "Indication",
                  "value": "epithelial predominant Wilms' tumor"
                },
                {
                  "name": "Indication",
                  "value": "lung papillary adenocarcinoma"
                },
                {
                  "name": "Indication",
                  "value": "pancreatic acinar cell adenocarcinoma"
                },
                {
                  "name": "Indication",
                  "value": "anaplastic oligodendroglioma"
                },
                {
                  "name": "Indication",
                  "value": "thyroid gland Hurthle cell carcinoma"
                },
                {
                  "name": "Indication",
                  "value": "salivary gland cancer"
                },
                {
                  "name": "Approval Status",
                  "value": "Phase Ib/II"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell culture"
                },
                {
                  "name": "Indication",
                  "value": "stomach cancer"
                },
                {
                  "name": "Indication",
                  "value": "spermatic cord cancer"
                },
                {
                  "name": "Indication",
                  "value": "salivary gland carcinoma"
                },
                {
                  "name": "Indication",
                  "value": "ovarian serous carcinoma"
                },
                {
                  "name": "Indication",
                  "value": "Her2-receptor negative breast cancer"
                },
                {
                  "name": "Indication",
                  "value": "thyroid gland anaplastic carcinoma"
                },
                {
                  "name": "Indication",
                  "value": "low grade glioma"
                },
                {
                  "name": "Approval Status",
                  "value": "FDA approved"
                },
                {
                  "name": "Indication",
                  "value": "anaplastic pleomorphic xanthoastrocytoma"
                },
                {
                  "name": "Indication",
                  "value": "IDH-wildtype glioblastoma"
                },
                {
                  "name": "Indication",
                  "value": "Advanced Solid Tumor"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Dabrafenib + Rabeprazole + Rifampin"
                },
                {
                  "name": "Indication",
                  "value": "endometrial adenocarcinoma"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Dabrafenib + Pembrolizumab + Trametinib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Dabrafenib + KRT-232 + Trametinib"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Pdx"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Dabrafenib + Panitumumab"
                },
                {
                  "name": "Approval Status",
                  "value": "Phase I"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Dabrafenib + Panitumumab + Trametinib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Dabrafenib + GSK2126458"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Cetuximab + Dabrafenib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Cetuximab + Dabrafenib + Trametinib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Cetuximab + Dabrafenib + SCH772984"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Dabrafenib + SCH772984"
                },
                {
                  "name": "Indication",
                  "value": "thyroid gland cancer"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Cell line xenograft"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Dabrafenib + Spartalizumab + Trametinib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Dabrafenib + SCH772984 + Trametinib"
                },
                {
                  "name": "Response Type",
                  "value": "decreased response"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Dabrafenib + JSI-1187"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Dabrafenib + Regorafenib + Trametinib"
                },
                {
                  "name": "Indication",
                  "value": "colon adenocarcinoma"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Pdx & cell culture"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Dabrafenib + LXH 254 + Trametinib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Dabrafenib + RAF709 + Trametinib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Dabrafenib + Rabeprazole + Rifampin + Trametinib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Dabrafenib + DS03090629"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Celecoxib + Dabrafenib + Trametinib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Celecoxib + Dabrafenib + Panitumumab + Trametinib"
                },
                {
                  "name": "Response Type",
                  "value": "resistant"
                },
                {
                  "name": "Indication",
                  "value": "lung adenocarcinoma"
                },
                {
                  "name": "Response Type",
                  "value": "predicted - resistant"
                },
                {
                  "name": "Response Type",
                  "value": "conflicting"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Dabrafenib + Enzalutamide + Trametinib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Dabrafenib + Everolimus + Trametinib"
                },
                {
                  "name": "Combination Therapy",
                  "value": "CGM097 + Dabrafenib + Navitoclax + PF-04217903"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Alpelisib + Dabrafenib + Erlotinib + Navitoclax"
                },
                {
                  "name": "Indication",
                  "value": "pancreatic endocrine carcinoma"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Dabrafenib + Nivolumab + Trametinib"
                },
                {
                  "name": "Approval Status",
                  "value": "Phase III"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Dabrafenib + Hydroxychloroquine + Trametinib"
                },
                {
                  "name": "Approval Status",
                  "value": "Preclinical - Biochemical"
                },
                {
                  "name": "Indication",
                  "value": "breast cancer"
                },
                {
                  "name": "Indication",
                  "value": "mucosal melanoma"
                },
                {
                  "name": "Indication",
                  "value": "collecting duct carcinoma"
                },
                {
                  "name": "Indication",
                  "value": "pancreatic cancer"
                },
                {
                  "name": "Indication",
                  "value": "ovarian cancer"
                },
                {
                  "name": "Clinical Trial ID",
                  "value": "NCT01677741"
                },
                {
                  "name": "Cancer Type",
                  "value": "Colorectal cancer"
                },
                {
                  "name": "Indication",
                  "value": "Purpose: dabrafenib in pediatric subjects with advanced BRAF V600 mutation-positive solid tumors. %Official title: Dabrafenib in Pediatric Subjects Aged 1 Month to <18 Years With Advanced BRAF V600-Mutation. %Inclusion criteria: BRAF V600 mutation-positive tumor."
                },
                {
                  "name": "Clinical Trial ID",
                  "value": "NCT01713972"
                },
                {
                  "name": "Indication",
                  "value": "Purpose: Dabrafenib and pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. %Assigned intervention: BRAF inhibitor GSK2118436. %Inclusion criteria: Tumors must carry the BRAF mutation"
                },
                {
                  "name": "Clinical Trial ID",
                  "value": "NCT01750918"
                },
                {
                  "name": "Indication",
                  "value": "Official title: BRAF Inhibitor. %Detailed description: subjects with BRAF-mutation"
                },
                {
                  "name": "Cancer Type",
                  "value": "GIST"
                },
                {
                  "name": "Cancer Type",
                  "value": "Lung cancer"
                },
                {
                  "name": "Clinical Trial ID",
                  "value": "NCT01701037"
                },
                {
                  "name": "Indication",
                  "value": "Official title: B-RAF and MEK Targeted Therapy. %Inclusion criteria: B-RAF V-600 mutation positive."
                },
                {
                  "name": "Clinical Trial ID",
                  "value": "NCT01721603"
                },
                {
                  "name": "Indication",
                  "value": "Purpose: dabrafenib (a BRAF inhibitor)."
                },
                {
                  "name": "Clinical Trial ID",
                  "value": "NCT01726738"
                },
                {
                  "name": "Indication",
                  "value": "Purpose: BRAF inhibitor (dabrafenib) %Exclusion criteria: Prior treatment with a BRAF inhibitor (including but not limited to dabrafenib (GSK2118436), vemurafenib, and LX281/BMS-908662)"
                },
                {
                  "name": "Clinical Trial ID",
                  "value": "NCT01767454"
                },
                {
                  "name": "Indication",
                  "value": "Official title: BRAF Inhibitor Dabrafenib"
                },
                {
                  "name": "Cancer Type",
                  "value": "Thyroid Cancer"
                },
                {
                  "name": "Clinical Trial ID",
                  "value": "NCT01723202"
                },
                {
                  "name": "Indication",
                  "value": "Official title: GSK2118436 (BRAFi). %Intervention: BRAF inhibitor GSK2118436"
                },
                {
                  "name": "Clinical Trial Name",
                  "value": "GSK2118436"
                },
                {
                  "name": "Novel Drug Target",
                  "value": "Established target"
                },
                {
                  "name": "Approval Status",
                  "value": "early trials"
                },
                {
                  "name": "Approval Status",
                  "value": "FDA-approved"
                },
                {
                  "name": "Variant Effect",
                  "value": "gain-of-function"
                },
                {
                  "name": "Pathway",
                  "value": "activation"
                },
                {
                  "name": "Approval Status",
                  "value": "case report"
                },
                {
                  "name": "Cancer Type",
                  "value": "Ovarian cancer"
                },
                {
                  "name": "Indication",
                  "value": "Purpose: GSK2118436 is a potent and selective inhibitor of BRAF kinase activity. %Inclusion criteria: Presence of a V600E BRAF mutation in lung cancer tissue."
                },
                {
                  "name": "Clinical Trial ID",
                  "value": "NCT01336634"
                },
                {
                  "name": "Clinical Trial ID",
                  "value": "NCT01738451"
                },
                {
                  "name": "Indication",
                  "value": "Purpose: provide continued access to GSK2118436 for eligible subjects with BRAF mutation-positive tumors. %Official title: Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors."
                },
                {
                  "name": "Clinical Trial ID",
                  "value": "NCT01231594"
                },
                {
                  "name": "Mechanism of Action",
                  "value": "Serine/threonine-protein kinase B-raf inhibitor"
                },
                {
                  "name": "Direct Interaction",
                  "value": "true"
                },
                {
                  "name": "Combination Therapy",
                  "value": "Panitumumab + Dabrafenib + Trametinib"
                },
                {
                  "name": "Mechanism of Action",
                  "value": "BRAF kinase inhibitor"
                }
              ],
              "drug": {
                "name": "DABRAFENIB",
                "approved": true
              },
              "interactionScore": 2.796582330802086,
              "interactionTypes": [
                {
                  "type": "inhibitor"
                }
              ],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Rudin CM et al., 2013, Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer., J Thorac Oncol",
                      "pmid": 23524406
                    },
                    {
                      "citation": "Falchook GS et al., 2012, Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial., Lancet",
                      "pmid": 22608338
                    },
                    {
                      "citation": "Bland RD et al., 1976, Rapid infusion of sodium bicarbonate and albumin into high-risk premature infants soon after birth: a controlled, prospective trial., Am J Obstet Gynecol",
                      "pmid": 2013
                    },
                    {
                      "citation": "Fioravanti CF et al., 1976, Pyridine nucleotide transhydrogenases of parasitic helminths., Arch Biochem Biophys",
                      "pmid": 8009
                    },
                    {
                      "citation": "Poole-Wilson PA et al., 1975, Effect of pH on ionic exchange and function in rat and rabbit myocardium., Am J Physiol",
                      "pmid": 2014
                    },
                    {
                      "citation": "Garner CW et al., 1975, Effect of pH on substrate and inhibitor kinetic constants of human liver alanine aminopeptidase. Evidence for two ionizable active center groups., Biochemistry",
                      "pmid": 38
                    },
                    {
                      "citation": "Flaherty KT et al., 2010, Inhibition of mutated, activated BRAF in metastatic melanoma., N Engl J Med",
                      "pmid": 20818844
                    },
                    {
                      "citation": "Kim KB et al., 2013, Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation., Thyroid",
                      "pmid": 23489023
                    },
                    {
                      "citation": "Planchard D et al., 2016, Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial., Lancet Oncol",
                      "pmid": 27080216
                    },
                    {
                      "citation": "Falchook GS et al., 2013, BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance., Oncotarget",
                      "pmid": 23470635
                    },
                    {
                      "citation": "Corcoran RB et al., 2015, Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer., J Clin Oncol",
                      "pmid": 26392102
                    },
                    {
                      "citation": "Silen W et al., 1975, Acid-base balance in amphibian gastric mucosa., Am J Physiol",
                      "pmid": 2015
                    },
                    {
                      "citation": "Sakaguchi H et al., 1976, Microbiological oxidation of synthetic chalcocite and covellite by Thiobacillus ferrooxidans., Appl Environ Microbiol",
                      "pmid": 8006
                    }
                  ],
                  "source": {
                    "sourceDbName": "CGI"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "CancerCommons"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "ChEMBL"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "ClearityFoundationClinicalTrial"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "COSMIC"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "FDA"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "MyCancerGenome"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "MyCancerGenomeClinicalTrial"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "MyCancerGenomeClinicalTrial"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "OncoKB"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TALC"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TALC"
                  }
                },
                {
                  "publications": [
                    {
                      "citation": "Davies H et al., 2002, Mutations of the BRAF gene in human cancer., Nature",
                      "pmid": 12068308
                    },
                    {
                      "citation": "Gautschi O et al., 2012, A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib., J Thorac Oncol",
                      "pmid": 22743296
                    },
                    {
                      "citation": "Xing M et al., 2014, BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence., J Clin Oncol",
                      "pmid": 25024077
                    },
                    {
                      "citation": "Naoki K et al., 2002, Missense mutations of the BRAF gene in human lung adenocarcinoma., Cancer Res",
                      "pmid": 12460919
                    },
                    {
                      "citation": "Paik PK et al., 2011, Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations., J Clin Oncol",
                      "pmid": 21483012
                    },
                    {
                      "citation": "Falchook GS et al., 2012, Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial., Lancet",
                      "pmid": 22608338
                    },
                    {
                      "citation": "Ohashi K et al., 2012, Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1., Proc Natl Acad Sci U S A",
                      "pmid": 22773810
                    },
                    {
                      "citation": "Flaherty KT et al., 2010, Inhibition of mutated, activated BRAF in metastatic melanoma., N Engl J Med",
                      "pmid": 20818844
                    },
                    {
                      "citation": "Chen D et al., 2014, BRAFV600E mutation and its association with clinicopathological features of colorectal cancer: a systematic review and meta-analysis., PLoS One",
                      "pmid": 24594804
                    },
                    {
                      "citation": "MacConaill LE et al., 2014, Prospective enterprise-level molecular genotyping of a cohort of cancer patients., J Mol Diagn",
                      "pmid": 25157968
                    },
                    {
                      "citation": "Andrulis M et al., 2013, Targeting the BRAF V600E mutation in multiple myeloma., Cancer Discov",
                      "pmid": 23612012
                    },
                    {
                      "citation": "Falchook GS et al., 2012, Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial., Lancet Oncol",
                      "pmid": 22805292
                    },
                    {
                      "citation": "Kurman RJ et al., 2011, Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm., Hum Pathol",
                      "pmid": 21683865
                    },
                    {
                      "citation": "Coffee EM et al., 2013, Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer., Clin Cancer Res",
                      "pmid": 23549875
                    },
                    {
                      "citation": "Flaherty KT et al., 2012, Improved survival with MEK inhibition in BRAF-mutated melanoma., N Engl J Med",
                      "pmid": 22663011
                    },
                    {
                      "citation": "Wan PT et al., 2004, Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF., Cell",
                      "pmid": 15035987
                    },
                    {
                      "citation": "De Roock W et al., 2011, KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer., Lancet Oncol",
                      "pmid": 21163703
                    },
                    {
                      "citation": "Ascierto PA et al., 2013, Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma., J Clin Oncol",
                      "pmid": 23918947
                    },
                    {
                      "citation": "Chang MT et al., 2016, Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity., Nat Biotechnol",
                      "pmid": 26619011
                    },
                    {
                      "citation": "Hayes DN et al., 2012, Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements., Clin Cancer Res",
                      "pmid": 22241789
                    },
                    {
                      "citation": "Zecchin D et al., 2013, BRAF V600E is a determinant of sensitivity to proteasome inhibitors., Mol Cancer Ther",
                      "pmid": 24107445
                    },
                    {
                      "citation": "Nissan MH et al., 2014, Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence., Cancer Res",
                      "pmid": 24576830
                    },
                    {
                      "citation": "Lam ET et al., 2010, Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer., J Clin Oncol",
                      "pmid": 20368568
                    },
                    {
                      "citation": "Patel SP et al., 2013, Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma., Cancer",
                      "pmid": 22972589
                    },
                    {
                      "citation": "Sen B et al., 2012, Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib., Sci Transl Med",
                      "pmid": 22649091
                    },
                    {
                      "citation": "Morris EJ et al., 2013, Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors., Cancer Discov",
                      "pmid": 23614898
                    },
                    {
                      "citation": "Tol J et al., 2010, Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab., Eur J Cancer",
                      "pmid": 20413299
                    },
                    {
                      "citation": "Chapman PB et al., 2011, Improved survival with vemurafenib in melanoma with BRAF V600E mutation., N Engl J Med",
                      "pmid": 21639808
                    },
                    {
                      "citation": "Sarker D et al., 2015, First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors., Clin Cancer Res",
                      "pmid": 25370471
                    },
                    {
                      "citation": "Crescenzi A et al., 2014, Immunohistochemistry for BRAF(V600E) antibody VE1 performed in core needle biopsy samples identifies mutated papillary thyroid cancers., Horm Metab Res",
                      "pmid": 24570209
                    },
                    {
                      "citation": "Dienstmann R et al., 2011, BRAF as a target for cancer therapy., Anticancer Agents Med Chem",
                      "pmid": 21426297
                    },
                    {
                      "citation": "Kim KB et al., 2013, Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation., Thyroid",
                      "pmid": 23489023
                    },
                    {
                      "citation": "Rubinstein JC et al., 2010, Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032., J Transl Med",
                      "pmid": 20630094
                    },
                    {
                      "citation": "Rudin CM et al., 2013, Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer., J Thorac Oncol",
                      "pmid": 23524406
                    },
                    {
                      "citation": "Boulalas I et al., 2009, Mutational analysis of the BRAF gene in transitional cell carcinoma of the bladder., Int J Biol Markers",
                      "pmid": 19404918
                    },
                    {
                      "citation": "Prahallad A et al., 2012, Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR., Nature",
                      "pmid": 22281684
                    },
                    {
                      "citation": "Hauschild A et al., 2012, Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial., Lancet",
                      "pmid": 22735384
                    },
                    {
                      "citation": "Gandhi J et al., 2009, Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines., PLoS One",
                      "pmid": 19238210
                    },
                    {
                      "citation": "Jalili A et al., 2012, Dual suppression of the cyclin-dependent kinase inhibitors CDKN2C and CDKN1A in human melanoma., J Natl Cancer Inst",
                      "pmid": 22997239
                    },
                    {
                      "citation": "Flaherty KT et al., 2012, Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations., N Engl J Med",
                      "pmid": 23020132
                    },
                    {
                      "citation": "Greger JG et al., 2012, Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations., Mol Cancer Ther",
                      "pmid": 22389471
                    },
                    {
                      "citation": "Cardarella S et al., 2013, Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer., Clin Cancer Res",
                      "pmid": 23833300
                    },
                    {
                      "citation": "Meckbach D et al., 2014, BRAF-V600 mutations have no prognostic impact in stage IV melanoma patients treated with monochemotherapy., PLoS One",
                      "pmid": 24586605
                    },
                    {
                      "citation": "Kirkwood JM et al., 2012, Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma., Clin Cancer Res",
                      "pmid": 22048237
                    },
                    {
                      "citation": "Paraiso KH et al., 2012, The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms., Clin Cancer Res",
                      "pmid": 22351686
                    },
                    {
                      "citation": "Ponti G et al., 2012, Overwhelming response to Dabrafenib in a patient with double BRAF mutation (V600E; V600M) metastatic malignant melanoma., J Hematol Oncol",
                      "pmid": 23031422
                    },
                    {
                      "citation": "Kloos RT et al., 2009, Phase II trial of sorafenib in metastatic thyroid cancer., J Clin Oncol",
                      "pmid": 19255327
                    },
                    {
                      "citation": "Agaimy A et al., 2009, V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours., J Clin Pathol",
                      "pmid": 19561230
                    },
                    {
                      "citation": "Faber AC et al., 2014, mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1., Cancer Discov",
                      "pmid": 24163374
                    },
                    {
                      "citation": "Howell GM et al., 2011, Both BRAF V600E mutation and older age ( 65 years) are associated with recurrent papillary thyroid cancer., Ann Surg Oncol",
                      "pmid": 21594703
                    },
                    {
                      "citation": "Tejpar S et al., 2010, Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery., Oncologist",
                      "pmid": 20350999
                    },
                    {
                      "citation": "Corcoran RB et al., 2012, EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib., Cancer Discov",
                      "pmid": 22448344
                    },
                    {
                      "citation": "De Roock W et al., 2010, Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis., Lancet Oncol",
                      "pmid": 20619739
                    },
                    {
                      "citation": "Tiacci E et al., 2011, BRAF mutations in hairy-cell leukemia., N Engl J Med",
                      "pmid": 21663470
                    },
                    {
                      "citation": "Haldar K et al., 2011, Epidermal growth factor receptor blockers for the treatment of ovarian cancer., Cochrane Database Syst Rev",
                      "pmid": 21975775
                    },
                    {
                      "citation": "Rowland A et al., 2015, Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer., Br J Cancer",
                      "pmid": 25989278
                    },
                    {
                      "citation": "De Roock W et al., 2009, Clinical biomarkers in oncology: focus on colorectal cancer., Mol Diagn Ther",
                      "pmid": 19537845
                    },
                    {
                      "citation": "Rad R et al., 2013, A genetic progression model of Braf(V600E)-induced intestinal tumorigenesis reveals targets for therapeutic intervention., Cancer Cell",
                      "pmid": 23845441
                    },
                    {
                      "citation": "Mao C et al., 2011, BRAF V600E mutation and resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer: a meta-analysis., Mol Biol Rep",
                      "pmid": 20857202
                    },
                    {
                      "citation": "McArthur GA et al., 2014, Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study., Lancet Oncol",
                      "pmid": 24508103
                    },
                    {
                      "citation": "Yang H et al., 2012, Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer., Cancer Res",
                      "pmid": 22180495
                    },
                    {
                      "citation": "Pratilas CA et al., 2008, Genetic predictors of MEK dependence in non-small cell lung cancer., Cancer Res",
                      "pmid": 19010912
                    },
                    {
                      "citation": "Peeters M et al., 2013, Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer., Clin Cancer Res",
                      "pmid": 23325582
                    },
                    {
                      "citation": "Hatzivassiliou G et al., 2013, Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers., Nature",
                      "pmid": 23934108
                    },
                    {
                      "citation": "Huillard E et al., 2012, Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy., Proc Natl Acad Sci U S A",
                      "pmid": 22586120
                    },
                    {
                      "citation": "Nakayama N et al., 2008, KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer., Br J Cancer",
                      "pmid": 19018267
                    },
                    {
                      "citation": "Mao M et al., 2013, Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents., Clin Cancer Res",
                      "pmid": 23251002
                    },
                    {
                      "citation": "Falchook GS et al., 2013, BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance., Oncotarget",
                      "pmid": 23470635
                    },
                    {
                      "citation": "Di Nicolantonio F et al., 2008, Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer., J Clin Oncol",
                      "pmid": 19001320
                    },
                    {
                      "citation": "Lovly CM et al., 2012, Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials., PLoS One",
                      "pmid": 22536370
                    },
                    {
                      "citation": "Rizzo S et al., 2010, Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?, Cancer Treat Rev",
                      "pmid": 21129611
                    },
                    {
                      "citation": "Ji Z et al., 2013, Vemurafenib synergizes with nutlin-3 to deplete survivin and suppresses melanoma viability and tumor growth., Clin Cancer Res",
                      "pmid": 23812671
                    },
                    {
                      "citation": "Ho AL et al., 2013, Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer., N Engl J Med",
                      "pmid": 23406027
                    },
                    {
                      "citation": "Gupta-Abramson V et al., 2008, Phase II trial of sorafenib in advanced thyroid cancer., J Clin Oncol",
                      "pmid": 18541894
                    },
                    {
                      "citation": "Menzies AM et al., 2014, Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma., Clin Cancer Res",
                      "pmid": 24583796
                    },
                    {
                      "citation": "Brose MS et al., 2002, BRAF and RAS mutations in human lung cancer and melanoma., Cancer Res",
                      "pmid": 12460918
                    },
                    {
                      "citation": "Sosman JA et al., 2012, Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib., N Engl J Med",
                      "pmid": 22356324
                    },
                    {
                      "citation": "Villanueva J et al., 2010, Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K., Cancer Cell",
                      "pmid": 21156289
                    },
                    {
                      "citation": "Maldonado JL et al., 2003, Determinants of BRAF mutations in primary melanomas., J Natl Cancer Inst",
                      "pmid": 14679157
                    },
                    {
                      "citation": "Nagore E et al., 2014, Prognostic value of BRAF mutations in localized cutaneous melanoma., J Am Acad Dermatol",
                      "pmid": 24388723
                    },
                    {
                      "citation": "Hoftijzer H et al., 2009, Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma., Eur J Endocrinol",
                      "pmid": 19773371
                    },
                    {
                      "citation": "He G et al., 2014, Prognostic value of the BRAF V600E mutation in papillary thyroid carcinoma., Oncol Lett",
                      "pmid": 24396464
                    },
                    {
                      "citation": "Walczyk A et al., 2014, The BRAF(V600E) mutation in papillary thyroid microcarcinoma: does the mutation have an impact on clinical outcome?, Clin Endocrinol (Oxf)",
                      "pmid": 24354346
                    },
                    {
                      "citation": "Nicolaides TP et al., 2011, Targeted therapy for BRAFV600E malignant astrocytoma., Clin Cancer Res",
                      "pmid": 22038996
                    },
                    {
                      "citation": "Penna I et al., 2016, Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade., Oncotarget",
                      "pmid": 26678033
                    },
                    {
                      "citation": "Dienstmann R et al., 2015, Database of genomic biomarkers for cancer drugs and clinical targetability in solid tumors., Cancer Discov",
                      "pmid": 25656898
                    }
                  ],
                  "source": {
                    "sourceDbName": "DoCM"
                  }
                },
                {
                  "publications": [
                    {
                      "citation": "Bahadoran P et al., 2013, Major clinical response to a BRAF inhibitor in a patient with a BRAF L597R-mutated melanoma., J Clin Oncol",
                      "pmid": 23715574
                    },
                    {
                      "citation": "Hauschild A et al., 2012, Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial., Lancet",
                      "pmid": 22735384
                    },
                    {
                      "citation": "Ceccon G et al., 2018, Dabrafenib Treatment in a Patient with an Epithelioid Glioblastoma and BRAF V600E Mutation., Int J Mol Sci",
                      "pmid": 29621181
                    },
                    {
                      "citation": "Planchard D et al., 2016, Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial., Lancet Oncol",
                      "pmid": 27080216
                    },
                    {
                      "citation": "Falchook GS et al., 2015, BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer., Thyroid",
                      "pmid": 25285888
                    },
                    {
                      "citation": "Rothenberg SM et al., 2015, Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib., Clin Cancer Res",
                      "pmid": 25549723
                    },
                    {
                      "citation": "Burkart J et al., 2018, Targeting BRAF Mutations in High-Grade Neuroendocrine Carcinoma of the Colon., J Natl Compr Canc Netw",
                      "pmid": 30181415
                    },
                    {
                      "citation": "Drobysheva A et al., 2017, Targeted MAPK Pathway Inhibitors in Patients With Disseminated Pilocytic Astrocytomas., J Natl Compr Canc Netw",
                      "pmid": 28784858
                    },
                    {
                      "citation": "Wang J et al., 2018, A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAF(V600E)-Mutant Brain Tumor., Cancer Discov",
                      "pmid": 29880583
                    },
                    {
                      "citation": "Falchook GS et al., 2013, BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance., Oncotarget",
                      "pmid": 23470635
                    },
                    {
                      "citation": "Hirschi B et al., 2014, Genetic targeting of B-RafV600E affects survival and proliferation and identifies selective agents against BRAF-mutant colorectal cancer cells., Mol Cancer",
                      "pmid": 24885690
                    },
                    {
                      "citation": "Klempner SJ et al., 2016, BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy., Cancer Discov",
                      "pmid": 27048246
                    },
                    {
                      "citation": "Schreuer M et al., 2017, Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF(V600)-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial., Lancet Oncol",
                      "pmid": 28268064
                    },
                    {
                      "citation": "Robert C et al., 2015, Improved overall survival in melanoma with combined dabrafenib and trametinib., N Engl J Med",
                      "pmid": 25399551
                    },
                    {
                      "citation": "Greger JG et al., 2012, Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations., Mol Cancer Ther",
                      "pmid": 22389471
                    },
                    {
                      "citation": "Butt SU et al., 2021, BRAF/MEK inhibitors for BRAF V600E-mutant cancers in non-approved setting: a case series., Cancer Chemother Pharmacol",
                      "pmid": 33537843
                    },
                    {
                      "citation": "Schreck KC et al., 2018, Concurrent BRAF/MEK Inhibitors in BRAF V600-Mutant High-Grade Primary Brain Tumors., J Natl Compr Canc Netw",
                      "pmid": 29632053
                    },
                    {
                      "citation": "Kanemaru Y et al., 2019, Dramatic response of BRAF V600E-mutant epithelioid glioblastoma to combination therapy with BRAF and MEK inhibitor: establishment and xenograft of a cell line to predict clinical efficacy., Acta Neuropathol Commun",
                      "pmid": 31345255
                    },
                    {
                      "citation": "Kushnirsky M et al., 2020, Prolonged Complete Response With Combined Dabrafenib and Trametinib After BRAF Inhibitor Failure in BRAF-Mutant Glioblastoma., JCO Precis Oncol",
                      "pmid": 32923904
                    },
                    {
                      "citation": "Woo PYM et al., 2019, Regression of BRAF (V600E) mutant adult glioblastoma after primary combined BRAF-MEK inhibitor targeted therapy: a report of two cases., Oncotarget",
                      "pmid": 31217909
                    },
                    {
                      "citation": "Wen PY et al., 2022, Dabrafenib plus trametinib in patients with BRAF(V600E)-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial., Lancet Oncol",
                      "pmid": 34838156
                    },
                    {
                      "citation": "Venkatesh A et al., 2021, Response to BRAF and MEK1/2 inhibition in a young adult with BRAF V600E mutant epithelioid glioblastoma multiforme: A Case Report and Literature Review., Curr Probl Cancer",
                      "pmid": 33461766
                    },
                    {
                      "citation": "Li HS et al., 2021, Remarkable response of BRAF (V600E)-mutated metastatic pancreatic cancer to BRAF/MEK inhibition: a case report., Gastroenterol Rep (Oxf)",
                      "pmid": 35382161
                    },
                    {
                      "citation": "Planchard D et al., 2016, Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial., Lancet Oncol",
                      "pmid": 27283860
                    },
                    {
                      "citation": "Planchard D et al., 2017, Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial., Lancet Oncol",
                      "pmid": 28919011
                    },
                    {
                      "citation": "Brandenburg T et al., 2021, Therapeutic Effect of Combined Dabrafenib and Trametinib Treatment of BRAF V600E-Mutated Primary Squamous Cell Carcinoma of the Thyroid: A Case Report., Eur Thyroid J",
                      "pmid": 34956922
                    },
                    {
                      "citation": "Owen DH et al., 2019, KRAS G12V Mutation in Acquired Resistance to Combined BRAF and MEK Inhibition in Papillary Thyroid Cancer., J Natl Compr Canc Netw",
                      "pmid": 31085763
                    },
                    {
                      "citation": "Subbiah V et al., 2020, Dabrafenib plus trametinib in patients with BRAF(V600E)-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial., Lancet Oncol",
                      "pmid": 32818466
                    },
                    {
                      "citation": "Vogel A et al., 2023, Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up., Ann Oncol",
                      "pmid": 36372281
                    },
                    {
                      "citation": "Obasaju P et al., 2020, BRAF V600E-mutated metastatic pediatric Wilms tumor with complete response to targeted RAF/MEK inhibition., Cold Spring Harb Mol Case Stud",
                      "pmid": 32238401
                    },
                    {
                      "citation": "Jiang J et al., 2021, Case Report: Vemurafenib Treatment in Brain Metastases of BRAF(S365L) -Mutant Lung Papillary Cancer by Genetic Sequencing of Cerebrospinal Fluid Circulating Tumor DNA Detection., Front Oncol",
                      "pmid": 34178685
                    },
                    {
                      "citation": "Busch E et al., 2020, Successful BRAF/MEK inhibition in a patient with BRAF(V600E)-mutated extrapancreatic acinar cell carcinoma., Cold Spring Harb Mol Case Stud",
                      "pmid": 32843432
                    },
                    {
                      "citation": "Corcoran RB et al., 2015, Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer., J Clin Oncol",
                      "pmid": 26392102
                    },
                    {
                      "citation": "Oddo D et al., 2016, Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer., Cancer Res",
                      "pmid": 27312529
                    },
                    {
                      "citation": "Saijo K et al., 2022, BRAF and MEK Inhibitor Treatment for Metastatic Undifferentiated Sarcoma of the Spermatic Cord with BRAF V600E Mutation., Case Rep Oncol",
                      "pmid": 36157689
                    },
                    {
                      "citation": "Lin VTG et al., 2018, First-Line Treatment of Widely Metastatic BRAF-Mutated Salivary Duct Carcinoma With Combined BRAF and MEK Inhibition., J Natl Compr Canc Netw",
                      "pmid": 30323086
                    },
                    {
                      "citation": "Tholander B et al., 2020, Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma., Ups J Med Sci",
                      "pmid": 33043759
                    },
                    {
                      "citation": "Lima B et al., 2022, Impressive and durable clinical responses obtained with dabrafenib and trametinib in low-grade serous ovarian cancer harbouring a BRAF V600E mutation., Gynecol Oncol Rep",
                      "pmid": 35242981
                    },
                    {
                      "citation": "Lpez de S A et al., 2022, Case report: Clinical success targeting BRAF-mutated, hormone receptor positive, HER2- negative advanced breast cancer patient with BRAF-inhibitor plus MEK- inhibitor., Front Oncol",
                      "pmid": 36531075
                    },
                    {
                      "citation": "Agarwal R et al., 2016, Response to Targeted Therapy in BRAF Mutant Anaplastic Thyroid Cancer., J Natl Compr Canc Netw",
                      "pmid": 27697975
                    },
                    {
                      "citation": "Subbiah V et al., 2022, Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study., Ann Oncol",
                      "pmid": 35026411
                    },
                    {
                      "citation": "Filetti S et al., 2019, Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up., Ann Oncol",
                      "pmid": 31549998
                    },
                    {
                      "citation": "Filetti S et al., 2022, ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer., Ann Oncol",
                      "pmid": 35491008
                    },
                    {
                      "citation": "Brown NF et al., 2017, Dabrafenib and trametinib in BRAFV600E mutated glioma., CNS Oncol",
                      "pmid": 28984141
                    },
                    {
                      "citation": "Munjapara V et al., 2022, BRAF V600E-Mutant Glioblastoma with Extracranial Metastases Responsive to Combined BRAF and MEK Targeted Inhibition: A Case Report., Case Rep Oncol",
                      "pmid": 36825105
                    },
                    {
                      "citation": "Shattuck-Brandt RL et al., 2020, Metastatic Melanoma Patient-Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition., Clin Cancer Res",
                      "pmid": 32234759
                    },
                    {
                      "citation": "Corcoran RB et al., 2018, Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF(V600E)-Mutant Colorectal Cancer., Cancer Discov",
                      "pmid": 29431699
                    },
                    {
                      "citation": "Hicks HM et al., 2021, Inhibition of BRAF and ERK1/2 has synergistic effects on thyroid cancer growth in vitro and in vivo., Mol Carcinog",
                      "pmid": 33595872
                    },
                    {
                      "citation": "Tian J et al., 2023, Combined PD-1, BRAF and MEK inhibition in BRAF(V600E) colorectal cancer: a phase 2 trial., Nat Med",
                      "pmid": 36702949
                    },
                    {
                      "citation": "Xue Y et al., 2017, An approach to suppress the evolution of resistance in BRAF(V600E)-mutant cancer., Nat Med",
                      "pmid": 28714990
                    },
                    {
                      "citation": "Adamopoulos C et al., 2021, Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling., Cancer Discov",
                      "pmid": 33568355
                    },
                    {
                      "citation": "Takano K et al., 2023, Discovery of a Novel ATP-Competitive MEK Inhibitor DS03090629 that Overcomes Resistance Conferred by BRAF Overexpression in BRAF-Mutated Melanoma., Mol Cancer Ther",
                      "pmid": 36622773
                    },
                    {
                      "citation": "Ruiz-Saenz A et al., 2023, A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAF(V600E) colorectal tumors., Nat Cancer",
                      "pmid": 36759733
                    },
                    {
                      "citation": "Abravanel DL et al., 2018, An Acquired NRAS Q61K Mutation in BRAF V600E-Mutant Lung Adenocarcinoma Resistant toDabrafenib Plus Trametinib., J Thorac Oncol",
                      "pmid": 29631033
                    },
                    {
                      "citation": "Mizuno S et al., 2023, High-Throughput Functional Evaluation of MAP2K1 Variants in Cancer., Mol Cancer Ther",
                      "pmid": 36442478
                    },
                    {
                      "citation": "Wagle N et al., 2014, MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition., Cancer Discov",
                      "pmid": 24265154
                    },
                    {
                      "citation": "Vellano CP et al., 2022, Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy., Nature",
                      "pmid": 35705814
                    },
                    {
                      "citation": "Van Allen EM et al., 2014, The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma., Cancer Discov",
                      "pmid": 24265153
                    },
                    {
                      "citation": "Carlino MS et al., 2015, Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients., Clin Cancer Res",
                      "pmid": 25370473
                    },
                    {
                      "citation": "Gibson WJ et al., 2017, Genomic Heterogeneity and Exceptional Response to Dual Pathway Inhibition in Anaplastic Thyroid Cancer., Clin Cancer Res",
                      "pmid": 27797976
                    },
                    {
                      "citation": "Olbryt M et al., 2020, Genetic Profiling of Advanced Melanoma: Candidate Mutations for Predicting Sensitivity and Resistance to Targeted Therapy., Target Oncol",
                      "pmid": 31980996
                    },
                    {
                      "citation": "Persky NS et al., 2020, Defining the landscape of ATP-competitive inhibitor resistance residues in protein kinases., Nat Struct Mol Biol",
                      "pmid": 31925410
                    },
                    {
                      "citation": "Ponti G et al., 2012, Overwhelming response to Dabrafenib in a patient with double BRAF mutation (V600E; V600M) metastatic malignant melanoma., J Hematol Oncol",
                      "pmid": 23031422
                    },
                    {
                      "citation": "Torresetti M et al., 2020, A case report of metastatic giant sarcomatoid melanoma with BRAF V600E mutation: a complete response to targeted therapy., Oncotarget",
                      "pmid": 32922664
                    },
                    {
                      "citation": "Sasankan S et al., 2020, Metastatic Pancreatic Cancer with BRAF and P53 Mutations: Case Report of Therapeutic Response to Doublet Targeted Therapy., Case Rep Oncol",
                      "pmid": 33250737
                    },
                    {
                      "citation": "Facchinetti F et al., 2020, Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAF(V600E) non-small cell lung cancer., Eur J Cancer",
                      "pmid": 32388065
                    },
                    {
                      "citation": "Guo W et al., 2022, Lung adenocarcinoma harboring complex EML4-ALK fusion and BRAF V600E co-mutation responded to alectinib., Medicine (Baltimore)",
                      "pmid": 36221356
                    },
                    {
                      "citation": "Seto K et al., 2022, Sensitivity to dabrafenib and trametinib treatments in patients with non-small-cell cancer harboring BRAF compound mutations: A pooled analysis of BRAF p.V600E-positive advanced non-small-cell lung cancer., Cancer Genet",
                      "pmid": 35598548
                    },
                    {
                      "citation": "Falchook GS et al., 2012, Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial., Lancet",
                      "pmid": 22608338
                    },
                    {
                      "citation": "Noeparast A et al., 2016, Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib., Oncotarget",
                      "pmid": 28947956
                    },
                    {
                      "citation": "2016, Triple Therapy Improves Colorectal Cancer Response., Cancer Discov",
                      "pmid": 27770002
                    },
                    {
                      "citation": "Horn T et al., 2016, High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells., Cancer Res",
                      "pmid": 27659046
                    },
                    {
                      "citation": "Algazi AP et al., 2020, Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial., Nat Med",
                      "pmid": 33020646
                    },
                    {
                      "citation": "Long GV et al., 2017, Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma., N Engl J Med",
                      "pmid": 28891408
                    },
                    {
                      "citation": "Dankner M et al., 2018, Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas., Clin Cancer Res",
                      "pmid": 29903896
                    },
                    {
                      "citation": "Negrao MV et al., 2020, Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations., J Thorac Oncol",
                      "pmid": 32540409
                    },
                    {
                      "citation": "Dagogo-Jack I, 2020, Durable Response to Dabrafenib Combined With Trametinib in a Patient With NSCLC Harboring a BRAF G469A Mutation., J Thorac Oncol",
                      "pmid": 32981611
                    },
                    {
                      "citation": "Melin A et al., 2019, BRAF exon 11 mutant melanoma and sensitivity to BRAF/MEK inhibition: Two case reports., Eur J Cancer",
                      "pmid": 31569065
                    },
                    {
                      "citation": "Reyes R et al., 2019, Clinical Benefit From BRAF/MEK Inhibition in a Double Non-V600E BRAF Mutant Lung Adenocarcinoma: A Case Report., Clin Lung Cancer",
                      "pmid": 30926357
                    },
                    {
                      "citation": "Karoulia Z et al., 2016, An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling., Cancer Cell",
                      "pmid": 27523909
                    },
                    {
                      "citation": "Casadevall D et al., 2016, Dabrafenib in an elderly patient with metastatic melanoma and BRAF V600R mutation: a case report., J Med Case Rep",
                      "pmid": 27255157
                    },
                    {
                      "citation": "Comito F et al., 2022, Clinical characteristics and treatment outcomes of non-V600 E/K BRAF mutant melanoma patients: a single-institution experience., Melanoma Res",
                      "pmid": 36039514
                    },
                    {
                      "citation": "Allen A et al., 2019, Rare BRAF mutations in pancreatic neuroendocrine tumors may predict response to RAF and MEK inhibition., PLoS One",
                      "pmid": 31158244
                    },
                    {
                      "citation": "Rogiers A et al., 2019, Dabrafenib plus trametinib in BRAF K601E-mutant melanoma., Br J Dermatol",
                      "pmid": 30248172
                    },
                    {
                      "citation": "Su PL et al., 2021, Durable Response to Combined Dabrafenib and Trametinib in a Patient With BRAF K601E Mutation-Positive Lung Adenocarcinoma: A Case Report., JTO Clin Res Rep",
                      "pmid": 34590045
                    },
                    {
                      "citation": "Hargrave DR et al., 2019, Efficacy and Safety of Dabrafenib in Pediatric Patients with BRAF V600 Mutation-Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa Study., Clin Cancer Res",
                      "pmid": 31811016
                    },
                    {
                      "citation": "Kieran MW et al., 2019, A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory BRAF V600 Mutation-Positive Solid Tumors., Clin Cancer Res",
                      "pmid": 31506385
                    },
                    {
                      "citation": "Long GV et al., 2016, Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib., J Clin Oncol",
                      "pmid": 26811525
                    },
                    {
                      "citation": "Planchard D et al., 2018, Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up., Ann Oncol",
                      "pmid": 30285222
                    },
                    {
                      "citation": "Michielin O et al., 2019, Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up., Ann Oncol",
                      "pmid": 31566661
                    },
                    {
                      "citation": "Bouffet E et al., 2023, Efficacy and Safety of Trametinib Monotherapy or in Combination With Dabrafenib in Pediatric BRAF V600-Mutant Low-Grade Glioma., J Clin Oncol",
                      "pmid": 36375115
                    },
                    {
                      "citation": "Dummer R et al., 2020, Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i., Nat Med",
                      "pmid": 33020648
                    },
                    {
                      "citation": "Mehnert JM et al., 2022, BAMM (BRAF Autophagy and MEK Inhibition in Melanoma): A Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Advanced BRAFV600-mutant Melanoma., Clin Cancer Res",
                      "pmid": 35022320
                    },
                    {
                      "citation": "Yap J et al., 2021, The stability of R-spine defines RAF inhibitor resistance: A comprehensive analysis of oncogenic BRAF mutants with in-frame insertion of C-4 loop., Sci Adv",
                      "pmid": 34108213
                    },
                    {
                      "citation": "Rogiers A et al., 2017, Response to targeted therapy in two patients with metastatic melanoma carrying rare BRAF exon 15 mutations: A598_T599insV and V600_K601delinsE., Melanoma Res",
                      "pmid": 28800030
                    },
                    {
                      "citation": "Bjursten S et al., 2019, Response to BRAF/MEK Inhibition in A598_T599insV BRAF Mutated Melanoma., Case Rep Oncol",
                      "pmid": 31824282
                    },
                    {
                      "citation": "Lampasona G et al., 2022, Locoregionally Advanced, BRAF V600L-Positive, Mucosal Melanoma of the Hypopharynx Treated With a Combination of BRAF and MEK Inhibitors., JCO Precis Oncol",
                      "pmid": 35709404
                    },
                    {
                      "citation": "Bernocchi O et al., 2021, Tumor Type Agnostic Therapy Carrying BRAF Mutation: Case Reports and Review of Literature., Pharmaceuticals (Basel)",
                      "pmid": 33669326
                    },
                    {
                      "citation": "Sasaki-Saito N et al., 2023, BRAF N581S and NRAS Q61R-mutated malignant melanoma and sensitivity to BRAF/MEK inhibitors., J Dermatol",
                      "pmid": 36217799
                    },
                    {
                      "citation": "Wrzeszczynski KO et al., 2019, Identification of targetable BRAF N486_P490 variant by whole-genome sequencing leading to dabrafenib-induced remission of a BRAF-mutant pancreatic adenocarcinoma., Cold Spring Harb Mol Case Stud",
                      "pmid": 31519698
                    },
                    {
                      "citation": "Chen SH et al., 2016, Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120., Cancer Discov",
                      "pmid": 26732095
                    },
                    {
                      "citation": "Shin JE et al., 2022, Efficacy of dabrafenib/trametinib in pancreatic ductal adenocarcinoma with BRAF NVTAP deletion: A case report., Front Oncol",
                      "pmid": 36505826
                    },
                    {
                      "citation": "Zhang S et al., 2023, BRAF L485-P490 deletion mutant metastatic melanoma sensitive to BRAF and MEK inhibition: A case report and literature review., Front Pharmacol",
                      "pmid": 36686670
                    },
                    {
                      "citation": "Marchand A et al., 2018, A rare BRAF T599dup mutation conferring sensitivity to BRAF inhibitor in a patient with metastatic melanoma., Br J Dermatol",
                      "pmid": 29494756
                    },
                    {
                      "citation": "Oberl M et al., 2022, Response to BRAF and MEK Inhibitors in BRAF Thr599dup-Mutated Melanoma., JCO Precis Oncol",
                      "pmid": 35319964
                    },
                    {
                      "citation": "Turshudzhyan A et al., 2020, A Rare p.T599dup BRAF Mutant NSCLC in a Non-Smoker., Curr Oncol",
                      "pmid": 33704186
                    },
                    {
                      "citation": "Lu H et al., 2017, Engineering and Functional Characterization of Fusion Genes Identifies Novel Oncogenic Drivers of Cancer., Cancer Res",
                      "pmid": 28512244
                    },
                    {
                      "citation": "Johnson DB et al., 2018, BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy., Pigment Cell Melanoma Res",
                      "pmid": 29171936
                    }
                  ],
                  "source": {
                    "sourceDbName": "JAX-CKB"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TdgClinicalTrial"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "PharmGKB"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "CIViC"
                  }
                },
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TTD"
                  }
                }
              ]
            }
          ]
        },
        {
          "name": "EREG",
          "longName": "epiregulin",
          "geneCategories": [
            {
              "name": "DRUGGABLE GENOME"
            },
            {
              "name": "GROWTH FACTOR"
            },
            {
              "name": "KINASE"
            }
          ],
          "interactions": [
            {
              "interactionAttributes": [],
              "drug": {
                "name": "CETUXIMAB",
                "approved": true
              },
              "interactionScore": 0.3469414935062527,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "CIViC"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [],
              "drug": {
                "name": "FEPIXNEBART",
                "approved": false
              },
              "interactionScore": 5.898005389606295,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "TTD"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [],
              "drug": {
                "name": "HUMAN CHORIONIC GONADOTROPIN",
                "approved": true
              },
              "interactionScore": 1.241685345180272,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [
                    {
                      "citation": "Shimada M et al., 2006, Paracrine and autocrine regulation of epidermal growth factor-like factors in cumulus oocyte complexes and granulosa cells: key roles for prostaglandin synthase 2 and progesterone receptor., Mol Endocrinol",
                      "pmid": 16543407
                    }
                  ],
                  "source": {
                    "sourceDbName": "NCI"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [],
              "drug": {
                "name": "PANITUMUMAB",
                "approved": true
              },
              "interactionScore": 0.6208426725901364,
              "interactionTypes": [],
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "CIViC"
                  }
                }
              ]
            },
            {
              "interactionAttributes": [
                {
                  "name": "Mechanism of Action",
                  "value": "Proepiregulin inhibitor"
                },
                {
                  "name": "Direct Interaction",
                  "value": "true"
                }
              ],
              "drug": {
                "name": "FEPIXNEBART",
                "approved": false
              },
              "interactionScore": 5.898005389606295,
              "interactionTypes": [
                {
                  "type": "inhibitor"
                }
              ],
              "interactionClaims": [
                {
                  "publications": [],
                  "source": {
                    "sourceDbName": "ChEMBL"
                  }
                }
              ]
            }
          ]
        }
      ]
    }
  }
}
